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ABSTRACT 
REGULATION OF CASPASE-9 BY NATURAL AND SYNTHETIC INHIBITORS 
 
MAY 2012 
 
KRISTEN L. HUBER, B.S., QUINNIPIAC UNIVERSITY 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Jeanne A. Hardy 
 
 
Tight regulation of caspase-9, a key initiator of apoptosis, is required to uphold 
cellular homeostasis. Although it is controlled on a multifactorial level, misregulation of 
this process does occur, which is a characteristic of a variety of diseases from ischemic 
injury to cancer. Therefore it remains important to gain a detailed understanding of the 
mechanisms behind native caspase-9 regulatory pathways and harness these mechanisms 
for therapeutic purposes. 
 Based on known mechanisms, such as the unique inhibitory complex of caspase-
9 and XIAP-BIR3, development of synthetic regulators can be envisioned, while other 
mechanisms such as zinc-mediated inhibition and CARD activation of caspse-9 remain 
undefined. Intrigued by the multiple ways to control caspase-9’s activity, we sought after 
designing synthetic caspase-9 inhibitors in addition to defining the mechanistic details 
metal regulation and CARD domain activation. 
We report the first stabilized α-helical peptides that harness the native regulatory 
mechanism of caspase-9 and the BIR3 domain which lead to the understanding of the 
importance of exosites in inhibitory complexes. Our studies also revealed that there are 
two distinct zinc binding sites, one at the active site and another at a novel zinc binding 
site of yet unknown function in caspase-9 however this site may have the potential to 
vii 
 
control caspase-6 based on its regulatory mechanism.  Furthermore, an interaction was 
discovered between CARD and the catalytic core of caspase-9 in the presence of a 
properly formed substrate binding groove, a potential mechanism utilized by the 
apoptosome for activation of the enzyme.  
All in all, the regulation of caspase-9 occurs on a variety of levels that requires 
almost every surface of the enzyme. Through exploring these underlying molecular 
details behind the various mechanisms, not only has the field of caspase-9 regulation 
mechanisms been extended, essential information was gained for further pursuit in an 
advancement towards the design of caspase-9 activators and inhibitors.  
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CHAPTER I 
APOPTOSIS, DISEASE, AND THE REGULATION OF CASPASE-9 
Apoptosis, otherwise known as programmed cell, has been established as a key 
component for a variety of disease. Pivotal roles are played by the facilitators of this 
process, the caspases, with caspase-9 (ICE-LAP6, Mch6) being of particular interest due 
to its role in initiating the cascade. Its activation mechanism and regulatory checkpoints 
are targets for treatment of a variety of apoptosis-related diseases. Thus, an improved 
understanding of these processes would improve our ability to create new therapies to 
treat diseases in which apoptosis has gone awry.  
1.1. The Roles of Apoptosis in Disease 
Cells go through a highly regulated process called apoptosis. Apoptosis is critical 
for the normal development and stability or homeostasis of all multi-cellular organisms. 
Apoptosis plays a role in sculpting and structuring developing tissue and organs 
throughout the all stages of an organism‟s development. It is responsible for eliminating 
tissue or appendages that were once required in early development but are no longer 
necessary for the mature stages of life, for controlling the number of cells during the 
developmental process to achieve proper organ function, as well as, for eliminating 
defective or damaged cells from the developing system
1,2
. Therefore, any disturbance in 
the apoptotic process is harmful to the system.  
Apoptosis has been found to play a role in a variety of diseases. Upregulation of 
apoptosis has been observed in a variety of cardiovascular diseases such as myocardial 
infarction, dilated cardiomyopathy and end-stage heart failure
3-6
. A build-up of apoptotic 
macrophages and smooth muscle cells have been observed in rupturing atherosclerotic 
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plaques resulting in macrophage build-up, clogging and weakening of the arterial cell 
wall. Furthermore, increased levels of cardiac-myocyte apoptosis is observed in patients 
suffering from chronic heart failure, which reduces the ability of the heart to maintain 
contractile function, providing a strong impetus for further investigating the role of 
apoptosis in heart disease.  In addition, diabetes, a disease characterized by inappropriate 
blood glucose levels and insulin imbalance, has also been linked to an increase in 
apoptosis
7-10
.  For both Type 1 and Type 2 diabetic patients, apoptotic beta cells in the 
islets of the pancreas have been observed. Although not clearly understood, beta-cell 
apoptosis in Type 1 diabetes is thought to be the main cause of the disease whereas the 
beta-cell death found in Type 2 diabetes is thought to be triggered by increased toxins in 
the beta cells themselves, such as glucose, saturated fatty acids, and islet amyloid 
polypeptides, which together induce oxidative stress and thus apoptosis. Given that 25.8 
million children and adults in America have diabetes
11
, an improved understanding of the 
involvement of apoptosis is strongly warranted.  
Further evidence of the harmful effects of a apoptotic imbalance can be observed 
in chronic airway inflammatory diseases such as bronchial asthma. This condition affects 
34 million Americans
12
 and is caused by damage to the epithelium lining of the airways 
also caused by an increase in apoptotic cells. Although apoptosis is a normal process for 
clearing damaged cells from the epithelium layer of the nasal passage, trachea, and 
bronchia, an excessive amount of apoptosis is undesirable and thought to highly 
contribute to the pathogenesis of this class of disease
13,14
. Hepatitis C, a viral disease of 
the liver has been shown to cause an increase in apoptosis of infected cells, a process 
thought to provide a mechanism for viral shedding
15
 in addition to the host‟s own 
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mechanism of eliminating the virus from liver cells
16
.  It has also been shown that during 
a systematic inflammatory response caused by a bacterial infection, otherwise known as 
sepsis, the body tries to regain homeostasis via initiating a compensatory anti-
inflammatory response.  Although this process is not highly understood, one area of focus 
has been lymphocyte apoptosis, characterized by reduced levels of CD4, B-, T- and 
dendritic cells
17-19
. Treatment of these cells with apoptotic inhibitors has shown increased 
survival rates in sepsis models
17,20
.  Furthermore, neuronal cell death has been shown as a 
characteristic of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), 
Huntington's disease, Alzheimer's disease, and Parkinson's disease. Upregulation of the 
apoptotic machinery is evident in early and late stages of disease progression, 
characterized by increased activation of pro-apoptotic proteins. Treatment with apoptotic 
inhibitors, however, provides protection from additional cell death in mouse models, 
further highlighting apoptosis as an important area of study. 
Down regulation of apoptosis is also prevalent in a variety of diseases, such as 
rheumatoid arthritis and cancer. Rheumatoid arthritis is a chronic inflammatory disorder 
affecting 2.1 million adults and approximately 1 in every 250 children under the age of 
18 in America. Rheumatoid arthritis is caused by an imbalance between proliferating and 
apoptotic cells resulting in synovial hyperplasia and angiogenesis
21
. A defective apoptotic 
pathway by means of increase apoptotic inhibitors in synovial tissue has been discovered 
and prevention of apoptotic cell death is thought to restore the synovial membrane 
tissue
22
. In a similar respect, the apoptotic machinery is found to be absent or in low 
cellular levels in breast, gastric, colorectal and lung cancers, which also show an 
increased level of apoptotic inhibitors
23-25
. Not only is there a change in oncogenic and 
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pro-apoptotic-protein expression levels in cancer cells, mutations in other pro-apoptotic 
proteins
26-31
 have also been observed. 
Because it is an ongoing area of research interest, irregularities within apoptosis 
are continually being discovered in a wide array of diseases. It is thought that  
irregularities in apoptosis may account for up to 50% of all diseases in which there are no 
suitable therapies
32
. Therefore, a further understanding of the apoptotic process and its 
regulators is still necessary in order to understand how diseases are able to evade this 
important cellular process. 
1.2. Caspases: Facilitators of Apoptosis 
Facilitators of this lethal cellular mechanism of apoptotic cell death are the 
cysteine aspartate proteases, or caspases. Caspases are classified into two subgroups 
based on their function in the cascade, structural characteristics, and substrate 
specificity
33
. The apoptotic caspases are commonly classified as in the initiator or 
executioner subgroups. Initiator caspases, caspase-2, -8, -9, and -10 emerge in the initial 
stages of the apoptotoic cascade and are known for their ability to be involved in large 
oligomeric activation assemblies. The executioner caspases-3, -6, and -7 are located in 
the latter half of the cascade and are responsible for the majority of proteolytic events 
resulting in the orderly demise of the cell. Caspases-1, -4, -5, -11, -12 and -14 are 
involved in the inflammatory response or other cell processes, but play no known role in 
apoptosis. 
Caspases are synthesized as three-domain polypeptide chains (Fig. 1.1 A). The N-
terminal domain, called the prodomain, is unique to each caspase, ranging from 16 to 220 
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amino acids in length. Prodomains shorter in length, found on the executioner caspases, 
are yet to have a specific function identified, although they have been hypothesized to 
 be involved in subcellular targeting
34,35
 or chaperoning folding of the core domain
36
. The 
longer prodomains observed in the initiator caspases act as recruitment or regulatory 
domains. Examples include the Caspase Activation and Recruitment Domain (CARD) 
found in caspase-2 and -9 and the Death Effector Domain (DED) of caspase-8 and -10. 
 
Figure 1.1 Caspase Structure. (A) Caspase polypeptide chain consists of a pro or CARD domain 
(yellow), large subunit (dark purple), and small subunit (light purple). (B) Caspase-9 CARD domain 
(PDB ID: 3YGS). (C) Caspase-9 catalytic core (PDB ID: 1JXQ). Individual monomers represented in 
purple and green about the two fold axis () with position of catalytic cysteine (cyan) and histidine 
(orange) indicated. (D-E) Caspase-9 active site loop bundle. The active loop bundle conformation is 
disordered in the (D) absence of substrate and becomes ordered (E) upon binding substrate (gray). 
Images generated in the PyMOL Molecular Graphics System, Version 1.3, Schrödinger, LLC.  
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Although CARD and DED domains are highly dissimilar, both fold into an anti-parallel 
six-α-helix Greek key structure and facilitate the formation of large protein complexes 
(Fig, 1.1 B).  The two domains C-terminal to this prodomain region are the large and 
small subunits connected via the intersubunit linker. Together, these domains fold into a 
heterodimer structure, common to all caspases. Homodimers of the heterodimer large and 
small subunits are formed about a two-fold axis which in turn makes up the catalytic core 
of the enzyme. The large subunit, averaging 17-20 kDa in size, houses the catalytic Cys-
His dyad. The small subunit, averaging 10-12 kDa, comprises the main portion of the 
homodimer interface. This catalytic core region of the caspases folds into a canonical 12-
strand β-sheet core packed between two α-helical layers (Fig 1.1 C). Specific loops which 
connect portions of the catalytic core secondary structure known as L1, L2 and L2„(the 
product of cleavage of the intersubunit linker), L3 and L4 also form the catalytic loop 
bundle.  These loops are known to alter their structural position based upon the activation 
state of the protease.  In the apo unliganded, state, these loops are disordered (Fig. 1.1 D) 
however upon binding of substrate, the L2 loop from one of the monomers interacts with 
the L2` loop from the opposing monomer (Fig. 1.1 E). Furthermore, L1, L3, and L4 loops 
are in an ordered state around the substrate binding groove to complete the formation of 
the catalytic loop bundle in the active state.   
1.3. Caspase Active Site and Catalytic Mechanism  
 Caspases have evolved to be highly specific enzymes with the moderate catalytic 
properties: Km in the range of 4 to 408 μM and a kcat of 0.2 to 9.1 s
-1
 
37
. Caspase-3 is the 
fastest in its class while caspase-9 possesses the slowest catalytic rates overall. The 
differences in catalytic properties most likely stem from their active site architecture and 
7 
 
target specificity. The active site structure of a caspase consists of a substrate binding 
groove, the catalytic Cys-His dyad, and four mobile loops. The substrate-binding groove 
(Fig 1.2 A) provides the specificity and binding determinants for a particular substrate 
sequence via four interaction interfaces or specificity subsites (S1 – S4). Closest to the 
catalytic cysteine lies the S1 pocket. This region provides the highest specificity for 
substrate recognition, essentially always accommodating an aspartate residue, although 
caspase-9 occasionally recognizes glutamate residues. The S2 substrate-binding site is 
thought to be involved in substrate differentiation
38-40
. S3 provides an anchoring function 
for substrate while S4 provides specificity between the subclasses of caspases. 
 
Figure 1.2 Caspase Active Site Structure and Mechanism. (A) Model of the caspase substrate binding 
groove with peptide z-EVD bound (gray). Catalytic Cys (blue) and His (orange) are in close proximity 
to the Asp recognition element found in the S1 pocket (white). S2 (yellow), S3 (tan), and S4 (green), 
accommodates the remainder of the peptide. (B) Catalytic mechanism of caspases adapted from 
Fuentes-Prior and Salvesen
43
. 
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Executioner caspases prefer to bind acidic amino acids in their S4 pocket
41
 while initiator 
caspase-9 prefers bulkier hydrophobic residues (reviewed in
42
). 
 The cysteine and histidine catalytic residues responsible for cleavage of the 
substrate peptide bond are located on the C-terminal end of the β4 strand and the N-
terminal end of the βI strand respectively. Caspases are thought to have similar catalytic 
mechanisms (Fig. 1.2 B) as that of other cysteine proteases (reviewed in
43
)  where the P1 
recognition element is anchored through hydrogen bonding to the oxyanion hole, thus 
polarizing the carbonyl carbon of the peptide bond. Deprotonation of the catalytic 
cysteine thiol via the catalytic acid/base, a histidine residue, occurs as the initial step of 
the cleavage mechanism. The anionic sulfur of the now deprotonated catalytic cysteine 
then performs a nucleophilic attack on the substrates carbonyl carbon, C-terminal to the 
P1 aspartate recognition element in the case of the caspases. The catalytic histidine then 
protonates the α-amino group of the peptide leaving group. After release of this C-
terminal peptide of the cleaved substrate, the deprotonated histidine abstracts a proton 
from water to restore its native state.  Activated water then hydrolizes the thioester bond 
that links the substrates carboxy-terminus to the cysteine thiol and thus restores the 
enzyme to its native, unliganded state.  
Alternative mechanisms to the classical cysteine protease reaction mechanism 
have also been proposed. For example, the catalytic histidine Nγ is proposed to stabilize 
the developing charge on the leaving group while a water is utilized as the proton donor 
for the peptide leaving group instead of a protonated histidine residue
44
. Additionally, 
based upon known crystal structures of the caspase family of proteases, the distance of 
the caspase catalytic residues are observed to be approximately 5Å apart which would be 
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too far for hydrogen abstraction of the cysteine thiol by the catalytic acid/base, making 
the common cysteine protease reaction mechanism difficult to achieve. Therefore, an 
alternative mechanism has been proposed by having the active site cysteine nucleophile 
develop along the reaction coordinate instead of being polarized by the catalytic 
histidine
45
. This particular part of the mechanism would be governed by the pH optimum 
requirement for these enzymes where the executioner caspases lie more toward the 
neutral to slightly basic pH range of 7.0-8.0 while initiator caspases-8 and -9 have a 
lower pH optimum of 6.5-7.0
37
.  Further experimental data is required however, in order 
to discern which reaction mechanism is proper for caspase catalytic function. 
1.4. Apoptotic Pathways 
Although apoptosis‟ final phenotype is cell death, the cascade can be initiated via 
different mechanisms which would activate either the extrinsic and intrinsic pathways 
(Fig 1.3). The decision of which pathway to initiate depends on the type of cellular stress 
signal received.  
 
Figure 1.3 Intrinsic and extrinsic pathways of apoptosis. Caspases and other important proteins 
involved in apoptosis are shown. Figure by Kristin Paczkowski. 
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Activation of the extrinsic pathway through triggers such as cytokine release 
induces signaling of the pro-apoptotic receptors associated with the TNF or TRAIL 
family of proteins that reside on the cell surface. These membrane bound receptors bind 
ligands, such as FasL, TNF-α, or TRAIL, triggering the recruitment and clustering of 
adapter molecules, such as Fas-associated death domain (FADD), to the cytoplasmic 
death domain region of the receptor. Additional molecules, caspase-8 or -10 are also 
recruited ultimately forming the death inducing signaling complex (DISC)
46-49
. Once 
bound, the caspases are thought to undergo autoproteolysis and thus activation. As 
activated caspases, the initiators -8 and -10 can continue the cascade by cleaving their 
downstream targets, caspases-3, -6, and -7.  
If a stress signal, such as DNA damage or build up of reactive oxygen species, 
occurs from within the boundaries of the cellular membrane, the intrinsic pathway is 
initiated.  This type of stress induces recruitment of the pro-apoptotic Bcl-2 proteins to 
invade the outer mitochondrial membrane. This event, which controls mitochondrial 
integrity, induces translocation of other stress dependent proteins known as Bax
50
, Bad
51
, 
or Bid
52
 to the mitochondrial membrane, resulting in pore formation. As a result, a 
release of cytochrome c from the mitochondria into the cytosol occurs. Within the cytosol 
an inactive form of apoptotic protease activating factor-1 (Apaf-1) resides. Upon binding 
of cytochrome c, Apaf-1 undergoes a conformational change which exposes the Apaf-1 
CARD
53,54
 resulting in the oligomerization of the molecule in an ATP/dATP dependent 
manner
55-57
. The now heptameric Apaf-1 complex with exposed CARD domains is able 
to recruit the zymogen form of caspase-9 through an interaction between the caspase 
recruiting domains (CARD) on both Apaf-1 and the caspase-9 full length protein. This 
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allows for multiple procaspase-9 monomers to be within close distance for activation and 
for intermolecular self-processing. This large oligomeric complex formed of cytochrome 
c, Apaf-1 and pro-caspase-9 is known as the apoptosome.  Cryo electron microscopy of 
the holo form of the apoptosome
58,59
 indicate the seven Apaf-1 monomers oligomerize 
into a wheel-shape with each monomer representing one spoke. There is a central hub 
which houses Apaf-1 CARD which associates with caspase-9. Once bound to the 
apoptosome, procaspase-9 can become activated and cleave the executioner caspases-3, -
6, and -7 while still associated to the apoptosome.  
1.5. Natural Regulation of Caspase-9 
Regulating the caspases is a crucial step in controlling unwanted cell death. For 
this reason, a variety of regulatory check points have evolved to make sure caspase 
activation does not go awry. These precautions throughout the apoptotic pathway ensure 
that caspase activation occurs only upon the appropriate cellular signals. In particular, 
multiple levels of regulation exist for the initiator caspase of the intrinsic pathway, 
caspase-9.  Caspase-9 is a 416 amino acid protein consisting of a 15 kDa CARD domain 
which facilitates its binding to the apoptosome, an 18 kDa large subunit which houses the 
catalytic Cys287 and His 237 residues and a 10 kDa small subunit. Caspase-9 not only 
begins the apoptotic cleavage cascade of the intrinsic pathway, it is a focal point for 
regulation.  
In a natural non-apoptotic state, caspase-9 exists as an inactive, monomeric 
zymogen. In order to become active, the CARD domain of caspase-9 becomes involved 
in a protein-protein interaction with the Apaf-1 CARD resulting in a profound increase in 
caspase-9 activity
55,57,60
.  This is further supported by the increase in activity gained by a 
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stepwise addition of the domains involved in this interaction to the caspase-9 catalytic 
core, the simplest active unit which possesses the least amount of enzymatic activity. 
Addition of caspase-9 CARD increases enzymatic activity by 20 % which is five-fold 
further enhanced by the addition of Apaf-1 CARD
61
. Maximal activity is only achieved 
upon association with the entire apoptosome.  Furthermore, caspases are known to be 
active as dimers. The dimerization constant, KD, for caspase-9 is in the μM range
62,63
, 
enforcing a fairly weak complex considering cellular concentrations of ~20 nM
54
.  In 
comparison, KD of the executioner caspases is <50 nM
64
. Initial models of the 
apoptosome predict a monomeric caspase-9 which dimerizes via increasing the local 
concentration of monomeric caspase-9 resulting in recruitment of the dimeric partner
65
 or 
dimerization amongst the apoptosome bound monomers
66
 or induced conformations 
around the active site region of the enzyme
67
. However, evidence is emerging from high-
resolution cryo electron microscopy that caspase-9 monomers are active bound to the 
apoptosome
58
.  
In general, for caspases to reach their full activity, they need to be proteolytically 
processed within their intersubunit linker, which connects the large and small subunits of 
the enzyme. Full activation upon this cleavage serves as a secondary form of regulation.  
In the case of caspase-9 this occurs either through autoprocessing or aid from an 
additional caspase or other protease such a granzyme B. As a cleaved dimer, the L2 loop 
from one half of the dimer is able to interact with the L2` loop from the other half in the 
presence of substrate, thus positioning the active site loop bundle
62
 for catalysis. Caspase-
9, which becomes cleaved at Asp315 has a ten-fold increase in activity upon cleavage in 
vitro
45
. This value rises to 2000-fold
54
 when caspase-9 is associated as part of the 
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apoptosome. However, it should be noted that caspase-9 does not require cleavage of its 
intersubunit linker to have some minimal activity
54
. Furthermore, proteolytic removal of 
the CARD domain from the large subunit, which results in decreased activity, has also 
been observed in addition to processed caspase-9 being displaced from the apoptosome 
by additional molecules of procaspase-9
68
. Without these early checks and balances of 
caspase-9 activation in place, caspase-9 would prematurely activate the caspase cleavage 
cascade resulting in unwanted cell death. 
 As a failsafe, protein-based inhibitors also exist in the cell to control caspase 
activity. The most potent inhibitors
69
 of both the intrinsic and extrinsic pathways of 
apoptosis
70
 are known as the inhibitors of apoptosis or IAP‟s. These multidomain 
inhibitors consist of baculoviral IAP zinc-binding repeat (BIR) domains which are 
approximately 70 to 80 residues in length and contain a characteristic zinc-binding motif 
of -CX2CX16HX6C-. A single IAP consists of one to three BIR domains. Typically a 
carboxy-terminal RING domain is also associated, which allows targeting for 
ubiquitination and thus proteosomal degredation.  Mammalian IAPs including X-
chromosome-linked inhibitors of apoptosis (XIAP), cIAP1, cIAP2, Livin/ML-IAP, and 
neuronal apoptosis inhibitor protein also share this same baculoviral zinc motif. 
XIAPs have been shown to inhibit both the initiator and executioner caspases in 
human cells. They consist of three tandem BIR domains named BIR1, BIR2 and BIR3 
followed by a ring domain consisting of one zinc ion chelated to three cysteines and one 
histidine and an additional zinc ion bonded to four cysteines. Although similar in 
structure and sequence with approximately 30% sequence identity, each BIR domain 
possesses its own individual functions. Caspases-3 and -7 can be regulated by blocking of 
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the active site through binding of a small linker region N-terminal to the BIR2 domains of 
IAPs (residues 164–235). Binding this linker prevents substrate from entering the active 
site
71-73
. In addition, a BIR2 domain interaction with the caspase interaction binding motif 
distal from the active site of the enzyme
74
 with a Ki of 0.2-5 nM is present
73,75
. In the case 
of caspase-9, the BIR3 domain, residues 251-350, causes inhibition of the enzyme
73,76
 
with a Ki of 10-20 nM
76-78
 (Fig 1.4). BIR3 binds to the dimerization interface of the 
inactive caspase-9 monomer and sequesters the N-terminus of the small subunit, thus 
controlling its activity on multiple levels by preventing dimerization and formation of the 
active site loop bundle
79
.  Interestingly, not only has the cell adapted ways to control 
unwanted apoptosis, viruses have adapted means of survival by mimicking these natural 
inhibitory mechanisms. For example, viral IAPs are found in insects
80,81
 and animal 
viruses such as African swine fever
82
.  
 
Figure 1.4 Inhibitory complex of caspase-9 monomer (purple) with XIAP-BIR3 domain (blue). A 
structural zinc molecule in BIR3 is shown in red. 
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In addition to enzymatic cleavage, binding platforms and protein based inhibitors, 
binding of metal ions and post-translational modifications, such as phosphorylation, can 
alter the function of the caspase class of enzymes. Metal ions commonly used for both 
biological structure and cellular processes, such as zinc and copper, have been observed 
as specific regulators of apoptosis by targeting the caspases
83
. HeLa cells depleted of zinc 
for nine hours resulted in the processing of caspase-9
84
 while the presence of zinc 
protected caspase-9 activation from manganese mediated apoptosis
85
. Further correlations 
linking zinc and caspases have been observed via the cellular localization of zinc and 
caspases under apoptotic and zinc deficient conditions
13
, however, the cellular processes 
which trigger metal based regulation in addition to how metal ions regulate caspase 
activity still remain unclear.  Kinases, on the other hand, such as Akt, ERK MAPK‟s, and 
c-Abl regulate caspase-9 activity, both through activation and inhibition of the enzyme. 
This occurs based on the position of the phosphorylation. For example, phosphorylation 
at position T153 increases the activity of the enzyme
86
 whereas T125 phosphorylation 
prevents processing of caspase-9 and subsequent executioner caspase activation
87
. These 
alternate modes of caspase regulation further enhance the idea of a multi-factorial 
requirement for controlling caspase activity and unwanted cell death.   
1.6. Synthetic Regulation of Caspase-9 
Discovery of the caspases and their crucial role in apoptosis opened a new area of 
therapeutic interest and thus the discovery and design of small synthetic inhibitors. Initial 
inhibitor designs were inspired by the substrate specificity elements of the enzymes 
themselves. Designed amino acid analogues (Fig 1.5 A) utilized the caspase substrate 
recognition element aspartate to target all caspases, including caspase-9. Additional 
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analogues branched out into di-, tri-, and tetrapeptides that incorporated the sequence 
requirements for the remainder of the substrate binding groove. Sequences such as Val-
Asp and Val-Ala-Asp targeted a broad spectrum of caspases and are classified as pan-
caspase inhibitors
88
. As sequence specificities for individual caspases were determined, 
specific peptide inhibitors were designed such as Leu-Glu-His-Asp (LEHD) in case of 
caspase-9
33
 (Fig 1.5 A).  
 
Figure 1.5 Synthetic Inhibitors of Caspase-9 Activity. (A) Protected amino acid monomers to 
tetrapeptide substrate mimics are tuned for caspase-9 active site specificity. The recognition element 
Asp is utilized for capped amino acids while LEHD is utilized for tetrapeptide sequences which can be 
functionalized on the N- and C- terminus. (B) N-terminal protective groups and C-terminal electrophilic 
warheads provide variation and increase potency of the peptide-based inhibitors. (C-E) Small molecule 
and α-helical peptide inhibitors are designed to disrupt caspase-9 activation via binding to Apaf-1 and 
preventing the CARD-CARD interactions. Images generated in ChemBioDraw Ultra 12.0, 
CambridgeSoft Corporation and the PyMOL Molecular Graphics System, Version 1.3, Schrödinger, 
LLC. 
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Caspase targeting and potency of peptide-based inhibitors can be altered through 
addition of protective groups, fluorophores, and reactive electrophilic warheads (Fig. 1.5 
B). Functionalization on the N-terminus of the peptide sequence has included protective 
groups such as the N-acetyl (ac), benzyloxycarbonyl (Z), or quinolyl (Q) moieties. 
Fluorophores such as FITC have also been included on the amino terminal end of this 
class of peptides to enable detection.  The C-terminal portion of the peptide inhibitors 
typically comprise electrophilic warheads that react with the catalytic nucleophile. 
Aldehydes, nitriles and ketones are used for reversibility, while halomethylketones (e.g. 
FMK, fluoromethyketone; CMK, chloromethylketone), diazomethylketones and 
acylomethylketones serve as irreversible warheads
33,89,90
. The C-terminal O-phenoxy 
group was also incorporated into the warhead class of substrate based inhibitors due to its 
improved leaving properties and reactivity compared to fluoromethylketones. Peptide 
inhibitor Q-VD-Oph was determined to have an IC50 of 25-430 nM against a broad 
spectrum of caspases, with caspase-9 being on the highest end of the spectrum
91
. Potency 
and specificity vary greatly amongst these inhibitors with dissociation constants ranging 
anywhere from pM to μM. Caspase-9-specific, warhead driven inhibitors such as LEHD-
FMK, are potent against enzymatic activity. Compound IDN-6556 ((3 2-[(2-tert-butyl-
phenylaminooxalyl)-amino]-propionylamino 4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-
pentanoic acid)) (Fig 1.5 C), a broad-spectrum irreversible inhibitor of the caspases with 
an IC50 of 25 nM
92
, encompasses a similar premise with incorporation of a peptide 
backbone and the aspartate recognition element however, IDN-6566 utilizes an N-
terminal oxamide and C-terminal tetrafluorophenoxy warhead. This class of substrate 
mimicking inhibitors have been studied in the treatment of acute liver failure
93
, 
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myocardial ischemia-reperfusion injury
94
, and traumatic brain injury
95
. In this thesis, we 
have explored an entirely new class of inhibitors (Chapter III). 
Caspase-9‟s mechanism for activation via binding to the apoptosome complex has 
also been targeted to control its enzymatic activity. Small molecule and α-helical peptide 
inhibitors have been designed to either disrupt oligomerization of Apaf-1, which creates 
the bulk of the apoptosome platform, or caspase-9‟s association with the apoptosome. N-
alkylglycine peptoid inhibitors (Fig 1.5 D) and their solubility-enhancing analogues
96
 
bind to Apaf-1 (KD = 57 ± 12 nM) and prevent recruitment of caspase-9 to the 
apoptosome. Fusion of cell penetrating peptides and a polymeric carrier to the N-
alkylglycine peptoid inhibitors have also been explored to enhance membrane 
permeability and efficacy respectively for their ability to decrease apoptosis in neonatal 
rat cardiomyoctyes under hypoxic conditions. Diarylurea based compounds also inhibit 
formation of the apoptosome
97
 however the mechanism is slightly less clear. This class of 
inhibitor is determined to either prevent recruitment cytochrome c, dATP, or caspase-9 to 
Apaf-1. α-helical polypeptide modulators  on the other hand, specifically target the 
CARD-CARD mediated interaction of caspase-9 and Apaf-1
98
. Synthetic peptides were 
derived from the acidic patch region of helices 2 and 3 of Apaf-1 CARD domain (Fig 1.5 
D) and the basic patch of helices 1 and 3 of the caspase-9 CARD. This class of inhibitors 
successfully disrupted the interaction of Apaf-1 and caspase-9, thus preventing caspase-9 
activation both in vitro and in cell extracts with an IC50 of 68-102 μM for apoptosome 
activity as judged by cleavage of caspase-3 and 63-113 μM in human embryonic kidney 
293 (HEK 293) cellular extracts.  
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1.7. Caspase-9 and its Role in Disease 
Caspase-9 is of high interest due to its entry point into the apoptotic pathway and 
its involvement in disease. As an initiator caspase in the intrinsic pathway of apoptosis, 
targeting caspase-9 provides flexibility between the upstream apoptotic signals and the 
cleavage cascade, making this a critical target point for cell survival or cell death. This 
role is reflected by its specific involvement in a variety of diseases. 
Down regulation of caspase-9 has been observed in cancers as well as viral 
infections. In colonic carcinoma cells, expression levels are found to be low or even 
absent when compared to normal cells
99
 suggesting caspase-9 as the critical apoptotic 
checkpoint within this cell line. In the case of testicular cancer, caspase-9 fails to 
activate
100
. Through the targeting caspase-9 in this manner, the testicular cancer cells are 
also able to resist treatment with cisplatin, a treatment in which cell death is a priority, 
further confirming the importance of this cell death protease in cancer. The viral infection 
caused by the vaccinia virus, has also adopted means of controlling caspase-9. Viral 
protein F1L has been found not only to mimic apoptosis-like proteins upstream of the 
caspase cascade
101,102
 but to directly affect caspase-9 function
103
. F1L inhibits caspase-9 
activity by preventing zymogen caspase-9‟s association with the apoptosome in addition 
to blocking the enzymes protease function, driving home the significance of caspase-9 in 
controlling apoptosis.  
Up regulation of caspase-9 has also been observed in a variety of neurological 
diseases and immune disorders. Amyotrophic lateral sclerosis (ALS) exhibits increased 
caspase-9 activity in the spinal motor neurons of ALS mouse models
104
 and has been 
found to be a key player in the progression of the disease. Increased caspase-9 expression 
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levels and activity are also observed in the severe neuropathological cases of 
Huntington‟s disease patients and in a Huntington mouse model, implicating caspase-9‟s 
involvement in neuronal death at the end stage of the disease
105
. The same trend is also 
observed in the endothelial cells of patients with a rare multisystemic immune disorder 
known as Behçet's disease
106
, further confirming caspase-9‟s pivotal role in the 
progression of a disease. 
In addition to direct action of caspase-9, diseases also co-opt the regulators of 
caspase-9 in order to ensure activation of the apoptotic pathway. A characteristic of renal 
cell carcinoma
107,108
, lung cancer
109
, testicular germ cell tumors
110
 and hepatocellular 
cancer
111
 is the release of caspase inhibitor antagonist, Smac/Diablo, which is a direct 
antagonists of BIR3 resulting in the release its inhibition over caspase-9. This allows 
caspase-9 to activate and initiate the caspase cascade. In a similar fashion, while 
experiencing ischemia-reperfusion injury of the heart, the BIR3 antagonist, Omi/HtrA2, 
is released thus causing activation of caspase-9 as well
112
.  
Given these unique roles of caspase-9 in a wide variety of diseases, fully 
understanding the process of apoptosis is vital to understanding the normal homeostasis 
of a cell and to controlling a variety of diseases in which the cellular death process has 
been altered. By focusing on the caspases, the ultimate “hit men” of the cell, control can 
be achieved, specifically when targeting the initiator caspase-9. By controlling caspase-9 
activity, the transmission of the cell death signal can be controlled as well.  For this 
reason, the focus of this thesis is to harness and further understand the natural regulatory 
events inhibition of caspase-9 by BIR3, CARD domain activation and metal inhibition 
via biochemical and biophysical means.  
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CHAPTER II 
ROBUST PRODUCTION OF A LIBRARY OF CASPASE-9-INHIBITOR 
PEPTIDES USING METHODOLOGICAL SYNCHRONIZATION 
 
This chapter was published as: Huber, K. L., Olsen, K. D.* and Hardy, J. A., 2009. “Robust 
Production of a Peptide Library using Methodological Synchronization.” Protein Expression 
and Purification, 67,139-147. KLH designed initial parent construct and mutational sites, in 
addition to performing metal ion affinity and reverse HPLC purifications, ESI-MS, and peptide 
expression analysis. KDO performed site directed mutagenesis and affinity purification steps. 
Abstract 
Peptide libraries have proven to be useful in applications such as substrate profiling, drug 
candidate screening and identifying protein-protein interaction partners. However, issues 
of fidelity, peptide length and purity have been encountered when peptide libraries are 
chemically synthesized. Biochemically produced libraries, on the other hand, circumvent 
many of these issues due to the fidelity of the protein synthesis machinery. Using 
thioredoxin as an expression partner, a stably folded peptide scaffold (avian pancreatic 
polypeptide) and a compatible cleavage site for human rhinovirus 3C protease, we report 
a method that allows robust expression of a genetically-encoded XIAP-Bir3 inspired 
peptide library, which yields peptides of high purity. In addition, we report the use of 
methodological synchronization, an experimental design created for the production of a 
library, from initial cloning to peptide characterization, within a five-week period of time. 
Total peptide yields ranged from 0.8 to 16%, which corresponds to 2-70 milligrams of 
pure peptide per one liter of cell culture. Additionally, no correlation was observed 
between the ability to be expressed or overall yield of peptide-fusions and the intrinsic 
chemical characteristics of the peptides, indicating that this system can be used for a wide 
variety of peptide sequences with a range of chemical characteristics. 
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2.1. Introduction 
Peptide libraries are commonly used in a variety of endeavors including identifying 
peptide-DNA interactions 
1
, as surrogates for screening protein-protein interactions
2-5
, 
and as a basis for finding potential peptidic drug molecules.  Peptide libraries have also 
been used for profiling substrate specificities of proteases
6-11
, phosphatases
12-14
, kinases
15-
18
 and other drug targets
19-22
. Thus, the production of high quality peptide libraries is of 
wide interest for many applications.  
Typically, peptides for libraries have been produced via solid-phase synthesis, which 
involves sequential coupling of amine-protected amino acids to resin-bound amino acids. 
The resulting libraries generally contain peptides no longer than 15-20 amino acids, 
which can prove limiting in applications requiring longer peptides. The length constraints 
for chemically synthesized peptides are the result of coupling and deprotection 
efficiencies at each step, such that an exponential decrease in sequence fidelity is 
observed as a function of length. In addition, enantiomerization of nineteen of the twenty 
naturally-occurring amino acids and the associated difficulties in purification of the D-
isomer-containing peptides from the L-isomers set practical limits to peptide lengths in 
library synthesis
23,24
. Sometimes peptide sequences are restricted due to steric clash of 
adjacent amino acids with bulky chemical catalysts or intermolecular aggregation which 
results in a low efficiency of the chemical coupling reaction
25-27
.  Overall, chemically 
synthesized peptide libraries of longer lengths tend to have decreased sample quality, be 
costly and have increased production time. 
Genetically-encoded peptide libraries offer several advantages in library design. The  
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resulting libraries can contain longer peptide lengths and significantly increased yields 
while avoiding the more common limitations of chemical synthesis. Biological synthesis 
of peptides of longer lengths can be particularly important for production of isotopically-
labeled peptides for use in heteronuclear Nuclear Magnetic Resonance (NMR) 
spectroscopy.  The principle advantages of biological production result from the fidelity 
of protein machinery, particularly because the ribosome is not limited in sequence or 
length of synthesized peptides and has an error rate of only 0.01% error per amino acid 
added
28
. Genetically-encoded peptide libraries have not been widely used due to 
difficulties in the expression and purification of small peptides. This problem has been 
overcome by the use of protein-expression fusion partners such as glutathione-s-
transferase
29
, maltose binding protein
30
 and thioredoxin
31
 being the three most widely-
used fusions. While fusion proteins often promote production, this method can be time 
consuming and requires post expression protease processing and purification of the 
peptide from the protease. However, the addition of fusion partners has resulted in the 
improvement of the overall yields by enhancing solubility of the peptide of choice.  
We report a method that allows robust expression of a genetically-encoded XIAP-
Bir3 inspired peptide library that addresses the issues of purity, yield, length of the 
purified peptide, batch-to-batch variability which we have observed with chemically 
synthesized peptides, in addition to cost and time of production. This genetically-encoded 
system features thioredoxin as a fusion tag for the stably-folding peptide scaffold avian 
pancreatic polypeptide (aPP). aPP is a 36 amino acid peptide that contains a hydrophobic  
core and hydrogen bond network between the α-helix and polyproline helix of the  
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Figure 2.1 aPP structure. (A) aPP backbone (lightest 
gray) has a hydrophobic core created by three 
prolines located on the poly-proline helix (medium 
gray) and various residues on the α-helix (dark gray). 
(B) aPP’s internal hydrogen bond network, 
highlighted in dashed lines, is responsible for the 
impressive structural stabilization of a peptide that is 
just 36 amino acids long. 
peptide
32,33
 (Fig. 2.1 A and B). These 
properties are responsible for its fold 
and stability. Previous work has 
demonstrated that the presence of the 
hydrophobic core and hydrogen bond 
network render aPP insensitive to 
mutations over much of the amino acid 
sequence
34,35
 or to a c-terminal 
truncation
33,36
.  
A common difficulty with peptide 
expression is residual amino acid overhangs following the protease cleavage event. The 
native sequence of aPP allows inclusion of an N-terminal cleavage site for human 
rhinovirus 3C protease, a highly specific protease, without any unwanted amino acid 
additions to the peptides. Human rhinovirus 3C protease cleaves the sequence LEVLFQ-
GP, generating a gly-pro overhang upon cleavage. In aPP the first two amino acids are 
gly-pro, so no residual amino acids are left upon cleavage. Combining this optimized 
expression system with methodological synchronization of site-directed mutagenesis, 
protein expression and purification, a twenty-member aPP variant library of peptides 27 
amino acids in length was generated. This method allowed production of the desired 
library with overall improved yields, purity, and cost, all on a time frame that is 
comparable to synthetic peptide library methods on the same production scale. 
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Figure 2.2 Schematic representation of expression vector, 
pET32-Peptide. The T7 promoter, a fusion partner 
thioredoxin (TrxA), 6xHis tag, human rhinovirus 3C 
cleavable linker, gene for peptide, and ampicillin resistance 
are shown. 
 
2.2.  Results 
2.2.1.  Construction of Peptide-Fusion Expression Vector and aPP Variants  
A peptide-expression system for the library of aPP-based peptides was generated 
that expressed thioredoxin fusion proteins. A goal of this project was to streamline all 
steps in the process of cloning, 
expression and purification. In 
order to limit subsequent 
subcloning events, the parent 
vector (Fig. 2.2) was created 
through a single PCR reaction 
that resulted in the gene for a 
human rhinovirus 3C protease 
cleavage site (LEVLFQ) and 
the truncated aPP sequence 
(GPSQPTYPGDDAPVE-DLIRFYNDLQQY). This gene product was then ligated into 
the thioredoxin fusion gene and 6xHis purification tag containing vector, pET32b via 
restriction sites NcoI and XhoI.  The resultant thioredoxin-peptide fusion construct then 
served as the first base sequence for further mutagenesis. 
aPP variant sequences were created by mutating codons for six to twelve of the 
amino acids in the truncated 27 amino acid peptide scaffold (Fig. 2.3 A) via a 
QuikChange (Stratagene) mutagenesis strategy. This limited library was designed as aPP  
mimics of the natural caspase inhibitor, XIAP-BIR3. Mutations included the desired 
variations in the original peptide sequences and took into consideration amino acids that  
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are known to be structurally important for scaffold stability. Sites of mutagenesis are 
throughout the truncated aPP sequence and are spread across the aPP structural elements 
(Fig. 2.3 B). Mutational sites include Q4, T6, D10 and D11 on the polyproline helix and 
D16, D17, I18, Y21, D23, L24 Q25, and Y26 on the α-helix.  In addition D11 was 
selected as a site to be extensively interrogated. By focusing our investigation in one 
region, we were able to produce many variants in a limited number of mutagenic steps. 
Moreover, all mutational oligonucleotides were designed to limit cost and allow rapid 
production of the new peptide encoding DNA constructs. These designs focused on 
producing an array of peptide sequences using the minimum number of rounds of  
 
Figure 2.3 Structure of peptide library. (A) Amino acid sequences of the twenty-member peptide 
library. Mutated residues are bold. (B) Cartoon representation of truncated aPP peptide scaffold 
with sites of mutations shown in stick representation and highly interrogated site D11 represented 
in spheres. 
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mutagenesis. If mutagenesis was performed not by sequential means, 123 rounds of 
mutagenesis would have been performed to complete the library. Mutations were quickly 
assessed by growing the transformed E. coli cells for eight hours and plasmid prepping 
the DNA in time for same day sequencing by an outsourced company (Genewiz Inc). 
Upon sequence analysis, one out of two or more clones tested obtained the desired 
mutations. The success rate was directly related to the thoroughness of the DpnI digestion 
step during the QuikChange protocol (data not shown). 
2.2.2. Expression and Purification of a Recombinant Peptide Library 
 Once the desired genetic mutations were verified, the vectors were transformed 
into the BL21(DE3) strain of E. coli, expressed and harvested. The resulting cell pellets 
were lysed and prepared for purification. Various avenues were tested to optimize the 
purification of the peptide-fusion from other bacterial proteins. This was done in order to 
minimize the potential additive loss of protein during each purification step. Therefore, a 
nickel affinity step gradient, alone or in combination with ion exchange methods as well 
as nickel affinity linear gradients were explored to obtain a peptide-fusion sample of 
adequate purity without sacrificing yield. For example, peptide B3NK was purified via a 
Ni-affinity step gradient and ion exchange methods while peptide B3NR was purified by 
a Ni-affinity linear gradient only (Fig. 2.4). It is clear that a two-step purification yields 
protein of higher purity compared to Ni-gradient alone. However, since only a few 
contaminants are removed by the ion-exchange chromatography step in  
spite of a significant loss of sample, the single-step linear Ni-gradient became the 
preferred method of purification. 
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 Once the peptide-fusions were purified to a satisfactory degree, cleavage of the 
peptide from its fusion partner and linkers was accomplished by the highly specific 
human rhinovirus 3C protease (Fig. 2.5). Various proteases to peptide fusion ratios were 
examined for optimal cleavage in minimal time. As a 5-hour digestion with a 1:25 
protease to protein ratio was sufficient for full cleavage of peptide from the fusion tag, 
this method emerged as the time-optimized protocol. To separate the liberated peptide 
from the other components in solution, reverse phase HPLC was employed. By 
employing a three phase gradient which changes in organic phase from steep for buffer 
component elution, to shallow for peptide elution, to a second steep phase to regenerate 
 
Figure 2.4 Peptide-fusion purifications. (A) SDS-PAGE gels of peptide-fusion B3NK purified by 
a Ni-Affinity Step gradient (Load-L, Flow through 1-F1, Flow through 2-F2, Flow through 3-F3, 
Wash 1-W1, Wash 2-W2, Wash3 W3, and Elution-E) and ion exchange (fractions A-G) are 
indicated. (B) SDS-PAGE gel of peptide-fusion B3NR purified by Ni-affinity linear gradient 
(Load-L, Wash1-W1, Wash 2-W2 and elution fractions A-C 250 mM Imidazole. Fraction D is the 
elution from 1M imidazole and shows tightly bound B3NK and contaminants.) Uncleaved 
peptide-fusion MW = 24 kDa. 
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the column and elute larger proteins such as thioredoxin and human rhinovirus 3C 
protease, the peptide was separated during a 21.5 minute gradient. For example, cleaved 
peptides B3DE, B3II and B3NR, all were successfully separated from the contaminating 
proteins and cleaved thioredoxin fusion partners via the three phase gradient (Fig. 2.6). 
Major peaks in the chromatogram correspond to buffer components (peak 1) and larger 
proteins such as the thioredoxin tag and protease (peak 3) as verified by SDS-Page 
analysis. To verify the peptide identity and purity from the expected peptide samples 
(peak 2) on the reverse phase HPLC chromatogram, electrospray ionization mass 
spectrometry (ESI-MS) was performed. The spectra indicate peptides are of the expected 
molecular weights (3,119.1 – 3,201.3 Da) (Fig. 2.7). In addition, the chromatogram for 
the liquid chromatography that is in line with the mass spectrometer showed only a single 
peak. Averaging of spectra from all regions of the peak resulted in uniform mass spectra 
indicating only one molecular species was present. These data suggest that the purified 
 
Figure 2.5 Peptide-thioredoxin fusion protein cleavage. SDS-PAGE gel of the purified thioredoxin-
peptide fusion (Lane 1). Purified human rhinovirus 3C protease (Lane 2) and cleavage reaction including 
human rhinovirus 3C protease, cleaved thioredoxin and free aPP peptide (Lane 3). Peptide MW = 3176 
Da. Human rhinovirus 3C protease MW = 46,000 Da. Thioredoxin with tags MW = 27,912 Da. 
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Figure 2.7 Mass spectra of peptides. (A) B3NQ MW=3143.2 Da (B) B3II MW=3119.1 Da (C) B3DE 
MW=3174.2 Da (D) B3DR MW=3201.3 Spectra show double (+2) triply (+3), and quadruply (+4) 
charged ions. 
 
 
Figure 2.6 HPLC purification chromatograms of cleaved peptide-fusion samples. (A-C) SDS-PAGE 
gel of uncleaved and cleaved peptide-fusion with corresponding HPLC separation chromatograms. 
Peak 1 consists of buffer components, peak 2 is eluted peptide indicated by * and peak 3 is cleaved 
thioredoxin and human rhinovirus 3C protease. (A) B3II (B) B3DE (C) B3NR (D) SDS-PAGE gel of 
peaks 1 and 3 from HPLC separation. (E) Mass spectra of HPLC peak 2, the purified peptide B3II, 
MW = 3119.1 Da.  
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peptides are of extremely high purity. 
  To assess the overall utility of the peptide library construction system, the total 
amount of peptide fusion that was expressed in E. coli lysates is compared to the overall 
yield of each of the purification methods (Table 2.1). Total peptide yield ranged from 0.8 
to 16% from the overall expression. A major contributor to low peptide yield is 
 
likely loss of protein at the step of column loading in the flow through during initial 
purification due to overloaded resin. In addition, other contributing losses are observed at 
the ionic exchange and reverse phase HPLC portions of the purification. For each  
Table 2.1 Peptide Expression, Yield and Chemical Characteristics. Total peptide fusion expressed is 
compared to the overall yield of the peptide as a function of purification method used. Peptide 
characteristics such as charge, isoelectric point (IEP), the number of acidic, basic, polar, and non-
polar amino acid residues are also tabulated. 
 
Percent peptide in raw E. coli lystates was calculated using GeneTools (SynGene). * Indicates % 
peptide calculated was estimated by inspection of the stained SDS-PAGE gels. Ni: Ni-Affinity 
chromatography. IE: ionic exchange chromatography. Acidic, Basic, Polar and Non-polar represent 
the number of amino acids in the 27-residue peptide that have the particular chemical characteristic. 
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peptide, the ability to be expressed and the overall yield after purification was compared 
to different peptide features including charge, isoelectric point, and amino acid 
characteristics. Peptide charge ranged from -0.06 to -4.06 and calculated isoelectric point 
from 3.77 to 6.92. The number of acidic residues in the peptide sequences ranged from 
two to five while one to three basic residues, six to twelve polar residues and seven to 
nine hydrophobic residues were present in the various sequences. Favorably, no 
correlation between the expressability of the peptide-fusion and intrinsic chemical 
characteristics of the peptides was found. Likewise, no correlation between peptidic 
character and overall yield of pure peptide was observed. This suggests that our system 
can be used for a wide variety of peptide sequences with a range of chemical 
characteristics. 
2.3.Discussion 
 During chemical synthesis of peptides, sequence errors are a likely result due to 
the imperfect coupling efficiency at each step. For chemically synthesized peptides, the 
contaminants are extremely similar to the desired product in size and chemical 
characteristics and are therefore difficult to separate based on chromatography. Peptides 
produced by biochemical synthesis by the E. coli ribosome are expected to be very 
homogeneous due to the ribosome’s low error rate. In the system described here, any 
contaminants that remain after affinity purification and protease cleavage of the 
biochemically synthesized peptide fusions are unlikely to be chemically similar to the  
peptides. Our method for production of peptides uses reverse-phase HPLC purification as 
the final step. Because the non-peptide components are not chemically related to the  
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peptides themselves, HPLC purification allows for simultaneous removal of the fusion  
partner, the protease, and any residual components of the buffer solution. This makes a 
simple, two-step purification possible. In addition, because of the high fidelity of 
biochemical synthesis, the homogeneity of our peptides is very impressive. This results in 
a library of extremely high purity. 
 All of the peptide-fusion proteins described here were purified using a six-
histidine affinity tag. Following a Ni-affinity step gradient purification the peptide 
fusions were approximately 50% pure. We probed the effect of more extensively 
purifying the peptide fusions to >95% purity by subsequent anion exchange 
chromatography or to 80% purity by using a linear gradient of imidazole on the Ni-
affinity column. Employing reverse-phase HPLC, we were able to robustly purify the 
cleaved peptide to homogeneity after either of these protocols. This finding significantly 
shortened our production time by eliminating the ion-exchange purification step.  
 An additional advantage of the method described is that it is unnecessary for the 
peptide and the protease to be tagged with the same affinity tag, as is the case in some 
commercial protein-fusion purification systems. The method described here is compatible 
with any fusion partner and any protease. Since both the fusion partner and the protease 
are likely to be much larger than peptide products, it will be possible to separate the 
product from the contaminants in the final reverse-phase HPLC purification step. This 
fact is of particular importance in production of peptide libraries where additional amino 
acids at either the N- or C-termini can have significant effects on the overall properties of 
the peptide. Since any protease can be used, the overhanging amino acids from the  
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protease cleavage site can be matched with the desired peptide sequence, or a protease  
that does not leave any overhang can be selected
37
. The facts that this method is not 
dependent on use of any particular affinity tags or on utilizing matching affinity tags also 
limit sub-cloning steps that are necessary to use the library production method. 
 This method of peptide production using genetically encoded peptides offers clear 
advantages in the length and fidelity of peptides that can be produced and the resultant 
purity of the final samples. In the field of chemical peptide synthesis, the concept of 
“difficult” sequences (e.g. hydrophobic sequences) exists. Conversely, the genetically-
encoded production method described here was insensitive to peptide sequence such that 
every sequence attempted worked the first time with no optimization of expression or 
purification procedure required.  To make this method truly competitive with chemical 
synthesis, it is essential that libraries can be produced on the same general time scale as 
chemical synthesis. The scheduling strategy for the twenty-member library we present 
here lays the foundation for production of much larger libraries using the same processes. 
To this end, we have time-optimized our expression, purification and characterization 
protocols. Using the protocols we report and have routinely executed, we have 
constructed a map for methodological synchronization (Fig. 2.8). By coordinating 
mutagenesis cycles, sequencing, transformation, expression, purification and 
characterization, this peptide library can be produced rapidly. We generated this map 
reflecting the methods that were actually used; however, we have also performed 
sequencing reactions after an eight-hour growth of cultures followed by mini-prepping of 
DNA for sequencing. If this were applied to each peptide construct, it would save one  
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Figure 2.8 Methodological Synchronization. An experimental map showing how synchronization of 
QuikChange-based mutagenesis and protein preparatory procedures allows the production of 20 
peptides in a five-week time frame. Mutagenesis daily cycle (top) outlines the number of days in 
which cloning steps such as QuikChange mutagenesis, transformation, DNA purification and 
sequencing proceeds. 1:3, 2:3, and 3a:3 represents mutagenesis steps to create first peptide construct 
B3. Protein daily cycle (bottom) outlines the number of days in which expression, purification, and 
characterization for each peptide proceeds. The resultant DNA constructs are represented in light gray 
and purified peptides are represented in dark gray. 
day from each segment of the mutagenesis portion of the plan. In addition, we have 
 developed methodology so that QuikChange-mutagenized plasmids can be directly 
transformed into an expression strain of bacteria (such as BL21(DE3)) rather than into a 
cloning strain, which can save one step in the protocol. With these developments, the 
entire library could be generated even more rapidly. As presented, this methodological 
synchronization scheme allows construction of twenty peptide-expressing plasmids and 
purification of the resultant peptides to homogeneity in a five-week period using one  
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chromatography system, one HPLC and one LC-MS.  
In this work, we have used no more than two liters of E. coli culture per peptide and 
have accepted losses at the affinity purification step. Nevertheless, the protocols 
discussed here could facilely be scaled up to produce even greater yields of pure peptide. 
For some of the peptide fusions we have constructed, the yield of the expressed fusion  
protein as a fraction of total E. coli proteins is high enough (45% of total E. coli protein) 
that we can nearly envision skipping purification of the fusion protein altogether. By co-
expressing the protease and the fusion protein it may be possible to perform a one-step 
purification by HPLC to yield large quantities of pure peptide. 
2.4. Materials and Methods 
2.4.1. Cloning of Recombinant Peptide-Fusion Variants 
In order to create the parent vector, pET32-Peptide, for the peptide-fusion DNA 
variants, the aPP gene was amplified by PCR from the pJC20
35
 vector (from Alana 
Schepartz and Doug Daniels). Using the forward primer 5’GTACAACCATGGCTGGA-
AGTGCTGTTTCAGGGTCCGTCCCAGCCGACCTACCC3’ that included the human 
rhinovirus 3C cleavage sequence (bold) and NcoI endonuclease restriction site (italics) 
and the reverse primer 5’TCGAGCCTCGAGCTAGTAACGGTGACGGGTAACAACG-
TTCAGG3’ which encodes the XhoI restriction site (italics) and stop codon (bold), the 
desired gene was produced. This gene product was then ligated into the thioredoxin 
fusion tag, 6xHis purification tag containing vector, pET32b (Novagen) via restriction  
sites NcoI and XhoI.  Insertion was confirmed by sequence analysis (Genewiz, Inc.).  
The newly constructed vector, pET32-Peptide, was used for PCR-based site directed  
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mutagenesis via QuikChange (Stratagene) to create the variable peptide sequences. Initial  
base constructs, B3 and B3II were created using two sets of primers. Mutational sites 
include Q4, T6, L17, I18, Y21, D23, Q25, L24 and Y27.  Secondary base constructs 
B3DQ and B3NQ were produced from the B3 parent sequence by mutating sites D10, 
D11, and D16 while B3IQ and 3INQ were produced from the B3II sequence using two  
sets of primers. Remaining peptide sequences were produced from single step 
mutagenesis at position D11 utilizing one set of primers. The nucleotide sequences were 
optimized for expression in E. coli and all constructs were verified via sequence analysis.  
2.4.2. Expression and Purification of Recombinant Peptide-Fusion Variants 
DNA sequences encoding desired peptide sequences were transformed into E. coli 
strain BL21(DE3) competent cells (Novagen) for expression. These cells were inoculated 
into 2xYT media containing 100 μg/mL ampicillin (Sigma). Cells were grown at 37°C 
until an OD600 of 0.6 was reached. Isopropyl β-D-1-thiogalactopyranoside (IPTG), 
(Anatrace) was then added to a final concentration of 1mM. Cells were allowed to grow 
at 37°C for an additional 3 hrs and then harvested by centrifugation at 5000 rpm (Sorvall 
SLC-4000 rotor) for 10 minutes. 
Cells were resuspended in lysis buffer (50 mM NaH2PO4 pH 8.0, 300 mM NaCl, 
2mM imidazole) and lysed using a microfluidizer system (Microfludics). The resulting 
solution was then centrifuged at 15,000 rpm (Sorvall SS-34 rotor) for one hour at 4°C to 
remove cellular debris. Lysates were passed over HiTrap
TM 
Chelating HP columns (GE  
Healthcare). aPP, B3, B3DQ, B3DE, B3DK, B3DR, B3NE, B3NQ, B3NK, and B3II 
bound proteins were washed and eluted using a step gradient that consisted of a wash step  
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using 50 mM NaH2PO4 pH 8.0, 300 mM NaCl, 10 mM imidazole and an elution step  
using 50 mM NaH2PO4 pH 8.0, 300 mM NaCl, 250 mM imidazole. Peptide fusions B3, 
B3DK, B3DR, B3NQ, B3NE, B3NK, B3II eluted proteins were subjected to ion 
exchange chromatography to obtain additional purity. The previously eluted proteins 
were diluted 1:5 using Buffer A (20 mM Tris pH 8.0, 2mM dithiothreitol (DTT)) and  
bound to Macro-Prep HighQ cartridge (Biorad) at 5% Buffer B (Buffer B: 20 mM Tris 
pH 8.0, 2 mM DTT, 1M NaCl). Peptide-fusion proteins were eluted via a linear gradient 
that ranged from 50 mM to 350 mM NaCl over 240 minutes. Peptide fusions B3NR, 
B3IQ, B3IK, B3IE, B3IR, B3IL, 3INQ, 3INE, 3INR and 3INK were purified by a Ni-
affinity gradient going from 0 mM imidazole to 50 mM imidazole over 300 minutes. All 
peptide-fusions were analyzed by 16% SDS-PAGE gels that were stained with comassie 
brilliant blue (Sigma). Peptide fusions were stored at -20°C until required for cleavage 
and separation. 
2.4.3. Expression and purification of Human Rhinovirus 3C Protease 
The human rhinovirus 3C gene in the pGEX vector (GE Healthcare) was 
transformed into E. coli strain BL21(DE3) competent cells (Novagen) for expression. 
These cells were inoculated into 2xYT media containing 100 μg/mL ampicillin (Sigma). 
Cells were grown at 37°C until an OD600 of 0.6 was reached. IPTG was then added to a 
final concentration of 1mM. Cells were allowed to grow at 20°C for 18 hours and then 
harvested by centrifugation at 5000 rpm (Sorvall SLC-4000 rotor) for 10 minutes. 
Cells were resuspended in binding buffer (20 mM NaH2PO4 pH 7.4, 150 mM NaCl, 2mM 
DTT) and lysed using a microfluidizer system (Microfludics). The resulting solution was  
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then centrifuged at 15,000 rpm (Sorvall SS-34 rotor) for one hour at 4°C to remove  
cellular debris. Lysates were passed over GSTrap
TM 
FF column (GE Healthcare) and 
washed with 50 mM Tris HCl, 5mM reduced glutathione, 2mM DTT to remove loosely 
binding contaminants. The majority of the protease was eluted using 50 mM Tris HCl, 
15mM reduced glutathione, 5mM DTT followed by a second elution step of  50 mM Tris 
HCl, 35mM reduced glutathione, 5mM DTT to release remaining protease and recharge 
the column. 
The elution was diluted 1:5 using Buffer A (20 mM Tris pH 8.0, 2mM DTT) and 
bound to Biorad Macro-Prep HighQ cartridge at 2% Buffer B (Buffer B: 20 mM Tris pH 
8.0, 2mM DTT, 1M NaCl). Protease was eluted via a linear gradient from 20 mM to 100 
mM NaCl over 50 minutes. 
2.4.4. Peptide-Fusion Cleavage by Human Rhinovirus 3C and Separation from 
Fusion Partners 
  
Peptide-fusion and protease were incubated at 4°C for a 5-hour digestion period 
in a 1:25 protease to protein ratio. Reverse phase HPLC was carried out on the cleaved 
peptide-fusion samples to separate the peptide from the protein components. Cleaved 
peptide-fusion samples were filtered through 0.22 μm syringe filter and loaded onto a 
Waters Sunfire Prep C18 column (10x50 mm, 5μm, and 300Å). Separation of the peptide 
from fusion protein and contaminants was carried out by reverse phase HPLC on a 
Shimadzu HPLC system equipped with a SPD-20AV Prominence UV/Vis detector and  
LC-20AT Prominence liquid chromatograph. The mobile phase was 0.1% trifluoroacetic 
acid in water (Buffer A), with an elutant of 0.1% trifluoroacetic acid in acetonitrile 
(Buffer B). The column was developed with a three phase gradient consisting of a steep 
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change in organic (5-30% Buffer B over 2.5 minutes) for buffer component elution, a 
shallow step (30-45% Buffer B over 15 minutes) for peptide elution, followed by a steep 
gradient (45-100% Buffer B over 4 minutes) to regenerate the column and elute larger 
proteins such as thioredoxin and human rhinovirus 3C. Absorbance was monitored at 
214nm and 280 nm.  
2.4.5. Mass spectrometry 
To determine peptide molecular weight and degree of purity, peptide samples were 
analyzed using electrospray mass spectrometry. Lyophilized peptide samples were 
resuspended in water to a peptide concentration of 50 μM. 5 μl of sample was analyzed 
using an Esquire-LC electrospray ion trap mass spectrometer (Bruker Daltonics, Inc) set 
up
 
with an ESI source and positive ion polarity. This system was equipped with an 
HP1100 HPLC system (Hewlett Packard). Scanning was carried
 
out between 200 m/z and 
2000 m/z, and the final spectra obtained
 
were an average of 10 individual spectra. 
Equipment used was located at the Mass
 
Spectrometry Center of the University of 
Massachusetts Amherst.  
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CHAPTER III 
INHIBITION OF CASPASE-9 BY STABILIZED PEPTIDES TARGETING 
THE DIMERIZATION INTERFACE 
This chapter has been in collaboration with Sumana Ghosh. Sumana perfomed all of 
the solid phase peptide synthesis and structural characterization of the resultant 
peptides by circular dichroism spectroscopy. The author performed all other aspects 
of the work described here. 
 
Abstract 
 Caspases comprise a family of dimeric cysteine proteases that control apoptotic 
programmed cell death and are therefore critical in both organismal development and 
disease. Specific inhibition of individual caspases has been repeatedly attempted, but has 
not yet been attained. Caspase-9 is an upstream or initiator caspase that is regulated 
differently from all other caspases, as interaction with natural inhibitor XIAP-BIR3 
occurs at the dimer interface maintaining capsase-9 in an inactive monomeric state. One 
route to caspase-9-specific inhibition is to mimic this interaction, which has been 
localized to the α5 helix of XIAP-BIR3. We have developed three types of stabilized 
peptides derived from the α5 helix, using incorporation of amino-isobutyric acid, the 
avian pancreatic polypeptide-scaffold or aliphatic staples. The stabilized peptides are 
helical in solution and achieve up to 32 μM inhibition, indicating that this allosteric site at 
the caspase-9 dimerization interface is regulatable with low-molecular weight synthetic 
ligands and is thus a druggable site. The most potent peptides are the avian pancreatic 
polypeptide-scaffolded peptides. Given that all of the peptides attain helical structures but 
cannot recapitulate the high-affinity inhibition of the intact BIR3 domain, it has become 
clear that interactions of caspase-9 with the BIR3 exosite are essential for high-affinity 
binding. These results explain why the full XIAP-BIR3 domain is required for maximal 
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inhibition and suggest a path forward for achieving allosteric inhibition at the 
dimerization interface using peptides or small molecules. 
 3.1. Introduction 
 The apoptotic process of programmed cell death has been well studied for its 
involvement in development in all multi-cellular organisms as well as for its roles in 
conditions including cancer, heart attack, stroke, Alzheimer's and Huntington disease. 
Irregularities in apoptosis may contribute up to 50% of all diseases in which there are no 
suitable therapies
1
, underscoring the need to both understand and control apoptosis. 
One promising approach to controlling apoptosis is through caspase regulation. The 
caspases are cysteine aspartate proteases known to propagate apoptosis through a cascade 
of cleavage reactions ultimately leading to the demise of the cell.  Apoptotic caspases are 
typically classified into two groups, the initiator caspases, caspase-8 and -9, and the 
executioners, caspase-3, -6 and -7. Caspase-8 is activated in response to upstream signals, 
which are transmitted to caspase-8 by the DISC complex
2-4
 while caspase-9 is activated 
by association with the apoptosome
5-7
. Once activated, caspase-8 and -9 further propagate 
the apoptotic cascade by cleaving and thus activating the executioner caspases, caspase-3, 
-6, and -7
8-11
. The executioner caspases are responsible for cleaving specific intracellular 
targets, ultimately resulting in cell death. Due to its central role in initiating and 
propagating apoptosis and it’s unique regulatory mechanism12, we have focused on 
controlling the apoptosis initiator, caspase-9. 
 Caspase-9 is synthesized as this three-domain polypeptide, which is able to form 
homodimers. Structurally, caspase-9 consists of three domains. A prodomain, categorized 
as a Caspase Activation and Recruitment Domain (CARD), a large subunit, which houses 
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the catalytic Cys-His dyad, and the small subunit which comprises the main portion of 
the dimer interface 
13
. The zymogen caspase-9 has very low activity as a monomer. 
Activity increases upon dimerization
13
 and increases even more profoundly upon 
interaction with the apoptosome
5-7
. The apoptosome is a heptameric complex formed by 
Apaf-1 and cytochrome c in an ATP dependent process
10,14,15
. The uncleaved zymogen 
form of caspase-9 is recruited to the apoptosome by binding of its CARD domain to the 
Apaf-1 CARD domain. For many years the oligomeric state of caspase-9 bound to the 
apoptosome has been debated. Evidence is emerging from high-resolution cryo electron 
microscopy that caspase-9 monomers are activated while bound to the apoptosome
16
. 
Caspase-9 does not require intersubunit cleavage for activation. However, when bound to 
the apoptosome, caspase-9 is processed at Asp315, resulting in a CARD-large subunit 
portion of the enzyme and a small subunit beginning with the N-terminal sequence of 
ATPF. Proteolytic removal of the CARD domain from the large subunit, which results in 
decreased activity, has also been observed. Processed caspase-9 can be displaced from 
the apoptosome by additional molecules of procaspase-9
17
, resulting in release of cleaved 
caspase-9, which can form active dimers. As a cleaved dimer, the L2 loop from one half 
of the dimer is able to interact with the L2` loop from the other half in the presence of 
substrate similar to other caspases
13
. In this state, the protein is catalytically competent to 
process substrate. Like other caspases, caspase-9 recognizes its substrates and cleaves 
after specific aspartic acid residues. 
 Once the caspase cascade is activated, apoptosis rapidly ensues. Treating diseases 
in which apoptosis is activated requires specific apoptotic caspase inhibitors. A naturally 
occurring family of caspase inhibitors, the inhibitor of apoptosis (IAP) proteins, show 
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promise as models for caspase-specific inhibition. Caspase-9 is inhibited by the x-linked 
inhibitor of apoptosis protein (XIAP) in a manner that is distinct from the inhibition of 
other apoptotic caspases, including caspase-3 and -7. XIAP comprises three baculovirus 
inhibitory repeats (BIR). The linker between BIR1 and BIR2 binds to the active sites of 
caspase-3 and -7 dimers, blocking access to substrate and thereby inhibiting these 
caspases. The third domain of XIAP, BIR3, docks at the dimer interface of caspase-9 
holding capase-9 in an inactive monomeric state. The most critical interactions occur 
between the α5 helix in BIR3 and the 8 strand of caspase-9 (Fig 3.1 A). In addition, the 
N-terminus of the caspase-9 small subunit binds to an exosite on the BIR3 domain. 
Critical interactions within these two regions of the BIR3 domain have been highlighted 
as essential for BIR3’s interactions with caspase-9 (Fig 3.1 B) and its inhibitory 
properties
12
. Many of these interactions are hydrogen bonds and salt bridges between the 
α5 helix of BIR3 and caspase-9, often BIR3 side chains interacting with caspase-9 
backbone atoms. In addition, some hydrophobic interactions are critical. For example, 
mutations of both polar H343 and hydrophobic L344 in the α5 helix of BIR3 result in a 
complete loss of its inhibitory properties
12,18
. Substitution of these two residues, within 
similar but non-functional IAP’s, such as cIAP1 and ML-IAP, restored caspase-9 
inhibition enforcing the idea of the α5 helix as a main component in the BIR3 inhibitory 
mechanism
19,20
. Another region of BIR, comprised of the amino acid sequence WYPG 
(residues 323 to 326), also improved the inhibitory properties when substituted in other 
IAP’s, suggesting that this region is also important for the interaction.  Although these 
key regions are localized to the first three helices of BIR3, truncation of BIR3’s N-
terminal residues 245-261 resulted in an extremely unstable protein with low potency for 
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caspase-9 inhibition
21
. Additionally, the C-terminal truncation, BIR3 residues 348-356 
had no affect on protein stability. Potency for caspsae-9 was increased only in the 
presence of the N-terminal region indicating that stabilization of the C-terminal region of 
BIR3 is required for its inhibitory properties against caspase-9
21
. We hypothesize that this 
unique mechanism of BIR3 inhibition of caspase-9 may enable development of caspase-9 
specific inhibitors if the α5 helix can be sufficiently stabilized.  
 
Figure 3.1 Interactions required for inhibition of caspase-9 are clustered in the 5 helix. (A) Structure 
of a caspase-9 monomer (purple) bound to XIAP-BIR3 (blue) observed in 1NW9 (upper panel). A 
structural zinc (red sphere) is observed in XIAP-BIR3.  The exosite is marked with a circle. The boxed 
region is highlighted in the lower panel. Hydrogen bonds (black dotted lines) between caspase-9 
monomer and the 5 helix from XIAP-BIR3 provide recognition specificity to the complex. These 
interactions are recapitulated in the native peptides. (B) Specific interactions observed in the structure 
of caspase-9 bound to XIAP-BIR3 and those present in the three classes of designs are listed. 
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 To date, the vast majority of work towards caspase-specific inhibition has focused 
on creating small-molecule and peptide-based active-site inhibitors.  Achieving 
specificity at the active site has been difficult because all caspases have a stringent 
requirement for binding aspartic acids in the S1 pocket. This means that both apoptotic 
and inflammatory caspases are subject to inhibition by very similar inhibitors. Most 
caspase inhibitors have consisted of a peptide or peptidomimetic with an acid 
functionality to bind in the S1 pocket of the active site and some kind of cysteine-reactive 
warhead. Utilizing the BIR3 mechanism of inhibition is promising in that it is unique to 
caspase-9 and should avoid inhibition of other caspases.  In this work we have developed 
peptide-based inhibitors that mimic BIR3 inhibition of caspase-9. 
 Peptide mimics as surrogates for large protein-protein interactions have been 
extensively pursued. In one early example, an entire interface of the vascular endothelial 
growth factor was reduced to a 20-amino acid peptide which could then be optimized via 
phage display to achieve the needed binding affinity
22
. The atrial natriuretic peptide was 
similarly minimized to half the original size using rational design and phage display and 
still bound
23. Some proteins, like the β-adrenergic receptor, can be controlled with small, 
unstructured peptides in which the principal requirement for binding is an available 
amine.  On the other hand, successful mimics of the vast majority of protein-protein 
interactions attempted to date have required a structured peptide to mimic the native 
protein interactions. Thus a number of approaches have been developed to stabilize 
fragments of proteins in their native structure. For helices the prominent methods are to 
initiate or stabilize helix formation or use small scaffolding proteins. Some approaches 
have targeted naturally occurring capping motifs or side-chain cross-linking methods 
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such as disulfide bonds, lactam bridges and metal mediated bridges
24-33
. Main chain 
conformational restrictions using unnatural α-methylated amino acids, such as 
aminoisobutyric acid (Aib), have also been explored.  The placement of Aib in peptides 
restricts the conformations of the peptide bonds, promoting proper torsion angles for α-
helical formation
34
. More recently, all hydrocarbon cross-linking side chains, sometimes 
called peptide staples have been introduced to maintain helical conformations of small 
peptides
35
. These hydrocarbon staples have been shown to improve helicity as well as cell 
permeability of peptides derived from a BID BH3 helix
36
, the NOTCH transcription 
factor complex
37
, and a p53 helix
38. In this ‘stapling’ method, unnatural α-methylated 
amino acids containing olefinic side-chains of the appropriate length, are placed at the i 
and i+4 or i and i+7 positions of the helix to be stabilized. These positions are selected 
because one turn of an α-helix is 3.6 residues in length thus the staples would span one or 
two turns of the helix.  Cyclization of these amino acids is performed through an olefin 
metathesis reaction, facilitated by Grubbs catalyst, thus locking the amino acids into a 
staple formation reinforcing nucleation of the α-helix39. Others have enforced main-chain 
interactions through hydrogen bond surrogates which places a covalent link between the 
backbone of the i and i+4 positions utilizing a similar olefin metathesis reaction
40
. An 
orthogonal approach utilizing stabilized scaffolds called miniature proteins has also 
proven useful in helix stabilization
41,42
. The critical amino acids for the protein-protein 
interface are grafted onto a stable helical scaffold in the appropriate register to obtain the 
proper amino acid orientation for the interaction. For example, the scaffold of avian 
pancreatic polypeptide (aPP) has been used to design Bcl-2 based inhibitors
43
, p53-hDM2 
interaction inhibitors
44
, herpes virus protease dimer disrupters
45
, as well as mimicking 
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protein-DNA interactions
46-48
. More recently, Peptide YY has also been used as a 
miniature protein scaffold
42
. 
 Upon analysis of the caspase-9/BIR3 complex and by understanding the successes 
of stabilized helices, our approach to caspase-9 inhibition is two-fold.  First, we aim to 
investigate which regions of the α5 helix of BIR3 are essential to achieve BIR3-like 
inhibition. Secondly, we aim to utilize the α5 helix region of BIR3 in order to achieve 
caspase-9 inhibition via small α-helical peptides42.  
3.2. Results 
 To achieve inhibition of caspase-9 utilizing the interactions observed between the 
BIR3 α5 helix and the caspase-9 8 strand (Fig 3.1A), we predicted that some type of 
helix stabilization or helical scaffold would be required. We have designed and 
synthesized three different classes of α5-stabilized peptides and tested them for their 
ability to inhibit caspase-9. These three classes: native and Aib-stabilized, aPP-
scaffolded, and aliphatic stapled peptides take three entirely different approaches to helix 
stabilization, but each of them recapitulates the most important interactions from the α5 
helix (Fig 3.1 B). The stabilized peptides are markedly more helical and are better 
inhibitors than the analogous native, non-stabilized peptides.  
3.2.1. Native and Aib-Stabilized Peptides 
 Our first approach was to isolate native sequences from the BIR3 α5 helix (Fig 
3.1 A, 3.2).  In some sequences, aminoisobutyric acid (Aib) was inserted at various 
positions to stabilize the helical conformation of the peptide. Aib is an α-branched amino 
acid analogous to the naturally-occurring amino acid alanine, but derivatized at the α- 
carbon with two equivalent methyl groups. The presence of two methyl groups on the α-
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carbon locks adjacent 
peptide bonds into the α-
helical confirmation which 
supports the desired 
dihedral angles, and thus 
has been widely used to 
stabilize helical 
peptides
34,49-51
. We 
designed peptides ranging from 11 to 35 amino acids in length. The longest, 
Peptide 1, composed of BIR3 residues 315-350, was designed to contain the α3-α5 
helices. The α3 helix forms part of the exosite; the 4 helix orients the WYPG region and 
the α5 helix contains the major elements for recognition of caspase-9. Peptides 2-4 are 
21-25 amino acids long and contain all of the core interactions from α3, α4 and α5 
helices. Peptide 9 is similar to Peptide 2 but is stabilized in four non-interacting positions 
by Aib. Peptide 5 is 11 residues long and derived directly from the α5 helix. In Peptide 6 
we added helix capping residues at the N- and C-termini. Peptides 7 and 8 are stabilized 
at non-interacting position by Aib. The circular dichroism (CD) spectra suggested that the 
native peptides were less helical than the Aib-stabilized peptides (Fig 3.3), predicting that 
the Aib-containing peptides were closer to their target structures than the peptides 
constructed solely from native amino acids derived directly from BIR3.  
 Caspase-9 is most active prior to catalytic removal of the 16 kD caspase 
activation and recruitment domain (CARD). The CARD domain is responsible for 
associating caspase-9 with the apoptosome. However, in the absence of the apoptosome, 
 
Figure 3.2 Sequences of the α5 region of XIAP-BIR3 (BIR3) and 
peptides 1-9. * represents aminoisobutyric acid (Aib) 
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the location of the CARD 
domain remains 
uncharacterized. 
 Due to the size of 
the CARD and its ability to 
enhance caspase-9’s basal 
catalytic activity through an as yet unknown mechanism, we reasoned that the peptide 
inhibitors may show a preference for interaction with either full-length caspase-9 (C9FL: 
containing the CARD, large and small subunits) due to positive interactions with the 
CARD or a preference for 
ΔN caspase-9 (C9ΔN: 
containing only the large 
and small subunits) due to 
negative interactions with 
the CARD. Finding no 
difference in the ability of 
the inhibitors to influence 
full-length or ΔN caspase-9 
would suggest that the 
peptides do not interact in 
any way with CARD. We 
tested both C9FL (Fig 3.4 
A) and C9ΔN (Fig 3.4 B) 
 
Figure 3.3 Circular dichroism spectra of the native Peptide 5 and 
the Aib-stabilized Peptide 8. These spectra demonstrate that the 
presence of Aib increases the helicity of the peptides. 
 
Figure 3.4 Native and Aib-stabilized peptides show some 
inhibition of caspase-9 activity. Peptides (1-9) exhibit some 
inhibition of (A) full-length caspase-9 (C9 FL) or  (B) the N-
terminal CARD-domain deleted caspase-9 (C9 N) activity to 
cleave a natural caspase-9 substrate, the caspase-7 zymogen (C7 
C186A)  to the caspase-7 large (C7 Lg) and small (C7 Sm) 
subunits in an in vitro cleavage assay monitored by gel mobility. 
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in an in vitro gel-based caspase-9 assay, which monitors cleavage of caspase-7 (substrate) 
(Fig 3.4, Table 3.1) and in a fluorescent peptide cleavage assay in which we observed no 
difference between the two enzymes (Table 3.1). Peptide concentrations were calculated 
by absorbance at 280 nm or by using densitometry measurements on the purified peptides 
analyzed by SDS-PAGE. Although it is difficult to quantify peptides in this manner, we 
have confirmed that the error in the determination of peptide concentrations is no more 
than 2-fold. 
  For peptides in this study an apparent IC50 (IC50 app) was fit from an inhibitor 
titration at a fixed substrate concentration. This was compared to the amount of inhibition 
observed in a gel-based assay where the peptide concentration was fixed at 66.7 μM, a 
concentration in excess of the best IC50 app observed (Table 3.1). The full BIR3 domain, 
with a reported Ki of 10-20 nM (18, 20, 52) is an effective inhibitor in both the 
fluorescence assay, which uses a small fluorogenic peptide substrate mimic and in the gel 
based assay, which uses a natural substrate. In both activity assay formats, we observed 
moderate inhibition by many of the peptides. Other investigators have traditionally relied 
on gel-based assays to assess caspase-9 inhibition and activation. This is likely due to the 
greater reproducibly and lowered requirements for peptide consumption in the gel-based 
assay, which we have also observed. The inhibition that we observe in the two assays 
formats, agrees qualitatively for the peptides we have tested. All of the native and Aib- 
stabilized peptides showed an IC50 app of >100 μM.  
 Peptide 2 routinely activated caspase-9 in samples of aged peptide (incubated for 
three weeks at 4°C). Initially we were intrigued by the ability of aged Peptide 2 to 
activate caspase-9. We confirmed that samples of aged Peptide 2 were of the same 
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Table 1: Overall Inhibition of Caspase-9 Full Length by Peptides 
Peptide % Inhibitiona IC50 app
b
   
  (66.7 μM peptide) (μM) 
1 0 >100 
2 0 >100 
3 0 >100 
4 1.1 ± 2.4 >100 
5 0.45 ± 1.1 >100 
6 0 >100 
7 6.3 ± 11 >100 
8 13 ± 16 >100 
9 15 ± 14 >100 
10 n.d.  64 ± 13 
11 24 ± 13 32 ± 11 
12 8 ± 11 >50   
13 0 >100 
14 13 ± 7.1 50 ± 3.8 
15 0 >100 
16 6.2 ± 2.6 >100 
17 22 ± 23 50 ± 5.1 
18 17 ± 9.6 >100 
19 24 ± 8.4 80 ± 4.8 
20 2.2 ± 1.2 >100 
21 2.9 ± 3 >100 
22 0 >100 
23 0 >100 
24 1.8 ± 2.6 >100 
25 2.5 ± 3.5 >100 
26 8.9 ± 12 >100 
27 0 > 100 
28 0 >100 
a
 Proteolytic cleavage gel-based caspase-9 activity assay which monitors cleavage of 
natural substrate, caspase-7. Percent inhibition was calculated using Gene Tools 
(SynGene by producing a standard curve from densiometry values for processed and 
unprocessed substrate, (caspase-7 C186A). 
b
 Fluorescence-based caspase-9 activity assays which monitor cleavage of fluorogenic 
substrate (LEHD-AFC). 
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molecular weight as the 
freshly diluted Peptide 2 
immediately following 
synthesis, confirming that 
there were no chemical 
modifications upon aging 
(Fig 3.5 A). Freshly 
diluted Peptide 2 samples 
were incapable of 
activation, whereas the 
incubated peptides were 
(Fig 3.5 B). Although 
aged Peptide 2 samples were capable of activating caspase-9 four-fold over basal rates of 
hydrolysis of the fluorogenic LEHD-AFC peptide, they were similarly capable of 
activating other caspases, including caspase-7 (Fig 3.5 C). Caspase active sites are highly 
mobile and are thus responsive to molecular crowding agents, including polymers like 
polyethylene glycol (PEG)
52
. The type of activation from aged Peptide 2 is similar to that 
observed by PEG 8000 (Fig 3.5 C), suggesting that aggregation occurring over a three-
week aging process at 4°C was responsible for this level of activation.  
3.2.2. aPP-Scaffolded Peptides 
 Our second approach for developing stabilized α5 helices used the avian 
pancreatic polypeptide (aPP) scaffold (Fig 3.6). aPP is a 36-amino acid peptide derived 
from the pancreas of turkey. Its native role is in the feedback inhibition loop halting 
 
Figure 3.5 Peptide 2 non-specifically activates caspase-9. (A) Peptide 
2 (MW 3118) is chemically stable even after a 3-week, 4˚C 
incubation. (B) Aged peptide 2 activates caspase-9 activity (C) 3-week 
aged peptide non-specifically activates both caspase-9 and caspase-7 
in a manner similar to the polymeric crowding agent PEG 8,000 
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pancreatic secretion after a meal (reviewed in
53
). In the crystal structure, aPP is composed 
of a standard alpha helix flanked by a polyproline helix (Fig 3.6 A)
54,55
. The interaction 
between these two helices provides stability for the folded conformation. 
aPP is amenable to substitution on many faces
41,48
 and can withstand a C-terminal 
truncation
55
 without negatively effecting the structure or function. α5-mimicing peptides 
were designed by structurally aligning the α-helical region of aPP with the α5 helix in the 
BIR3-Caspase-9 complex. aPP was aligned principally by superposition of the Cα 
positions and tested for maximum overlap in all possible helical registers. We ultimately 
selected one register (Fig 3.2, 3.6 A) because it maximized overlap of productive 
interactions between naturally-occurring aPP amino acids and caspase-9, such as the 
WYPG amino acid region which was found to be critical in converting other IAP’s to 
inhibit caspase-9
19,20,45
. In addition this orientation predicts no steric clashes between the 
 
Figure 3.6 BIR3 interactions grafted onto stabilized miniature protein aPP. (A) Modeled interactions of 
designed peptides based on an aPP scaffold (yellow) were designed to mimic the interactions between 
caspase-9 (purple) and the 5 helix. The polyproline helix labeled in the upper panel, has been removed 
from the lower panel for clarity. (B) Sequences of native BIR3, derivative Peptides 10-26 and native aPP, 
in which critical residues from the 5 region of XIAP-BIR3 have been inserted into the aPP scaffold. 
Highly varied positions are shaded. 
 
  68 
aPP N-terminus, the polyproline helix, and caspase-9. Ultimately we chose to truncate 
aPP to prevent steric clash between the aPP C-terminus and caspase-9. To make Peptide 
10, we grafted the critical BIR3 residues 323-6, 336-7 and 340-4 onto aPP at positions 
17-18 and 21-25 (Fig 3.6 B). We also grafted residues 323-326, which compose the 
sequence WYPG between the α3 and α4 helices of BIR3, at positions 6-9 of aPP. aPP 
positions 6-9 are in the polyproline helix and are designed to support the interactions of 
the WYPG region of BIR3 with caspase-9. In Peptides 11-14, we varied the identity of 
position 11 to enable novel interactions with the loop region in caspase-9 and changed all 
of the aspartates to glutamates. Caspases cleave exclusively following aspartate residues, 
so substitution of these residues was designed to limit their caspase substrate 
characteristic. In Peptides 15-18, the aspartates were substituted by asparagines to 
prevent caspase cleavage and position 11 was varied to introduce novel interactions. In 
Peptides 19-26, we systematically returned positions that had previously been shown to 
be important for the fold and stability of aPP to the identity in the native aPP sequence. 
To produce this series of caspase-9 inhibitors, Peptides 10-26, we developed a novel 
expression system that allowed robust production and purification of aPP-based 
peptides
56
. The mass spectra of peptides 10-26 indicated that each of these peptides are 
produced accurately in bacteria and that the peptides could be purified to a very 
homogenous state using our methodology
56
. The conformation of these truncated 
versions of aPP were predicted by Rosetta
57,58
 to fold into a helical structure (Fig 3.7). In 
all of our aPP scaffolded designs, additional interactions are created between Y7, D10 
and D11 of aPP’s polyproline helix and the caspase-9 interface. Neither truncation of aPP 
nor the insertion of the α5-derived residues appears to have a substantial effect on the 
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structure of aPP-derived peptides as the CD spectra of the designed peptides show the 
same conformation as the aPP parent (Fig 3.8 A). All spectra indicate that these peptides 
are mainly composed of polyproline helix character with a negative peak at 198-206 
nm
59,60
 and a predicted 5% of α-helical content61. Although these data suggest that the 
aPP peptides fold into a less helical conformation that the target helical conformation of 
the scaffold, the aPP-based peptides were still tested for their ability to inhibit full-length 
Figure 3.8 Properties of aPP based peptides. (A) The CD spectra of the aPP and Peptides 11 and 25 
indicate that the structure of the designed peptides is very similar to that of native aPP in solution. (B) 
aPP-based peptides show some inhibition of full-length caspase-9 (C9 FL) or the N-terminal CARD-
domain deleted caspase-9 (C9 N) to cleave a natural caspase-9 substrate, the caspase-7 zymogen (C7 
C186A) to the caspase-7 large (C7 Lg) and small (C7 Sm) subunits in an in vitro cleavage assay 
monitored by gel mobility. 
 
 
Figure 3.7 aPP and peptide structures predicted computationally (black) by Rosetta. Predicted structures 
are superimposed on the known structure of aPP (gray). RMSD for backbone atoms suggests the 
majority of the designed aPP-based peptides should adopt a helical conformation in aqueous solution. 
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and N caspase-9 in the gel based (Fig 3.8 B) and fluorescent peptide cleavage assays 
(Table 3.1). Of this class, the best inhibitors were peptides 10, 11, 14, 17 and 19 with  
IC50 app of 64, 32, 50, 50 and 80 M respectively. The majority of the aPP-based peptides 
had IC50 app greater than 100 M. Our four best peptides 10, 11, 14, and 17 each contain 
all of the interacting residues that make up the BIR3 interface while Peptide 19 
incorporates those residues important for the stability of the aPP scaffold. Exclusion of 
any of the critical BIR3 residues appears to be unfavorable for the peptides inhibitory 
properties based on our findings considering Peptide 19 could potentially pose as an 
active site competitor with three aspartate groups at positions ten, eleven and sixteen. 
Peptides 11, 14 and 17 are devoid of aspartate residues, which decreases the propensity of 
the peptides to interact with the caspase-9 substrate binding groove and thus increases the 
probability of interaction with the caspase-9 dimer interface. Interestingly, the only 
difference between peptides 10 and 11 is the substitution of three aspartates present in 
peptide 10 for three glutamates. Thus the improved potency of Peptide 11 over Peptide 
10 could be related to differences in caspase-9-mediated cleavage. In addition, position 
eleven on the scaffold in Peptide 11, 14, and 17 contains a glutamate, arginine or lysine, 
respectively, at residue 11. These residues were designed to form an additional salt bridge 
with the caspase-9 interface (not present in the native BIR3 domain) thus enhancing their 
ability to inhibit caspase-9 activity. This appears to have been successful as these 
peptides have the best inhibition properties. Interestingly, the addition of a glutamine at 
position 11 did not show any favorable effects on the inhibitory properties of the 
peptides, suggesting that glutamate, arginine, and lysine can form specific interactions 
that are not possible for glutamine.  
  71 
3.2.3. Aliphatic Stapled Peptides   
 The third 
approach to achieve 
caspase-9 allosteric 
inhibition at the 
dimer interface was 
to incorporate 
aliphatic staples to 
stabilize short 
helices derived 
directly from the α5 
helix in BIR3 (Fig 
3.9A). Aliphatic 
staples have been 
used successfully to stabilize helices and increase cell permeability of the peptides in 
which they are incorporated
36,62
. To synthesize the stapled peptides, we adapted the 
synthetic route reported by Seebach et.al
63-65
 to synthesize three unnatural Fmoc-
protected amino acids used in the stapling reactions (Fig 3.9B). In this synthetic approach 
we used a mild organic base, potassium trimethyl-silanolate that could perform both the 
CBz deprotection and five-membered ring opening reactions in a single step to obtain the 
final α-α-disubstituted amino acids. This method is less hazardous than traditional two-
step methods
35,66
, which require the use of sodium in liquid ammonia for hydrogenolysis 
of the five-membered ring, followed by a reaction with TFA to deprotect the Boc group  
 
Figure 3.9 Aliphatic stapled peptide design. (A) Modeled interactions of α5-
derived peptides stabilized by aliphatic staples (green) with caspase-9 
(purple). (B) Synthetic route for production of the pentyl alanine amino acid 
used to generate the aliphatic peptide staples 
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to obtain α-α-disubstituted amino 
acids. Our adapted method produced 
the non-native amino acids at yields 
comparable to the traditional 
published routes generally used to 
obtain the unnatural amino acids used 
in peptide stapling. We focused on 
two pairs of stapling peptides. 
Peptide 27 is 11 amino acids long and 
composed of residues 336 to 345 
from the α5 helix of BIR3. In peptide 
27 amino acids Y338 and I342 from 
BIR3, which point away from the 
caspase-9 dimer interface, were both 
replaced by S-2-(4’pentyl)alanine (Fig 3.10A). Catalysis of the ring closing metathesis 
forms an 8–carbon alkyl macrocyclic cross-link (Fig 3.10B). Peptide 28 is composed of 
an N-terminal threonine for helix capping of BIR3 residues 336-348. In Peptide 28 BIR3 
residues Y338 and T345 were replaced by R-2-(4’pentyl) alanine and S-2-
(4’octyl)alanine respectively. Threonine was added to the N-terminus of Peptide 28 
because it has a higher helix capping propensity than the native residue, glycine 
(reviewed in
67
). The C-terminus was likewise extended because of the improved helical 
propensity of the residues SLE (reviewed in
67
).  Ring closing metathesis results in an 11-
 
Figure 3.10 Properties of aliphatically stapled peptides. 
(A) Sequences of BIR3 and stapled Peptides 27 and 28. 
x, y and z represent the synthetic, non-native amino 
acids as listed. (B) Ring-closing metathesis reaction 
performed on the unstapled Peptide 27 to form the 
aliphatic stapled Peptide 27 with an 8-carbon 
macrocyclic linker. The structure of aliphatically 
stapled Peptide 28 contains an 11-carbon macrocyclic 
linker 
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carbon aliphatic linker (Fig 3.10B) which has been shown to be the optimal staple for i to 
i+7 stapling
35
. As predicted, both peptides appeared to be substantially more helical in 
aqueous solution following the ring closing metathesis reaction to generate the aliphatic 
staple than prior to closure of the staple (Fig 3.11A). Thus in both cases we can conclude 
that the peptides attain the designed helical structure.  The stapled peptides were both 
tested against caspase-9 full-length or ΔN caspase-9 (Fig 3.11B), but did not show strong 
inhibition at concentrations below 100 μM in either assay format on either caspase-9 
construct.  
3.3. Discussion  
 All three classes of peptides are capable of attaining helical structures to present 
the appropriate amino acids to the caspase-9 dimer interface. The length and the type of 
scaffold did appear to have a tremendous influence on the potency of the peptides. The 
aPP-scaffolded peptides were more successful than the native, Aib-stabilized or stapled 
peptides. Our data suggest peptides composed of 15 amino acids or less in length such as  
 
Figure 3.11 Analysis of aliphatic stapled peptides. (A) The CD spectra of Peptides 27 and 28 indicate a 
significant increase in the helicity following the formation of the aliphatic staple. (B) Stapled Peptides 
27 and 28 show some inhibition of full-length caspase-9 (C9 FL) or the N-terminal CARD-domain 
deleted caspase-9 (C9 ΔN) to cleave a natural caspase-9 substrate, the caspase-7 zymogen (C7 C186A) 
to the caspase-7 large (C7 Lg) and small (C7 Sm) subunits in an in vitro cleavage assay monitored by 
gel mobility. 
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Peptides 5-8 of the native and Aib stabilized class or Peptides 27-28 of the stapled 
peptides may be too short to have the requisite interaction for high-affinity binding to 
caspase-9. Models of these small peptides bound to caspase-9 bury 900Å
2
 of surface area 
in contrast to the 1700Å
2
 for models of the aPP-scaffolded peptides and the 2200Å
2
 
interface found in the native BIR3-caspase-9 complex. It is possible that other non-
critical residues found in the large interface potentially provide a hydrophobic interaction, 
which may be lacking in the short peptide sequences, thus decreasing their ability to 
efficiently inhibit caspase-9.  
 Peptides ranging in length from 11 to 39 amino acids have achieved high affinity 
binding utilizing the various stabilizing methods we have employed here
37,38,44-47,68-70
. An 
efficient peptide inhibitor of the hdm2–p53 interaction was shown to improve potency 
based on additional helical constraints imposed by Aib where incorporation of four Aib 
residues into a 12 amino acid peptide was required
68
. Our peptides utilized two Aib 
residues for an 11 amino acid stretch, so perhaps a greater number of Aib residues could 
further improve binding properties. The aPP-scaffolded Kaposi’s sarcoma-associated 
herpesvirus protease (KSHV Pr) inhibiting peptide, which was 30 amino acids long, was 
also designed with a five amino acid C-terminal truncation and altered ten amino acids 
within the α-helical region of aPP. This peptide was successful at disruption of 
dimerization, however it required 200-fold molar excess of peptide in order to obtain 
50% inhibition of protease activity
45
. Our best peptides were at least as effective. We 
observe 50% inhibition with an average of ~30-fold molar excess peptide. Additionally, a 
13 amino acid stapled peptide co-activator mimic of the estrogen receptor was able to 
achieve high affinity binding. The authors noted however, that in these short peptides, the 
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hydrocarbon staple can alter the binding geometry via its ability to interact with 
hydrophobic interfaces thus perturbing the desired interactions required for inhibition
70
. 
Thus, although our peptides were not as potent as the parent BIR3 domain, they are of 
similar efficacy as other stabilized peptides. Most importantly, these peptides 
demonstrate that the dimerization interface of caspase-9 can be targeted by small-
molecular weight inhibitors, indicating that this is indeed a druggable site. 
 Based on spectroscopic data, it is clear that all three classes of peptides we 
designed and synthesized have been stabilized in a helical conformation by incorporation 
of Aib, aliphatic staples or by the aPP scaffold. Despite the measured helicity, we have 
not been able to recapitulate the 10-20 nM interaction of BIR3 with caspase-9
18,20,71
. 
Consideration of critical residues, additional interface interactions, scaffold requirements, 
and fold led to production of some peptide inhibitors of caspase-9 in the micromolar 
range. The most potent inhibitors were all members of the aPP scaffolded class of 
peptides. This class provided the secondary structural requirements needed to mimic the 
α5 helix interactions, provided the additional interactions of the WYPG region of BIR3 
as well as providing a larger surface area coverage, which the other peptide classes lack. 
Although native and Aib-stabilized Peptides 1-9 and the stapled Peptides 27-28 contain 
all of the critical contacts for interacting with caspase-9 through the α5 helix and were 
helical in solution, they were still not highly potent inhibitors. This suggests that the α5 
helix alone is not sufficient for full inhibition of the intact BIR3 domain even when it is 
presented in a stable, helical structure. This observation further suggests that the exosite 
of BIR3 (composed of residues 306-314) which binds the N-termini of the small subunit 
of caspase-9 provides additional, mainly hydrophobic interactions, required for high 
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affinity inhibition (Fig 3.12 A,B). Prior reports suggested that lack of stability explained 
the inability of truncations of the BIR3 domain to inhibit caspase-9
21
. Together our data 
on stabilized α5 helices provide a model for why full length BIR3 is required for the 
interaction. Although the α5 helix has been shown to contain the most critical residues for 
recognizing caspase-9, the BIR3 exosite also appears to be essential. The BIR3 exosite is 
composed of residues 306-314. These residues do not fold into any regular element of 
secondary structure, but exist in an ordered loop. This loop is held in the appropriate 
conformation from behind by two other loops from the 270s and 290s region of BIR3 
(Fig 3.12 B). Furthermore, this region is stabilized via the N-terminal loop of BIR3 
indicating the lack of this region leaves the exosite residues unordered. The exosite must 
 
Figure 3.12 Full-length BIR3 is required for high-affinity caspase-9 inhibition. (A) Sequence of BIR3 
and regions of BIR3 contained in the caspase-9 inhibitory peptides. (B) Interactions of caspase-9 
monomer (purple) small subunit N-terminus (L2’ loop) with BIR3 (blue) exosite residues, which are 
contained within the box. 
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interact with the very flexible N-terminus of the caspase-9 small subunit also called the 
L2’ loop. Because the exosite region does not adopt any regular secondary structure it is 
difficult to envision how to recapitulate the high-affinity BIR3:caspase-9 interaction with 
any smaller, contiguous region of BIR3. Thus, we now understand why full-length BIR3 
is required for full-potency inhibition of caspase-9 via the dimer interface. Furthermore, 
these studies provide a roadmap for design of future BIR3-like small-molecule or peptide 
inhibitors. High potency inhibitors that block caspase-9 inhibition by a BIR3-type 
mechanism must necessarily encompass all the critical interactions in the exosite as well 
those in the α5 helix. 
3.4. Materials and Methods 
3.4.1. Caspase-9 Expression and Purification 
 The caspase-9 full-length gene (human sequence) construct in pET23b (Addgene 
plasmid 11829
72
) was transformed into the BL21 (DE3) T7 Express strain of E. coli 
(NEB). The cultures were grown in 2xYT media with ampicillin (100 mg/L, Sigma-
Aldrich) at 37°C until they reached an optical density of 1.2. The temperature was 
reduced to 15°C and cells were induced with 1 mM IPTG (Anatrace) to express soluble 
6xHis-tagged protein.  Cells were harvested after 3 hrs to obtain single site processing. 
Cell pellets stored at -20°C were freeze-thawed and lysed in a microfluidizer 
(Microfluidics, Inc.) in 50 mM sodium phosphate pH 8.0, 300 mM NaCl, 2 mM 
imidazole. Lysed cells were centrifuged at 17K rpm to remove cellular debris. The 
filtered supernatant was loaded onto a 5 ml HiTrap Ni-affinity column (GE Healthcare). 
The column was washed with 50mM sodium phosphate pH 8.0, 300 mM NaCl, 2 mM 
imidazole until base lined. The protein was eluted using a 2-100mM imidazole gradient 
  78 
over the course of 270 mL.  The eluted fractions containing protein of the expected 
molecular weight and composition were diluted by 10-fold into 20 mM Tris pH 8.5, 10 
mM DTT buffer to reduce the salt concentration. This protein sample was loaded onto a 5 
ml Macro-Prep High Q column (Bio-Rad Laboratories, Inc.). The column was developed 
with a linear NaCl gradient and eluted in 20 mM Tris pH 8.5, 100 mM NaCl, and 10 mM 
DTT buffer. The eluted protein was stored in -80°C in the above buffer conditions. The 
identity of the purified caspase-9 was analyzed by SDS-PAGE and ESI-MS to confirm 
mass and purity. 
 Caspase-9ΔCARD was expressed from a two plasmid expression system52,73,74. 
Two separate constructs, one encoding the large subunit, residues 140-305 and the other 
encoding the small subunit, residues 331-416, both in the pRSET plasmid, were 
separately transformed into the BL21 (DE3) T7 Express strain of E. coli (NEB).  The 
recombinant large and small subunits were individually expressed as inclusion bodies. 
Cultures were grown in 2xYT media with ampicillin (100 mg/L, Sigma-Aldrich) at 37°C 
until they reached an optical density of 0.6. Protein expression was induced with 0.2mM 
IPTG. Cells were harvested after 3 hrs at 37°C. Cell pellets stored at -20°C were freeze-
thawed and lysed in a microfluidizer (Microfluidics, Inc.) in 10mM Tris pH 8.0 and 1mM 
EDTA. Inclusion body pellets were washed twice in 100mM Tris pH 8.0, 1mM EDTA, 
0.5M NaCl, 2% Triton, and 1M urea, twice in 100mM Tris pH 8.0, 1mM EDTA and 
finally resuspended in 6M guanidine hydrochloride. Caspase-9 large and small subunit 
proteins in guanidine hydrochloride were combined in a ratio of 1:2, large:small subunits, 
and rapidly diluted dropwise into refolding buffer composed of 100mM Tris pH 8.0, 10% 
sucrose,0.1% CHAPS, 0.15M NaCl, and 10mM DTT, allowed to stir for one hour at 
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room temperature and then dialyzed four times against 10mM Tris pH 8.5, 10mM DTT, 
and 0.1mM EDTA buffer at 4°C.  The dialyzed protein was spun for 15 minutes at 
10,000rpm to remove precipitate and then purified using a HiTrap Q HP ion exchange 
column (GE Healthcare) with a linear gradient from 0 to 250mM NaCl in 20 mM Tris 
buffer pH 8.5, with 10 mM DTT. Protein eluted in 20 mM Tris pH 8.5, 100 mM NaCl, 
and 10 mM DTT buffer was stored in -80°C. The identity of the purified caspase-
9ΔCARD was analyzed by SDS-PAGE and ESI-MS to confirm mass and purity. 
3.4.2. Caspase-7 WT and Caspase-7 C186A Expression and Purification 
 The caspase-7 full-length human gene in the pET23b vector or the caspase-7 
C186A variant (zymogen), made by Quikchange mutagenesis (Stratagene) of the human 
caspase-7 gene in pET23b (gift of Guy Salvesen
72
) were transformed into BL21 (DE3) 
T7 Express strain of E. Coli.  Induction of caspase-7 was at 18°C for 18 hrs. These 
proteins were purified as described previously for caspase-7
75
.  The eluted proteins were 
stored in -80°C in the buffer in which they were eluted. The identity of purified caspase-7 
was assessed by SDS-PAGE and ESI-MS to confirm mass and purity.  
3.4.3. Peptide Production 
 Peptides 1-9 were synthetically produced by New England Peptide (Gardner, 
MA). The aPP scaffolded peptides 10-26 were designed and purified using methods 
previously described
56
. Unnatural amino acids for Peptides 27-28 were synthesized by the 
following reactions: 
3.4.3.1. Synthesis of N-Fmoc-S-2-(2’-pentyl)alanine (5) 
 (2S,4S)-2-Phenyl-3-(carbobenzyloxy)-4-methyloxazolidin-5-one(2S,4S), (1)   
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To a stirred solution of Z-D-Alanine (0.4 g, 1.8 mmol) and benzaldehyde dimethyl acetal 
(0.4 ml, 2.61 mmol) in Et2O (5 mL) was added 2 ml (15.7 mmol) of BF3• Et2O slowly by 
maintaining the reaction temperature at -78 °C. The mixture was allowed to reach -20°C 
and then stirring was continued at -20 °C for 4 days. At the end of this time period, the 
reaction mixture was slowly added to ice-cooled, saturated aqueous NaHCO3 (10 ml), 
and the mixture was stirred for additional 30 min at 0°C. After the aqueous work-up, the 
separated organic layer was washed thrice with saturated NaHCO3 and H2O and then 
dried over Na2SO4. The solvent was removed in vacuo. The residue was dissolved in 11 
ml of Et2O/hexane (4/7) for recrystallization and afforded white crystals of (2S,4S)-1 
(0.37 g, 70%). 
1
H NMR (CDCl3, 400 MHz): δ ppm 1.59 (d, J = 6.8 Hz, 3H), 4.49 (q, J = 
6.8 Hz, 1H), 5.13-5.16 (m, 2H), 6.64 (s, 1H), 7.26-7.42 (m, 10H).  
 (2S,4R)-Benzyl-4-methyl-5-oxo-4-(pent-4-enyl)-2-phenyloxazolidine-3carboxylate, 
(2S,4R), (3) 
 
  (2S,4S)-1 (0.22 g, 0.71 mmol) was dissolved in anhydrous THF/HMPA (4:1, 2 
ml) under an argon atmosphere. The resultant solution was cooled to -78
o 
C. Into that 1M 
LiHMDS solution (1.1 ml, 1.065 mmol) in THF was added slowly under nitrogen at -
78°C. After the addition of LiHMDS, the slightly yellow solution was stirred at this 
temperature for 1 h. Next 5-iodo-1-pentene (0.21 g, 1.06 mmol, synthesized from 5-
Bromo-1-pentene) was added dropwise into the reaction mixture under an argon 
atmosphere and the resultant mixture was slowly allowed to reach room temperature. The 
resultant reaction mixture was stirred at room temperature overnight. At end, saturated 
NH4Cl solution was added, and the reaction mixture was extracted in ether. The organic 
layer was washed subsequently with saturated NaHCO3 and saturated aqueous NaCl 
solutions, respectively. The organic phase was dried over Na2SO4 and evaporated. The 
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product was purified by flash column chromatography and elution with 30% DCM in 
hexane gives the gummy product (0.08 gm) with 30 % isolated yield. 
1
H NMR (CDCl3, 
400 MHz): δ ppm 1.26-1.33 (m, 2H), 1.69 (s, 1H), 1.79 (s, 3H), 2.06-2.08 (m, 2H), 2.14-
2.196 and 2.49-2.56 (m, 1H), 4.91-5.035 (m, 4H), 5.56-5.77 (m, 1H), 6.4 (d, 1H), 6.88 (d, 
J = 7.0 Hz, 1H), 7.20-7.416 (m, 10 H).  
S-2-Amino-2-methylhept-6-enoic-acid, (4)  
 A solution of 3 (1.1 gm, 2.9 mmol) in tetrahydrofuran (52 ml) was treated with 
potassium trimethylsilanolate (90% pure; 1.1 gm, 8.6 mmol) and the mixture was heated 
at 75°C for 2 h 30 min by which time all starting material was consumed. The mixture 
was diluted with methanol and the solvents were removed under reduced pressure. The 
resultant mixture was diluted with dichloromethane and evaporated under vacuum. The 
crude solid was used directly for the next step without further purification. 
Fmoc-S-2-(2’-pentyl)alanine, (5) 
  To a solution of 4 (0.1 gm, 0.64 mmol) in water (8 ml), DIEA (0.167 ml, 0.96 
mmol) was added followed by the addition of Fmoc-OSu (0.237gm, 0.7 mmol) in 
acetonitrile (8 ml). The resultant mixture was stirred at room temperature for 5-6 h. The 
solvent was evaporated and the resultant solution was dissolved in water and 
subsequently acidified with 2N HCl solution. The aqueous layer was extracted with 
ethylacetate for 3 times and purified by silica column chromatography using 
hexane/DCM and later MeOH/DCM as eluent. The product elutes with 3% MeOH/DCM 
mixture. This gives rise to 0.12 gm of the product with 50% isolated yield. 
1
H NMR 
(CDCl3, 400 MHz): δ ppm 1.24-1.43 (m, 2H), 1.63 (s, 3H), 1.87-1.89 (m, 1H), 2.06-2.16 
(m, 3H), 4.22 (t, J = 6.48 Hz, 1H), 4.41(bs, 2H), 4.96-5.03 (m, 2H), 5.52 (bs, 1H), 5.76 
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(m, 1H), 7.315 (t, J1= J2= 7.4 Hz, 2H), 7.40 (t, J = 7.4 Hz, 2H), 7.6 (d, J = 7.4 Hz, 2H), 
7.76 (d, J = 7.48 Hz, 2H), 10.66 (bs, 1H).  
5-iodo-1-pentene, (2)  
 5-Bromo-1-pentene (0.8 ml, 6.71 mmol) was added to a solution of sodium iodide 
(2.0 gm, 13.3 mmol) in acetone (22 ml). The reaction mixture was heated at 60 
o
C for 2 
h. The mixture was cooled to room temperature and diluted with water (100 ml) and 
extracted with pentane 3-times. The pentane layers were combined, washed with brine, 
dried over sodium sulfate and concentrated to give 5-iodo-1-pentene. The product was 
obtained as 90% isolated yield (1.2 gm). 
1
H NMR (CDCl3, 400 MHz): δ ppm 1.91 (p, J1 
= 7.12 Hz, J2 = 7.0 Hz, 2H), 2.16 (q, J1 = 6.7 Hz, J2 = 6.82 Hz, 2H), 3.19 (t, J1 = 6.88 Hz, 
J2 = 6.92 Hz, 2H), 5.00-5.10 (dd, J1 = 17.12 Hz, J2 = 10.12 Hz, 2H), 5.69-5.80 (m, 1H).  
Similarly Fmoc-S-2-(2’-octyl alanine)alanine, was obtained starting from Z-D-alanine 
using 8-iodo-1octene. Fmoc-R-2-(2’-pentyl)alanine was obtained starting from Z-L-
alanine using similar reaction conditions as described above. 
3.4.3.2. Synthesis of N-Fmoc-S-2-(2’-octyl)alanine 
 (2S,4R)-Benzyl-4-methyl-5-oxo-4-(oct-4-enyl)-2-phenyloxazolidine-3carboxylate, 
(2S,4R) 
 
1
H NMR (CDCl3, 400 MHz): δ ppm 1.05-1.31 (m, 8H), 1.69 (s, 1H), 1.8 (s, 3H), 2.03-2.2 
(m, 3H), 4.94-5.35 (m, 4H), 5.78-5.82 (m, 1H), 6.41 (d, 1H), 6.89 (m, 1H), 7.21-7.42 (m, 
10H).  
N-Fmoc-S-2-(2’-octyl)alanine 
1
H NMR (CDCl3, 400 MHz): δ ppm 1.09-1.37 (m, 8H), 1.66 (s, 3H), 1.88 (bs, 1H), 2.03-
2.18 (m, 3H), 4.25 (s, 1H), 4.43-4.72 (m, 2H), 4.96-5.05 (m, 2H), 5.71 (bs, 1H), 5.78-
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5.88 (m, 1H), 7.34 (t, J1 = 7.24, J2 = 7.32 Hz, Hz, 2H), 7.42 (t, J1 = 7.24, J2 = 7.0, 2H), 
7.63 (bs, 2H), 7.79 (d, J = 7.44 Hz, 2H), 11.6 (bs, 1H).  
8-iodo-1-octene 
1
H NMR (CDCl3, 400 MHz): δ ppm 1.25-1.43 (m, 6H), 1.82 (p, J1 = 7.12 Hz, J2 = 7.4 
Hz, 2H), 2.04 (q, J1 = 6.76 Hz, J2 = 6.84 Hz, 2H), 3.18 (t, J1 = J2 = 7.04 Hz, 2H), 4.92-
5.02 (m, 2H), 5.74-5.81 (m, 1H). 
 Peptides 27-28 were synthesized on solid phase by sequentially adding 
appropriate amino acids along with the peptide coupling reagents (HATU, DIEA) onto 
the Fmoc-Rink Amide resin
76,77
. Each amino acid coupling was done for 1.5 h to 2 h. 
Both peptides were obtained in 60-80% isolated yields after purification by RP-HPLC 
and characterized by ESI-MS. All solvents and reagents used were of highest purity 
available. Fmoc-Asp(tBu)-OH, 1 was purchased from Novabiochem and N,O-dimethyl 
hydroxylamine hydrochloride was bought from Acros. 
1
H-NMR spectra were recorded 
on Bruker 400 spectrometer. Chemical shifts () are reported in ppm downfield from the 
internal standard (TMS).  
 Peptide concentrations were tested by absorbance at 280 nm or densitometry 
measurements for the gel-based activity measurements. A consistent error of the peptide 
concentration was determined to be no more than two-fold more concentrated than the 
expected amount. The inhibitory constant, Ki, was adjusted accordingly. However, the 
ranking of our best peptides were not changed, therefore our overall conclusions remain 
the same.  
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3.4.4. Activity Assays 
 For measurements of caspase activity, 700 nM freshly purified protein was 
assayed over the course of 10 minutes in a caspase-9 activity assay buffer containing 100 
mM MES pH 6.5, 10% PEG 8,000 and 10 mM DTT
78
. 300 μM fluorogenic substrate, 
LEHD-AFC, (N-acetyl-Leu-Glu-His-Asp-AFC (7-amino-4-fluorocoumarin), Enzo 
Lifesciences) Ex395/Em505, was added to initiate the reaction. Assays were performed 
in duplicate at 37°C in 100 μL volumes in 96-well microplate format using a Molecular 
Devices Spectramax M5 spectrophotometer. Initial velocities versus inhibitor 
concentration were fit to a rectangular hyperbola using GraphPad Prism (Graphpad 
Software) to calculate Ki app.  
 Proteolytic cleavage gel-based caspase-9 activity assays were performed for 
testing the ability of each peptide to inhibit caspase-9 against a natural substrate. 
Cleavage of the full-length procaspase-7 variant C186A, which is catalytically inactive 
and incapable of self-cleavage, was used to report activity.  1 μM full-length procaspase-
7 C186A was incubated with 1 μM active caspase-9 in a minimal assay buffer containing 
100 mM MES pH 6.5 and 10 mM DTT in a 37°C water bath for 1 hr. Samples were 
analyzed by 16% SDS-PAGE to confirm the exact lengths of the cleavage products.  
Percent inhibition was calculated using Gene Tools (SynGene) by producing a standard 
curve from densiometry values for process and unprocessed substrate (caspase-7 C186A).   
3.4.5. Mass Spectrometry 
 Peptide 2 in water was diluted in α-cyano-4-hydroxycinnamic acid matrix to a 
final concentration of 5 µM. 1µl was spotted onto a target for analysis by Omniflex 
MALDI-TOF mass spectrometer (Bruker Daltonics, Inc, Billerica, MA) using linear 
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detection mode. Peptides 27 and 28 in water were diluted in 0.1% formic acid to a final 
concentration of 5 µM for direct injection onto Esquire-LC electrospray ion trap mass 
spectrometer (Bruker Daltonics, Inc.) set up with an ESI source and positive ion polarity. 
The MS instrument system was equipped with an HP1100 HPLC system (Hewlett-
Packard).  Scanning was carried out between 600-1400 m/z and the final spectra obtained 
were an average of 10 individual spectra. All mass spectral data were obtained at the 
University of Massachusetts Mass Spectrometry Facility, which is supported, in part, by 
the National Science Foundation.  
3.4.6. Secondary Structure Analysis by Circular Dichroism  
 The secondary structure of the peptide variants was monitored via CD spectra 
(250-190 nm) measured on a J-720 circular dichroism spectrometer (Jasco) with a peltier 
controller.  Peptides 2, 3, 5, 8, 27, and 28 in water and Peptides 11, 25 and aPP in 20mM 
Tris pH 8.0 were diluted to 15 μM and analyzed at room temperature. Peptides 27 and 28 
were monitored for secondary structure formation before and after the metathesis 
reaction. 
3.4.7. Computational Structure Prediction  
 The structures of aPP variants were predicted computationally using Rosetta
57,58
. 
Folding simulations were performed on the designed peptide sequences 10-26 using the 
scaffold aPP as a control. The structure of aPP was reasonably well simulated as assessed 
by backbone alignment and rotomer confirmation of the top 15 lowest scored predicted 
conformations. Structural visualization and model interrogation was performed in The 
PyMOL Molecular Graphics System, Version 1.3, Schrödinger, LLC
79
. 
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CHAPTER IV 
MECHANISM OF ZINC-MEDIATED INHIBITION OF CASPASE-9 
Abstract 
  Zinc-mediated inhibition is implicated in global caspase regulation, with relief of 
zinc-mediated inhibition central to both small-molecule and natively induced caspase 
activation. As an initiator, caspase-9 regulates the upstream stages of the apoptotic 
caspase cascade, making it a critical control point. Here we identify two distinct zinc-
binding sites on caspase-9. The first site, composed of H237, C239, C287 includes the 
active site dyad and is primarily responsible for zinc-mediated inhibition. The second 
binding site at C272 plays is distal from the active site. Given the amino-acid 
conservation in both regions, these sites appear to be conserved across the caspase family. 
4.1.  Introduction 
Apoptotic cell death is carried out by caspases, a family of cysteine proteases. 
Caspases function in a cascade of cleavage events leading to orderly destruction of cells, 
culminating in cell death. Initiator caspase-8 and -9 activate the executioner caspases-3,   
-6 and -7, which cleave select targets enabling cell death. Apoptosis is important for both 
organismal development and homeostasis and is implicated in diseases ranging from 
ischemic injury to cancer.  Understanding the mechanisms of the native regulatory 
pathways of caspases provides new insights for controlling and harnessing apoptosis. 
 Exposure of the apoptotic machinery to metal ions has been reported to influence 
apoptosis. Zinc, a metal commonly used for both biological structure and function, has  
been highlighted as a specific regulator of apoptosis, where even the smallest fluctuations  
95 
 
in cellular zinc concentrations can tip a cell towards survival or apoptotic cell death
1
. 
Zinc-based regulation of apoptosis had previously been thought to act upstream of the 
caspases
2
. However, in vitro and in vivo studies implicate caspases as the targets for zinc-
mediated inhibition of apoptosis
3,4
.   
The basis of the necessity for zinc regulation of caspases is not well understood, 
but may relate to protection of the essential active-site sulfhydryls during oxidative stress 
(reviewed in
5
). Misregulation of zinc and changes in caspase activity have been linked to 
a number of diseases. Patients with asthma and chronic bronchitis show a correlation 
between zinc deficiency and increased levels of apoptosis in airway epithelial cells
6,7
, 
suggesting a protective role for zinc-mediated caspase inhibition. Heliobacter Pylori 
based infections have also been linked to zinc-mediated regulation of the caspases
8,9
, 
where release of zinc from the bacterium inhibits caspase activity to avoid cell death. 
PAC-1, a serendipitous small-molecule caspase activator, relieves zinc-mediated caspase-
3 inhibition
10
 further suggesting that regulation of zinc-inhibition of caspases may be 
therapeutically exploited. In this work, we aim to understand the molecular mechanism of 
zinc-mediated caspase inhibition. 
4.2. Results 
4.2.1.  Metal Affects on the Properties of Caspase-9 
Caspase inhibition by zinc has been explored in the executioner caspases -3, -6, 
and -7, however, little is known about zinc’s function on initiator caspases, including 
caspase-9. Inhibition of the initiator caspases is particularly critical as the initiators  
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control the upstream steps of the proteolytic cascade. Previous studies have suggested 
that zinc disrupts caspase-9 activation and thus activity
11,12
; however a full analysis of 
zinc’s affect on caspase-9 or the mechanism of inhibition has not been investigated. We 
interrogated the effects of a panel of metal cations on the ability of caspase-9 to cleave its 
natural substrate, caspase-7. Both full-length caspase-9 (Fig 4.1 A) and caspase-9 lacking 
its pro domain (Caspase Activation and Recruitment Domain, CARD) (Fig 4.1 B) were 
inhibited by zinc but not by any other cations, including cobalt (Fig 4.1 C). Full inhibition 
of both caspase-9 variants by zinc indicates that the CARD domain is not involved in 
zinc’s mechanism of inhibition. Other caspases including caspase-3, -6, -7 and -8 have 
 
Figure 4.1 Zinc exclusively inhibits caspase-9 activity. (A, B) Zinc is the predominant metal cation to 
inhibit full-length caspase-9 (C9 FL) (A) or the N-terminal CARD-domain deleted caspase-9 (C9 N) 
(B) when monitored by cleavage of a natural caspase-9 substrate, the caspase-7 zymogen (C7 C186A) 
to the caspase-7 large (C7 Lg) and small (C7 Sm) subunits in an in vitro cleavage assay monitored by 
gel mobility.  (C) Caspase-9 full-length activity was not inhibited by cobalt or cadmium as judged by 
cleavage of fluorogenic peptide substrate LEHD-AFC. (D) Competition with metal chelator, EDTA, 
indicates zinc inhibition is reversible, as monitored by the cleavage of fluorogenic peptide substrate 
LEHD-AFC. 
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previously been shown to be inhibited in the presence of zinc
3
; however other metal 
cations, including copper also inhibit caspase-3 function
4
. In contrast, caspase-9 appears 
to be inhibited specifically by zinc but not by other metals. Zinc-mediated inhibition was 
fully reversible by the metal chelator EDTA (Fig 4.1 D) suggesting a regulatory role for 
zinc rather than a non-specific mechanism such as promotion of an irreversible protein 
aggregate. Inhibition by zinc lead to Michaelis-Menten like curves that fit best to a mixed 
model of inhibition (Fig 4.2). The observed error within the fit of the individual curves 
was not due to quenching of the fluorophore, AFC, by zinc (data not shown).  This 
suggests zinc inhibition functions allosterically or binds near the active site thus 
influencing the binding of substrate. The inhibitory constant, Ki, of 1.5 ± 0.3 μM is 
similar that reported for zinc inhibition of caspase-3, -6, -7 and -8 (IC50 = 8.8, 0.3, 1.7, 
 
Figure 4.2 Kinetics of full-length caspase-9 wild type in the presence of 0-50 μM ZnCl2. Measured data 
were fit to competitive, noncompetitive, and mixed models of inhibition. R
2
 values are presented for 
individual zinc concentrations and for the overall global fit of the curves fit by each model in which 
mixed model of inhibition represented the best fit model.  
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1.9 μM, respectively)3. Although physiological “free” zinc concentrations are reported to 
be in the femto- to pico-molar range
13,14, the “available” zinc pool is believed to be much 
higher. As a whole, the eukaryotic cell contains approximately 200 μM zinc14 where 
small shifts in the glutathione concentration or slight oxidative stress causes release of 
zinc from the metallothioneins
15
 or vesicles. Thus inhibition constants for caspases in the 
low micromolar range are likely to be functionally relevant. 
Zinc has been shown to influence oligomerization or structure for a variety of 
proteins including β-2-microglobulin16,17, α-synuclein18, and prion proteins19, so we 
likewise investigated the effect of zinc binding on the biophysical properties of caspase-
9. Unlike other caspases which are constitutive dimers, caspase-9 is predominantly a 
monomer in solution, which dimerizes upon binding of substrate
20
. Dimerization can be 
observed by native gel analysis (Fig 4.3 A) and size exclusion chromatography (Fig 4.3 
B). The presence of zinc does 
not influence dimerization (Fig 
4.3 A, B). Zinc also has no 
observed effect on the 
secondary structure of caspase-9 
as measured by circular 
dichrosim spectroscopy (Fig 4.3 
C), further suggesting that zinc-
mediated inhibition does not 
influence the overall structure of 
 
Figure 4.3 Zinc does not alter the biophysical properties of caspase-
9. (A, B) Native gel analysis (A) and size exclusion 
chromatography (B) both indicate zinc does not alter the 
oligomeric state of caspase-9 from monomer to dimer like the 
substrate-mimic z-VAD-FMK. (C) CD spectra of caspase-9 full 
length in the presence and absence of ZnCl2 indicate that zinc does 
not alter the caspase-9 secondary structure. 
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caspase-9 monomers. 
4.2.2. Determining the Location of Zinc Binding 
Zinc binding to caspase-9 was assessed by inductively coupled plasma-optical 
emissions spectroscopy (ICP-OES). Each wild-type caspase-9 monomer was observed to 
bind two zinc molecules. Caspase-9 monomers contain thirteen cysteine and eight 
histidine residues (Fig 4.4 A, B), all potential ligands for zinc. Most of these residues are 
located in the large subunit, either clustered near the active site or at the bottom of the 
210’s helix (Fig 4.4 C, D) suggesting the locations of two potential zinc-binding sites. 
 
Figure 4.4 Zinc binding in caspase-9. (A) Caspase-9, monomer, highlights clusters of cys and his metal-
binding residues. (B) Cys and his residues are mainly located in the large subunit of caspase-9. (C) Cys-
His clusters are conserved throughout the caspase family. (D) Location of the conserved active-site and 
210’s helix exosite-ligand clusters on caspase-9 (pdb ID 1JXQ). 
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The active site cluster comprises the conserved catalytic residues C287 and H237, in 
proximity to two cysteines that are unique to caspase-9, C172 and C239. Interestingly, the 
210’s helix region contains a conserved cysteine-histidine-cysteine triad of unknown 
function, comprising residues 272, 224, 230 respectively. Furthermore, both the active 
site region and the triad are highly conserved in the apoptotic class of caspases (Fig 4.4 
C).  
We interrogated five positions within 
these two cys-his clusters in caspase-9 for 
involvement in zinc binding (Table 4.1). 
Whereas two zinc molecules bind to one 
monomer of wild-type caspase-9, caspase-9 
variants which substitute the active-site residues 
C287A or H237A bind just one molecule of 
zinc. This suggests that the active-site region is one of the zinc binding sites. The two 
most likely proximal zinc-binding ligands were also substituted. C172A had little effect 
on zinc binding, but C239S lead to a more substantial loss of zinc binding. The 
C287A/C239S variant also lost binding of one molecule of zinc, suggesting that the 
active site zinc binding cluster comprises residues C239, H237 and C287. Although the 
identity at residue C239 is not conserved across caspases, it is Glu in all the executioner 
caspases, suggesting that this residue might be a conserved zinc ligand position across the 
apoptotic caspase family. 
Substitution of the residue C272A to alanine in the conserved 210’s-helix triad,  
Table 4.1 Zinc bincing as monitored by 
ICP-OES. 
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also resulted in loss of one zinc molecule (Table 4.1), suggesting that C272 is at the core 
of the second zinc-binding site. The loss of zinc binding at C272A was not due to 
unfolding of the protein as the substitution C272A has no effect on basal activity of the 
enzyme. The catalytic efficiency of C272A is nearly the same as wild-type caspase-9, 2.0 
± 0.16 and 2.7 ± 0.25 respectively. Given the proximity, we suggest that the second 
binding site comprises residues H224, C230 and C272. Together these data suggest that 
there are two distinct zinc-binding sites in caspase-9 (Fig 4.4 D). The presence of two 
independent binding sites was confirmed by caspase-9 C287A/C272A variant in which 
zinc binding is ablated.  
Binding of zinc to both the catalytic residues of caspase-9 is expected to block 
nucleophilic attack of the peptide bond by C287 rendering the enzyme inactive. The 
potential contribution of the second binding site to inhibition is less obvious. If the C272 
site contributes directly to zinc-mediated caspase-9 inhibition, then the caspase-9 C272A 
variant C272A might be expected to show a competitive mechanism of inhibition. 
Surprisingly, the C272A variant also shows a mixed model of inhibition (Fig 4.5), like 
wild-type caspase-9 and exhibited a comparable Ki value of 5.0 ± 2.8 μM. The Ki for zinc 
with the C272A variant is statically indistinguishable from that observed with wild type 
enzyme (Student’s t-test), suggesting this site does not contribute appreciably to the 
mechanism of caspase-9 inhibition by zinc.  
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4.3. Discussion 
Although no regulatory function was observed in the case of the caspase-9 second 
zinc binding site, this 210’s helix region (the 90’s helix in caspase-6) has been implicated 
in the mechanism of caspase-6 activation
21
. A 21° pivot about the bottom of this helix has 
been observed. The open conformation is adopted when caspase-6 is in an inactive state 
whereas the closed conformation is characteristic of the active enzyme. In light of the fact 
that zinc inhibition is most potent in caspase-6 (IC50 = 0.3 μM )
3,22
, and that this structural 
region is sensitive and critical for caspase-6 activity, it is tempting to hypothesize that 
zinc could control caspase-6 allosterically, via binding to this caspase conserved exosite 
triad. 
Our findings indicate that the reversible binding of zinc to the caspase-9 active  
 
Figure 4.5 Kinetics of full-length caspase-9 C272A variant in the presence of 0-50 μM ZnCl2. Measured 
data were fit to competitive, noncompetitive, and mixed models of inhibition. R
2
 values are presented 
for individual zinc concentrations and for the overall global fit of the curves fit by each model in which 
mixed model of inhibition represented the best fit model.  
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site residues H237, C239, and 
C287 is the predominant 
mechanism for caspase-9 
inhibition. A plausible model 
with reasonable metal-to-ligand 
bond distances between active-
site residues and zinc was 
obtained simply by changing 
the rotomeric conformations of 
H237, C239, and C287 (Fig 
4.6). Like the majority of zinc-
binding sites in proteins, the binding site is likely to be four-coordinate, tetrahedral. The 
fourth ligand could be water, solvent, or potentially a nearby glutamate residue, E290 
(Fig 4.6). E290 resides on a flexible loop just 3.8Å from the proposed position of the zinc 
ion. Optimal E290 ligand-binding distances may be achieved by loop movement or by a 
water-mediated interaction.  
Taken together, these results suggest a model for how zinc binds to the active site 
and inhibits caspase-9 and caspases generally. The function of the secondary zinc-binding 
exosite remains an open question; however the conservation of this site suggests that 
perhaps zinc does play a physiological role at this site as well.  The fact that zinc does not 
function in a strictly competitive manner with substrate at the active site, may suggest 
some flexibility in the zinc-binding ligands. Given that the zinc-mediated inhibition  
 
 
Figure 4.6 A model of caspase-9 active-site ligand interactions 
with a modeled zinc ion. Model was obtained by altering the 
H237, C239 and C287 rotomers. 
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constants for all the caspases are similar and that ligands are conserved in the active site 
region, suggests that the mechanism of active-site inhibition of the apoptotic caspases is 
conserved. Thus, utilization of zinc-based inhibition of caspases, like that used by PAC-
1
10
, remains a promising avenue for controlling caspases and apoptosis.  
4.4. Materials and Methods 
4.4.1. Caspase-9 Expression and Purification 
The caspase-9 full-length gene (human sequence) construct, encoding amino acids 
1-416, in pET23b (Addgene plasmid 11829
23
) was transformed into the BL21 (DE3) T7 
Express strain of E. coli (NEB). The cultures were grown in 2xYT media with ampicillin 
(100 mg/L, Sigma-Aldrich) at 37°C until they reached an optical density at 600 nm of 
1.2. The temperature was reduced to 15°C and cells were induced with 1 mM IPTG 
(Anatrace) to express soluble 6xHis-tagged full-length protein.  Cells were harvested 
after 3 hrs to obtain single site processing at Asp315. Cell pellets stored at -20°C were 
freeze-thawed and lysed in a microfluidizer (Microfluidics, Inc.) in 50 mM sodium  
phosphate pH 8.0, 300 mM NaCl, and 2 mM imidazole. Lysed cells were centrifuged at 
17,000 rpm to remove cellular debris. The filtered supernatant was loaded onto a 5-ml 
HiTrap Ni-affinity column (GE Healthcare). The column was washed with a buffer 
containing 50 mM sodium phosphate pH 8.0, 300 mM NaCl, 2 mM imidazole until 280 
nm absorbance returned to base line. The protein was eluted using a linear imidazole 
gradient of 2 to100 mM over the course of 270 mL. The eluted fractions containing 
protein of the expected molecular weight and composition were diluted by 10-fold into a 
buffer composed of 20 mM Tris pH 8.5, 10 mM DTT to reduce the salt concentration.  
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This protein sample was loaded onto a 5-ml Macro-Prep High Q column (Bio-Rad 
Laboratories, Inc.). The column was developed with a linear NaCl gradient and eluted in 
20 mM Tris pH 8.5, 100 mM NaCl, and 10 mM DTT buffer. The eluted protein was 
stored in -80°C in the above buffer conditions. The identity of the purified caspase-9 was 
analyzed by SDS-PAGE and ESI-MS to confirm mass and purity. Caspase-9 variants in 
the full-length expression construct (C287A, H237A, C172A, C239S, C287A/C239S, 
C272A, C272A/C287A) were purified by the same method as described here for the 
wild-type protein. 
Caspase-9 ΔCARD was expressed from a two-plasmid expression system. Two 
separate constructs, one encoding the large subunit, residues 140-305, and the other 
encoding the small subunit, residues 331-416, each in the pRSET plasmid, were 
separately transformed into the BL21 (DE3) T7 Express strain of E. coli (NEB). The 
recombinant large and small subunits were individually expressed as inclusion bodies for 
subsequent reconstitution. Cultures were grown in 2xYT media with ampicillin (100  
mg/L, Sigma-Aldrich) at 37°C until they reached an optical density at 600 nm of 0.6. 
Protein expression was induced with 0.2 mM IPTG. Cells were harvested after 3 hrs at 
37°C. Cell pellets stored at -20°C were freeze-thawed and lysed in a microfluidizer 
(Microfluidics, Inc.) in 10 mM Tris pH 8.0 and 1 mM EDTA. Inclusion body pellets were 
washed twice in 100 mM Tris pH 8.0, 1 mM EDTA, 0.5 M NaCl, 2% Triton, and 1M 
urea, twice in 100 mM Tris pH 8.0, 1 mM EDTA and finally resuspended in 6 M 
guanidine hydrochloride. Caspase-9 large and small subunit proteins in guanidine 
hydrochloride were combined in a ratio of 1:2, large:small subunits, and rapidly diluted  
106 
 
dropwise into refolding buffer composed of 100 mM Tris pH 8.0, 10% sucrose, 0.1% 
CHAPS, 0.15 M NaCl, and 10 mM DTT, allowed to stir for one hour at room 
temperature and then dialyzed four times against 10 mM Tris pH 8.5, 10 mM DTT, and 
0.1mM EDTA buffer at 4°C.  The dialyzed protein was centrifuged for 15 minutes at 
10,000 rpm to remove precipitate and then purified using a HiTrap Q HP ion exchange 
column (GE Healthcare) with a linear gradient from 0 to 250 mM NaCl in 20 mM Tris 
buffer pH 8.5, with 10 mM DTT. Protein eluted in 20 mM Tris pH 8.5, 100 mM NaCl, 
and 10 mM DTT buffer was stored in -80°C. The identity of the purified caspase-
9ΔCARD was analyzed by SDS-PAGE and ESI-MS to confirm mass and purity. 
4.4.2. Prediction of Metal Ligands and Construction of Ligand Substitution   
 Variants 
 
Potential zinc-binding ligands were predicted via the computational server which 
predicts metal ion-binding sites, HotPatch version 4.0 , by a computational program 
specific for zinc binding sites, PREDZINC version 1.1 , and by visual inspection of zinc  
ligand clusters and distances based on the caspase-9ΔCARD crystal structure (pdb ID: 
1JXQ) via the PyMOL Molecular Graphics System, Version 1.3 (Schrödinger, LLC). 
Sites predicted as potential zinc ligands were C172, C239, C272, H237, and C287.  
Individual active-site knockout variants, H237A and C287A, and cysteine knockout 
variants, C172A, C239S, and C272A, in the caspase-9 full-length gene were made by a 
single round of QuikChange site directed mutagenesis (Stratagene).  Double knockout 
variants, C239S/C287A and C272A/C287A, were made by an additional round of 
QuikChange site directed mutagenesis in the background of the caspase-9 full-length 
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C287A variant. Formation of the proper variant was confirmed by sequence analysis 
(Genewiz, Inc.). 
4.4.3. Caspase-7 C186A Expression and Purification 
The active site knockout variant, C186A, was made by QuikChange mutagenesis 
(Stratagene) of the human caspase-7 gene in pET23b (gift of Guy Salvesen ) The 
construct was transformed into BL21 (DE3) T7 Express strain of E. coli and protein 
expression was induced with 1 mM IPTG at 18°C for 18 hrs. The protein was purified as 
described previously for caspase-7. The eluted protein was stored in -80°C in the buffer 
in which they eluted. The identity of purified caspase-7 C186A was assessed by SDS-
PAGE and ESI-MS to confirm mass and purity.  
4.4.4. Activity Assays 
For measurements of caspase activity, proteolytic cleavage gel-based caspase-9 
activity assays were performed for testing the ability of a panel of metal cations to inhibit 
caspase-9 activity against a natural substrate. Cleavage of the full-length procaspase-7  
variant C186A, which is catalytically inactive and incapable of self-cleavage, was used to 
report caspase-9 activity. 1μM caspase-9 full-length in a minimal assay buffer containing 
100 mM MES pH 6.5 and 10 mM DTT was incubated in the presence of 1mM metal 
cation for 1hr at room temperature. 1 μM full-length procaspase-7 C186A was added to 
the reaction mix and incubated in a 37°C water bath for 1 hr. Samples were analyzed by 
16% SDS-PAGE to confirm the exact lengths of the cleavage products.   
To test the reversibility of zinc binding, 700 nM freshly purified caspase-9 full-
length was incubated in the presence and absence of 5 equivalents excess ZnCl2 for 1hr at  
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room temperature. Half of each protein sample was treated with 25-fold excess EDTA 
just prior to fluorescence activity assay measurements. Samples were assayed for activity 
over the course of 10 minutes in a caspase-9 activity assay buffer containing 100 mM 
MES pH 6.5, 10% PEG 8,000 and 10 mM DTT. 300 μM fluorogenic substrate, LEHD-
AFC, (N-acetyl-Leu-Glu-His-Asp-7-amino-4-fluorocoumarin), (Enzo Lifesciences) 
Ex395/Em505, was added to initiate the reaction. Assays were performed in duplicate at 
37°C in 100 μL volumes in 96-well microplate format using a Molecular Devices 
Spectramax M5 spectrophotometer.  
The inhibitory constant for zinc, Ki, was determined by incubating 700 nM 
caspase-9 full-length protein, diluted in 100 mM MES pH 6.5, 10% PEG 8,000, and 5  
mM DTT, in the presence of 0-50 μM ZnCl2 for 1.5 hours at room temperature. 
Samples from each ZnCl2 concentration were subjected to a substrate titration, performed 
in the range of 0-300 μM fluorogenic substrate, LEHD-AFC (Ex365/Em495) which was 
added to initiate the reaction. Assays were performed in duplicates at 37°C in 100 μL 
volumes  
in 96-well microplate format using a Molecular Devices Spectramax M5 spectro-
photometer. Initial velocities versus substrate concentration were globally fit to 
competitive, noncompetitive and mixed models of inhibition using GraphPad Prism 
(Graphpad Software) to determine inhibitory constant, Ki. Determination for the type of 
inhibition was based on four criteria. R
2
 values for the individual curve fits, criterion for 
the α-value reported by the mixed model of inhibition, overall visual inspection of the 
curve fits with the data and knowledge of the system were all taken into consideration.  
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The R
2
 values and visual inspection of the curve fits with the data ruled out competitive 
inhibition whereas these criteria were less clear between the noncompetitive and mixed 
models of inhibition. However, a slight improvement in the R
2
 values for the individual 
curve fits for the mixed model of inhibition was observed, suggesting that this is the best 
fit for the data. The α-value obtained from the mixed model of inhibition fits also reports 
on the inhibition mechanism. If the α-value is equal to one, the mixed model of inhibition 
is identical to the non-competitive model whereas if this value is very large, the model 
becomes identical to the competitive model of inhibition.  The reported α-value for the 
fits of both full-length caspase-9 wild-type and variant C272A match neither of these 
criteria, therefore the mechanism of inhibition is appears to follow a mixed model.  
Furthermore, based on our enzymatic system and the determined location of metal 
binding, a mixed model of inhibition appears to be the most likely.  
4.4.5. Oligomeric-State Determination 
Caspase-9 wild-type, full-length protein samples in 20 mM Tris pH 8.5, 110 mM 
NaCl, and 5 mM DTT were incubated alone (monomer), with covalent inhibitor z-VAD- 
FMK (carbobenzoxy-Val-Ala-Asp-fluoromethylkeytone) (dimer) or with 5 equivalents 
excess of ZnCl2  for 2 hours at room temperature. The oligomeric state of the caspase-9 
samples were determined via gel filtration and native gel analysis.  100 μL of 0.75 mg/ml 
protein sample was loaded onto a Superdex 200 10/300 GL (GE Healthcare) gel-filtration 
column. Apo and z-VAD-FMK incubated protein samples were eluted with 20 mM Tris 
pH 8.0, 100 mM NaCl, and 2 mM DTT while ZnCl2-incubated protein was eluted in the 
same buffer and one containing 50 μM ZnCl2 to ensure zinc was not be lost during the gel  
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filtration process.  Eluted peaks were analyzed by SDS-PAGE to ensure protein identity. 
Four different molecular weight standards from the gel-filtration calibration kit LMW 
(GE Healthcare) were run in the same conditions and a standard plot was generated to 
determine whether the peaks were caspase-9 monomer or dimer. For native gel analysis, 
samples were mixed with glycerol loading dye and fractionated on a 10% Tris/Glycine 
pH 8.3 polyacrylamide gel. The oligomeric state of the ZnCl2 treated caspase-9 was 
identified by comparison to the Apo (monomer) and z-VAD-FMK (dimer) caspase-9 full-
length samples. 
4.4.6. Secondary Structure Analysis by Circular Dichroism  
Caspase-9 full-length protein was buffer exchanged via dialysis against 100 mM  
sodium phosphate pH 7.0, 110 mM NaCl, and 2 mM DTT, and diluted to 7 μM. The 
sample was split in half and incubated in the presence or absence of five equivalents of 
ZnCl2 for 1hr at room temperature. The circular dichroism spectra of caspase-9 full-
length in the presence and absence of zinc was monitored from 250-190 nm, measured on 
a J-720 circular dichroism spectrometer (Jasco) with a peltier controller.   
4.4.7. Zinc Binding Analysis by ICP-OES 
Purified caspase-9 full-length, wild-type and variants (15 μM) in 20 mM Tris pH 
8.5, 110 mM NaCl, and 5 mM DTT were incubated with 5 equivalents excess of ZnCl2 
for 1 hour at room temperature. Unbound zinc was removed by incubating samples of 1 
mL volume in the presence of approximately 125 mg of Chelex® 100 for 1 hour, mixing 
every 20 minutes. A control sample of 1 mL of 20 mM Tris pH 8.5, 110 mM NaCl, and 5 
mM DTT buffer only was treated in the exact same manner to judge the completeness of  
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unbound zinc chelation. Wild-type caspase-9 full-length samples either treated with zinc 
or untreated were also used as controls for metal content pre and post zinc incubation.  
Zinc content of the sample supernatant was quantified using a PerkinElmer Optima 4300 
DV inductively coupled plasma-optical emission spectrometer (ICP-OES) equipped with 
a 40 MHz free-running generator and a segmented-array charge-coupled device (SCD) 
detector and a sample introduction system consisted of a concentric nebulizer with a 
cyclonic spray chamber. The concentration of zinc in each sample was determined at 
206.2 nm and converted from ppm to μM to obtain the zinc to monomer of caspase-9 
full-length ratio. Post ICP-OES analysis, remaining samples were tested via absorbance 
at 280 nm determine protein concentration. A 16% SDS-PAGE gel visualized with the  
Pierce Silver Stain Kit (Thermo Scientific) was used to determine the percentage of low 
concentration contaminants so the total caspase-9 concentration could be adjusted 
accordingly. This adjustment did not alter the overall trend observed. 
4.4.8. Model of Zinc Binding to Caspase-9 
A proposed model for zinc binding at the active site of caspase-9 ΔCARD was  
developed in PyMOL Molecular Graphics System, Version 1.3 (Schrödinger, LLC). The 
zinc ionic radius was contoured to the reported values for a tetrahedral geometry of 
ligand binding. The rotomeric conformations of the ligands which coordinate the zinc 
ion, H237, C239, and C287, as well as a putative ligand, E290, were sampled to obtain 
the best metal to ligand geometry and allowed bond distances for ligand character. 
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4.5. Structure Determination Trials of Caspase-9 and Zinc 
4.5.1. Crystallization of Caspase-9 in the Presence and Absence of Zinc 
To further understand the molecular details of zinc-mediated inhibition at the 
active site as well as zinc binding at the secondary binding site we aimed to obtain the 
crystal structure of caspase-9 full-length, wild-type protein in the presence of zinc.  
Previous caspase-9 structures have shown a dimeric caspase-9 enzyme without the N-
terminal CARD domain (ΔCARD) in complex with covalent peptide inhibitor z-VAD-
FMK (PDB ID: 1JXQ)
20
, a variant which shifts the enzymes oligomeric state from 
monomer to dimer by re-engineering the dimerization interface to mimic caspase-3 (PDB 
ID: 2AR9)
24
, and monomeric caspase-9 ΔCARD in complex with the protein inhibitor 
XIAP-Bir3 (PDB ID: 1NW9)
25
. Crystals from dimeric caspase-9 enzyme lacking the N-
terminal CARD domain (ΔCARD) in complex with a covalent peptide inhibitor grew in a  
0.1 M MES pH 6.0 and 12% PEG 20,000 solution when incubated at 20 °C. The sitting-
drop vapor diffusion method was utilized for crystal growth. On the other hand, the 
dimeric caspase-9 variant, (residues 140–416) made by altering the dimeric interface to 
mimic that of caspase-3 and knocking out the catalytic Cys (C287S), crystallized in 
grown in 5% (w/v) PEG 5,000 monomethylether, 0.1M MES pH 6.0 and 3% tacsimate  
when incubated at 17 °C utilizing the hanging drop vapor diffusion method. Crystals of 
the caspase-9/XIAP-Bir3 inhibitory complex were grown also grown using this method 
where drops were set up in 0.1 M Tris pH 8.0, 1.0 M potassium monohydrogen 
phosphate, and 0.2 M sodium chloride. These three conditions served as a starting point 
for initial screening for caspase-9 crystals in the presence of zinc.  
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Purified wild type caspase-9 full-length protein (residues 1-416) in 20 mM Tris 
pH 8.5, 100 mM NaCl, and 5 mM DTT was concentrated to 11 mg/mL using an Amicon 
Ultracell 3K concentrator (Millipore).  The concentrated protein was then incubated with 
five equivalents excess of ZnCl2 for one hour at room temperature and filtered using  a 
durapore-PVDF 0.22 μM filter (Millipore) to remove any dust, debris or protein 
precipitate prior to crystallization trials. Initial crystallization trials were set up using the 
hanging drop, vapor diffusion method in all known conditions previously described. 
However upon drop set-up, immediate protein precipitate was observed and no crystal 
formation was seen over time. Therefore, naïve crystallization screens were tested with 8 
to 20 mg/mL of the full-length form of caspase-9 wild-type protein pre-incubated with 
zinc. No crystal formation was observed in the naïve screens when using Crystallization 
Screen I & II, Index Screen, and JCSG+ Suite from Hampton Research. Crystallization  
trials of the apo wild-type caspase-9 in the full-length form were then pursued using the 
known crystallization conditions using 11 mg/mL protein. Initial drops result in a white 
cloudy precipitate in the drop, however, crystal growth was observed after 24 hours in the 
condition 0.1 M MES pH 6.0 and 12% PEG 20,000 in a 1:1 protein-to-mother-liquor 
ratio incubated at 20 °C. The crystals obtained formed clusters of thin plates measuring 
730 x 260 x 50 μM in size, which were unusable for data collection (Fig 4.7 A). 
  Further optimization was performed to obtain single crystals of caspase-9. 
Optimizations included varying the pH between 5.2 to 6.0, the identity of the PEG 
precipitant from PEG 200 to 20,000 average molecular weight and the concentration of 
PEG from 10 to 20%. Final conditions were 0.1 M MES pH 5.8 and 14% PEG 6,000,  
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 resulting in thin single crystals of approximately 100 x 40 x 10 μM in size and form in 
the shape of a half of a hexagon or a full hexagon in some instances (Fig 4.7 B). 
Microseeding, macroseeding, and additive screen experiments in addition to further  
purifying the protein via a HiLoad 26/600 Superdex gel filtration column in 20 mM Tris 
pH 8.5, 100 mM NaCl, and 2 mM DTT were used to improve consistency of the crystal 
form within a drop and overall thickness and size of crystals. Unfortunately these 
approaches did not result in a significant improvement in crystal morphology or growth. 
4.5.2. Data Collection on Crystals of Caspase-9 
  Crystals of full length caspase-9 wild-type apo protein in final mother liquor 
conditions of 0.1 M MES pH 6.0 and 15% PEG 6,000 were incubated in 20% glycerol, 
ethylene glycol or PEG 400 as a cryoprotectant for one hour and flash frozen in liquid 
nitrogen for storage. During crystal screening at a variety of different angles at the 
Brookhaven National Laboratory synchrotron x-ray light source, the caspase-9 wild-type  
 
 
Figure 4.7 Crystals of wild type caspase-9 full-length (A) pre and (B) post optimization.  
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crystals diffracted to approximately 3.0 Å, with nice rounded spot shape and minimal 
mosaicity, but a relatively weak intensity (Fig 4.8). This indicates that optimal 
crystallization and freezing conditions were obtained. Indexing the diffraction images 
was performed with ease, and indicated that the crystals showed C2 symmetry, similar to 
that of the previously reported N-terminal CARD domain (ΔCARD) in complex with 
covalent peptide inhibitor z-VAD-FMK (PDB ID: 1JXQ)
20
.  
4.5.3. Zinc Soaks of caspase-9 Crystals 
Therefore, these conditions were used for further experimentation. In order to 
obtain a structure of caspase-9 in the presence of zinc, full-length caspase-9 wild-type 
crystals needed to be soaked in mother liquor containing the zinc ion. The 0.1 M MES pH 
5.8 and 15% PEG 6,000 mother liquor was prepared to include 10 mM ZnCl2. Crystals 
 
Figure 4.8 Diffraction image of apo wild type caspase-9 crystals soaked in a 20% PEG 400 
cryoprotectant for one hour. 
 
116 
 
were transferred from their growth drops to a 3 μl drop of zinc containing mother liquor. 
Soaking of the crystals lasted for the duration of 15 minutes, 30 minutes, 1 hour, 2 hours, 
3 hours, 5 hours, or 18 hours. Crystals appeared to remain intact during the entire soaking 
process as no microfractures were observed microscopically. The zinc-soaked crystals 
were then either preserved in cryoprotectant containing zinc to ensure the bound zinc ions 
are not lost during the cryoprotectant incubation time due to the on/off rate of zinc to the 
binding sites or backsoaked in cryoprotectant to ensure excess zinc binding to random 
free thiols did not occur. Cryoprotectant incubation times lasted anywhere from 15 
minutes to overnight. Crystals were preserved by flash freezing in liquid nitrogen. Data 
collection was carried out at Brookhaven National Labs Synchrotron x-ray Light Source 
beamline X6A on the caspase-9 wild type crystals in the presence of zinc. These crystals 
did diffract, however, the diffraction was limited to approximately 7Å (Fig 4.9). In 
addition, within the diffraction image, a smeary/mosaic spot shape was observed as well 
as an anisotropic diffraction pattern. These characteristics provide clues as to the changes 
in conformation that may have occurred within the caspase-9 crystal upon binding zinc.  
The observed smeary spot shape, suggests increased mosaicity in the crystal form, which 
could not be corrected by annealing. In addition the diffraction images themselves 
indicate that crystals are directionally dependent or anisotropic in nature.   
 Based on the quality of the diffraction images for the apo caspase-9 
crystals, conditions and methods for soaking of the caspase-9 crystal in zinc soak should 
be reevaluated. Alternate metal salts such as zinc sulfate and zinc acetate which also 
inhibit enzymatic function could be explored. Furthermore, soaking methodology such as 
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the zinc concentration and time could also improve diffraction of zinc bound caspase-9 
crystal.  
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CHAPTER V 
CASPASE-9 CARD:CORE DOMAIN INTERACTIONS REQUIRE A 
PROPERLY-FORMED ACTIVE SITE 
Abstract 
 The activation mechanism of caspase-9 is unique in that the addition of individual 
domains or when bound to the large protein complex, the apoptosome, has a great affect 
on enzymatic activity. The N-terminal prodomain, CARD, of caspase-9 is the smallest 
unit capable of increasing caspase-9 activity.  We investigated CARD with respect to the 
activation, oligomerization and stability of caspase-9.  Our data suggest an increase in 
dimerization due to the presence of CARD is not the cause of the increased activity 
observed. We determined that caspase-9 undergoes conformational acrobatics by 
adopting one conformation in the uncleaved, monomeric form and cleaved active dimeric 
state where the active site is in an ordered state, while adopting another in the cleaved 
monomeric form in the presence of a disordered active site.  
5.1. Introduction 
 Caspase-9 is as a critical initiator of the intrinsic pathway of apoptosis or 
programmed cell death. It is responsible for activating downstream executioner caspases-
3, -6 and -7 which ultimately results in the breakdown of the cell. Defects in this pathway 
are a characteristic of diseases ranging from autoimmune disorders to cancer. In these 
diseases, activation of caspase-9 is particularly critical
1-3
, however, a full mechanistic 
understanding of caspase-9 activation is lacking. 
 In general, caspases, or cysteine aspartate proteases, are functional as homodimers 
of monomeric units that comprise an N-terminal prodomain and a catalytic large and 
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small subunit connected by an intersubunit linker.  Upon dimerization and cleaveage at a 
specific aspartate residue within the intersubuint linker, the enzyme becomes active. 
Unlike the executioner caspases, caspase-9 is active even in the absence of cleavage of 
the intersubunit linker
4
. Furthermore, the executioner caspases have short N-terminal 
prodomains whereas caspase-9’s catalytic core is preceded by a long regulatory domain 
called the Caspase Activation and Recruitment Domain (CARD). The caspase-9 CARD 
facilitates a protein-protein interaction with the CARD of the apoptotic protease 
activation factor 1(Apaf-1), which anchors caspase-9 to the activation platform known as 
the apoptosome
5-7
. This platform is created upon release of cytochrome c from the 
mitochondria following an internal cellular stress signal. Cytochrome c is then able to 
bind to Apaf-1. This binding event, initiates a conformational change in Apaf-1, resulting 
in the heptameric oligomerization of the protein, driven in an ATP-dependent manner. 
This Apaf-1 platform is then responsible for the recruitment and activation of caspase-9. 
The molecular details of caspase-9 activation by the apoptosome have not been 
elucidated.  
 The interaction of caspase-9 with the apoptosome increases caspase-9’s activity 
by approximately 2000-fold
4
. However, even in the absence of this platform, the presence 
of individual domains influence caspase-9 activity. Caspase-9 is 20% more active when 
caspase-9’s catalytic core remains covalently linked to the CARD domain8 (Fig 5.1). The 
authors hypothesized that increased tangling of CARD domains lead to an increase in the 
dimeric fraction of full-length caspase-9 over ΔCARD-caspase-9. Addition of the Apaf-1 
CARD in isolation further enhances caspase-9 activity by five-fold, in vitro. The greatest 
increase in activity is when full-length caspase-9, including both the CARD and core 
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domains, bind to the apoptosome through Caspase-9 CARD: Apoptosome CARD 
interactions. 
 Early models of the apoptosome activation of caspase-9 argued that the increased 
activity is due to a change in the oligomeric state of the enzyme via increasing the local 
concentration of monomeric caspase-9. Recruitment of additional molecules were 
hypothesized to participate as partners in dimerization
9
 or facilitate dimerization amongst 
the apoptosome-bound monomers
10
. This model is supported by the evidence that 
enhanced activity is associated with dimerized capase-9 molecules
11
. Alternative, 
competeting views of the activation mechanism invoke induced conformational changes 
around the active site region of the enzyme
12
. This conformational change model is 
potentially supported by the new evidence emerging from high-resolution cryo electron 
microscopy that shows that caspase-9 is monomeric when bound to the apoptosome in 
the highly active state and that caspase-9 activation can be achieved without apoptosome 
formation
13
. 
 
Figure 5.1 Model depicting the increase in enzymatic activity of caspase-9. Activity is lowest 
for the monomeric unit of the catalytic core (C9ΔCARD) and increases to the highest when 
full-length caspase-9 is bound to the apoptosome. 
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 Taking inspiration from the proposed mechanisms of capase-9 activation by the 
apoptosome we want to further investigate the affect of CARD with respect to the 
activation, oligomerization and stability of caspase-9. A goal in this work is to understand 
whether CARD influences the oligomeric state of caspase-9, specifically the ratio of 
monomer to dimer in vitro, thus causing the observed increase in activity. We probe 
interactions between the caspase-9 CARD and core domains. Finally we investigate 
whether the caspase-9 CARD induces or takes advantage of conformational changes in 
the loops that form the active site region as has been observed for caspase-6 and -7
14,15
. In 
caspase-6 and -7 conformational changes in the active-site loops can be observed by both 
thermal denaturation and circular dichroism spectral measurements. Defining CARD’s 
role in the activation of caspase-9 will provide much needed insight for exploiting 
caspase-9 for therapeutic means. 
5.2. Results 
5.2.1. The Influence of CARD on the Oligomeric State and Stability of Caspase-9 
 Activity measurements of caspase-9’s catalytic core (caspase-9 ΔCARD), in the 
absence of the apoptosome platform, have been previously observed to have a lower 
catalytic efficiently when compared to the full-length version of the enzyme. We 
interrogated the affect the presence of the CARD has on these specific biophysical 
properties of the capase-9 enzyme. To ensure that the caspase-9 ΔCARD and full-length 
reagents used for this study were comparable to the studies that show CARD’s ability to 
enhance caspase-9 activity, measurements of the enzymes catalytic properties were 
performed (Table 5.1). As previously reported, the ΔCARD variant of caspase-9 has a 
decreased catalytic efficiency when compared to the full-length version. Therefore we 
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reasoned that any differences observed between the two caspase-9 variants would be due 
to the presence or absence of the CARD domain.                                                             
 One potential reason for the increased in activity of full-length caspase-9 would 
be due to an altered oligomeric state of the enzyme in the presence of CARD as predicted 
previously
8
. Full-length and ΔCARD versions of the caspase-9 enzyme were subjected to 
size exclusion chromatography to determine the oligomeric state of both enzymes (Fig 
5.2). Both enzymes are predominantly monomeric in solution to such a great extent that 
no dimeric fraction could be observed. Both the full-length and ΔCARD versions of 
caspase-9 are both capable of completely converting to the dimeric state as observed 
when the enzyme is in the presence of an active-site ligand such as the covalent active-
site inhibitor z-VAD-FMK. Thus the CARD does not have a great influence on the 
 
Table 5.1 Measured kinetic parameters of full-length caspase-9 (C9FL) and caspase-9 in the absence of 
the N-terminal CARD domain (C9ΔCARD). 
 
 
Figure 5.2 Size exclusion chromatography of full-length caspase-9 (C9F) 
and caspase-9 ΔCARD (C9 ΔCARD) in the presence and absence of active 
site ligand z-VAD-FMK. 
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oligomeric state of the enzyme and cannot be the cause of the increased activity observed 
in the presence of CARD.  
 Another potential reason for the increased activity of caspase-9 full-length is an 
increased in stability in the presence of the CARD. Thermal denaturation studies were 
then pursued to determine if the presence of CARD changes the thermal stability of the 
enzyme and thus the reason for increased activity. Both the full-length and ΔCARD 
caspase-9 enzymes in their monomeric and dimeric forms were analyzed for changes in 
their thermal stability measurements. Full-length capase-9, which has been cleaved at the 
intersubunit linker between the large 
and small subunits, and includes the 
CARD domain, shows a three-state 
unfolding curve (Fig 5.3 A). The first 
melting transition occurs at 49 ± 2 °C 
while the second occurs at 62 ± 2 °C. 
To determine which component of the 
full-length caspase-9 enzyme was 
contributing to which melting 
transition, the catalytic core and CARD 
domains were expressed independently 
and interrogated in a similar fashion. 
The catalytic core of the enzyme 
(caspase-9ΔCARD), which is also 
cleaved at the intersubunit linker, is 
 
Figure 5.3 Thermal denaturation analysis and circular 
dichroism spectrum of monomeric, cleaved, caspase-
9 (A) full-length, (B) ΔCARD, and (C) CARD only. 
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responsible for the first melting transition at 49 ± 1 °C (Fig 5.3 B) while the second 
transition corresponds to CARD only with a melting temperature of 61 ± 2 °C (Fig 5.3 
C). These results indicate that when caspase-9 is in its cleaved monomeric state, the 
presence of CARD does not affect the overall thermal stability of the caspase-9 catalytic 
core and the two portions of the enzyme unfold independently. Caspase-9 can be forced 
to a dimeric state by binding of active-site ligand. Thermal denaturation studies were 
performed on the cleaved full-length and ΔCARD versions of caspase-9 when the 
enzyme is in a dimeric state with active site ligand bound (Fig 5.4). Both versions of 
caspase-9 show an increase in thermal stability. Caspase-9ΔCARD (Fig 5.4 A) has a 
14°C increase in thermal stability which is similar to the increase in stability observed 
 
when caspase-7 binds active site ligand
15
, while full-length caspase-9 (Fig 5.4 B) shows 
only a 6 °C increase in thermal stability, more similar to the 3 °C increase in stability 
observed for caspase-6 upon ligand bidning
14
. Strikingly, the three-state unfolding of the 
full-length caspase-9 is no longer observed in the presence of substrate. It appears that 
binding ligand to the active site of caspase-9, which induces dimerization and ordering of 
the active site loop bundle, transitions caspase-9 to a two-state unfolding mechanism. 
 
Figure 5.4 Thermal denaturation analysis and circular dichroism spectrum of dimeric, cleaved, 
caspase-9 (A) full-length, (B) ΔCARD. 
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Full-length caspase-9 is completely unfolded at 90 °C as observed in the circular 
dichroism spectrum. The single transition observed when cleaved full-length caspase-9 in 
the dimeric state indicates that binding substrate and dimerization either results in the 
complete unfolding of CARD or causes the catalytic core and CARD to unfold as one 
cooperative unit. An overlay of the circular dichorism spectra from the full-length 
cleaved caspase-9 in the monomeric and dimeric states (Fig 5.5) indicates that there is not 
a change in the secondary structure content. 
Therefore, CARD does not appear to unfold in 
the presence of substrate so the CARD and the 
caspase-9 catalytic core must be unfolding as 
a single cooperative unit. These results 
suggest that a physical interaction between the 
CARD and core domains occurs, which 
causes the two domains to unfold as a single 
unit. 
 It has been reported that uncleaved caspase-9 acts as an active zymogen 
4
 possibly 
due to its increased intersubunit linker length which enables the enzyme to support a 
properly formed active site.  Therefore, this form of caspase-9 can be utilized to 
interrogate whether the interaction observed between CARD and the catalytic core of 
caspase-9 is due to changes in the active site conformation. Analysis of the full-length 
monomeric caspase-9 in the uncleaved state, where the complete polypeptide chain is still 
intact, resulted in the similar two-state unfolding mechanism as observed for the cleaved 
active dimeric state (Fig 5.6). Therefore, the monomeric, uncleaved caspase-9 enzyme 
 
 
Figure 5.5 Overlay of the circular dichroism 
spectrum for full-length caspase-9 (C9F) in 
the presence and absence of active site ligand 
z-VAD-FMK 
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appears to support the interaction of 
the core and CARD domains 
because they unfold as a single unit. 
To further test this mechanism, we 
cleaved the same zymogen 
construct with caspase-3 (Fig 5.7). 
Cleavage of the intersubunit linker 
breaks the interaction of the CARD 
and catalytic core domains observed 
by the independent three-state 
unfolding property as seen in the 
cleaved wild-type enzyme (Fig 5.6 B, 5.7). Together, these data imply that the CARD 
domain and the catalytic core of caspase-9 do not physically interact and unfold 
independently in monomeric 
caspase-9 with a disordered active 
site, whereas, these domains 
physically interact and unfold 
cooperatively, as a single unit, in the 
uncleaved monomeric and cleaved 
dimeric states where the active site 
is in an ordered state. 
 
 
 
Figure 5.6 Thermal denaturation analysis and circular 
dichroism spectrum of (A) monomeric, uncleaved 
caspase-9 and (B) monomeric, cleaved caspase-9. 
 
Figure 5.7 SDS-PAGE analysis of full-length 
uncleaved caspase-9 (C9F-C287A) in the presence and 
absence of 3% active caspase-3 enzyme (C3).  Full 
length caspase-9 remains uncleaved due to Ala 
substitution of the catalytic residue Cys287.  
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5.2.2. Determining an Interaction Site Between Caspase-9 Catalytic Core and 
CARD Domains. 
 
 The cooperative unfolding observed between the CARD domain and the catalytic 
core of dimeric caspase-9 implies a physical interaction between the two domains. To 
confirm this interaction, the interaction between the isolated CARD and catalytic core 
domains in trans was interrogated (Fig 5.8). The catalytic core in its monomeric or 
dimeric forms was incubated with the CARD domain and analyzed by native gel analysis 
for an interaction between the two domains (Fig 5.8 A). An interaction between the two 
domains, would result in a band the molecular weight of the full-length enzyme by native 
gel analysis. The monomeric and dimeric forms of full-length caspase-9 served as 
reliable controls, but no interaction between the catalytic core and CARD domain was 
observed. Further confirmation of this result was observed via Ni-NTA pull-down 
analysis (Fig 5.8 B) where the bound 6x His-tagged CARD domain was not able to pull-
down the untagged catalytic core. In both gel-filtration and native gel analysis, the CARD 
was not observed to have a strong interaction with the catalytic core of caspase-9 
 
Figure 5.8 Analysis of a CARD: caspase-9 core domain interactions in trans. Interactions analyzed by 
by (A) native gel analysis, (B) Ni-NTA pull-down, and (C) activity assays using fluorogenic substrate 
LEHD-AFC. All experiments were performed in trans. Caspase-9 full-length (C9F); Caspase-9ΔCARD 
(C9Δ). These analyses all suggest that the interaction between these domain is too weak or too transient 
for detection. 
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suggesting that the interaction between the CARD and core domains is either too weak or 
too transient for detection by these methods or is exquisitely sensitive to buffer 
conditions.  
 It is possible that the conditions and experimental requirements for the native gel 
and pull-down analysis could disrupt the CARD and core interaction, so CARD’s ability 
to increase caspase-9 activity in trans was tested under conditions in which activity can 
be monitored (Fig 5.8 C). This equilibrium-based experiment should report on the 
strength of the interaction between the CARD and catalytic core domains and define the 
importance of the linker that attaches the CARD and core domains together. No change 
in caspase-9 ΔCARD activity was observed in the presence of excess CARD alone or in 
the presence of excess lysozyme as a crowding agent. This indicates that the tether 
between CARD and the catalytic core of caspase-9 is necessary for CARD’s impact on 
enzymatic activity. 
 Since the linker between the CARD and core domains is essential to increase the 
activity of caspase-9, we reasoned that 
perhaps there were either specific 
interactions with the tether and the 
adjacent domains or a length-dependence 
to the interaction. To test this, a five 
amino acid Ser-Gly extension was 
inserted within the linker between CARD 
and the large subunit of caspase-9’s 
catalytic core (Fig 5.9). This variant 
 
Figure 5.9 Characteristics of the Ser-Gly linker 
extension caspase-9 variant. Kinetic parameters, 
thermal denaturation analysis, and circular 
dichroism spectra of the Ser-Gly linker extension 
caspase-9 variant. 
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behaves like the native full-length-form of caspase-9 in both its catalytic parameters and 
thermal stability suggesting that longer potentially more flexible linker does not 
negatively impact the function of caspase-9. Further investigation into the linker length 
would be required to determine if a certain distance or flexibility can disrupt the 
activation property of CARD or if a tether alone is sufficient to obtain the desired effect 
no matter the length. Moreover, it is intriguing to consider, shortening the linker length 
between the CARD and core domains to determine if restricting the flexibility of CARD 
will reduce the activation effect of CARD. This will provide information on the shortest 
length required for the interaction to occur.  
 The previous studies suggest that the interaction between the CARD and core 
domains of caspase-9 are present, but are weak and potentially transient. Docking studies 
between reported crystal structures of the CARD and the dimeric form of the caspase-9 
catalytic core were performed using the RosettaDock server
16
 to predict potential 
interactions between the CARD and core domain to guide mutational studies.  Protein 
structure files for CARD (PDB ID: 3YGS
17
) and the catalytic core of caspase-9 (PDB ID: 
1JXQ
11
) were submitted for docking studies. The top docking models were analyzed 
using two criteria i) avoiding interactions with residues involved in the caspase-9 
CARD/Apaf-1 CARD complex and  ii) not allowing negative interactions to occur in the 
presence of Apaf-1 CARD. Two models, Model 2 and Model 10, fit these criteria (Fig 
5.10). In both, the CARD is positioned behind the substrate-binding groove where it 
could potentially affect active site loops L3 and L4 and there are no negative interactions 
observed. Charge swap variations were made in both Model 2, which places CARD in a 
helix-to-helix interaction with the catalytic core of caspase-9 (Fig 5.10 A), and Model 10, 
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 which places CARD in a loop-to-helix interaction with the catalytic core of caspase-9 
(Fig 5.10 B), in an attempt to disrupt the activating effect of CARD. Single variations of 
Arg7 and Arg11 and in combination, both changed to glutamate, would test Model 2 
while Asp23 and Arg51 charge swapped to glutamate would test Model 10. These 
variations were selected to be in the CARD domain only so the observed effect would 
report on CARD and not on change the catalytic activity, which is solely due to the 
catalytic portion of the enzyme. One variant, Glu365Arg, was selected in the catalytic 
core which had potential to disrupt either model of CARD binding to the catalytic core of 
caspase-9.  
 We expected that mutations that disrupted the interaction between the CARD and 
core domain would decrease the catalytic efficiency of the variant versions of caspase-9. 
Upon analysis of the charge swap affects on the catalytic efficiency of caspase-9, a two-
fold decrease in catalytic efficiency was observed for variant R7E (Table 5.2) which 
would support Model 2, the helix-to-helix binding mode of CARD to caspase-9. A 
similar affect was observed by the single site variant R11E which further supports a 
helix-to-helix binding model of CARD and the catalytic core of caspase-9. However the 
 
Figure 5.10 Top RosettaDock models of the potential interaction site between CARD and the catalytic 
core of caspase-9. (A) Model 2 provided a helix-to-helix mode of binding while (B) Model 10 provides 
a loop-to-helix mode of binding. 
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double site variant of R7E/R11E did not show an enhancement of this affect (Table 5.2).  
This could indicate that R7 and R11E are included in the activating affect of CARD; 
however, the combination of both these variants is not strong enough to completely 
eliminate the activation property of CARD, as the catalytic efficiency of the ΔCARD 
version of the enzyme was not recapitulated. This suggests that this region of the CARD 
domain is responsible for its activating effects however additional interactions are 
required.  
5.3. Discussion 
 Caspase activation mechanisms are relevant for treatment of diseases in which 
apoptosis has gone awry. Caspase-9 in particular has a unique activation mechanism 
including changes in its conformational and oligomeric state and its association with an 
activation platform called the apoptosome. Furthermore, individual domains which are 
linked to the enzyme such as CARD or which are associated with the caspase-9 activation 
mechanism, such as the Apaf-1 CARD also have the ability to increase enzymatic 
 
Table 5.2 Measured kinetic parameters of caspase-9 variants designed to disrupt the activation affect 
of the CARD domain. 
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activity. The property of  changing enzymatic activity by presence of additional domains 
such as the one observed with CARD and caspase-9 is also relevant in other proteins such 
as PAS Kinase
18
, Dnmt1 DNA methyltransferase
19
, and ADAMTS-4
20
. Therefore 
studying the individual activation effects of a particular domain provides further insights 
towards how caspase-9 becomes activated on the apoptosome. 
 Here we have investigated the effect of the caspase-9 CARD domain with respect 
to its ability to increase enzymatic activity. We have determined that the oligomeric state 
of both caspase-9 full-length and ΔCARD were comparable with respect to the presence 
of the monomeric and dimeric caspase-9 states, indicating the presence of CARD does 
not shift the oligomeric state equilibrium from monomer to dimer. Thus, the presence of 
CARD is not the cause for the increased enzymatic activity observed. Furthermore, we 
observed that the CARD and catalytic core domains of caspase-9 unfold independently 
and do not physically interact in the monomeric state of the cleaved enzyme where the 
active site is not able to form a properly ordered substrate-binding groove. However, 
these domains unfold cooperatively, or as a single unit, in a dimeric state indicating a 
physical interaction when the cleaved enzyme dimerizes and has a properly ordered 
active site. Moreover, cooperative unfolding of CARD and the catalytic core of caspase-9 
is also observed in the uncleaved form of full-length caspase-9 zymogen. Intriguingly this 
CARD-core domain interaction is alleviated by cleavage of the intersubunit linker by 
caspase-3. Thus, CARD appears to be interacting with any version of caspase-9 
presenting a properly formed substrate-binding groove. The substrate-binding groove is 
ordered in dimeric cleaved caspases (-1, -3, -6, -7 and -9)  and can also be formed in 
uncleaved zymogen of caspase-9, due to linkage effects which allow the intersubunit 
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linker to buttress the L3 and L4 loops in an ordered conformation  (Fig 5.11). Shortening 
of the intersubunit linker would show the length requirement necessary this stabilizing 
effect. 
 This alteration in conformational state of CARD observed between the cleaved 
inactive monomer and the uncleaved monomer or cleaved active dimer states is 
reminiscent of the conformational acrobatics observed in caspase-6. In this case, a helical 
conformation is observed in the mature enzyme which converts to a β-strand 
conformation in the active state. Furthermore, the uncleaved zymogen of caspase-6 
adopts a similar β-strand as observed in the active state of the enzyme. Our data suggest 
caspase-9 follows a similar trend to caspase-6 by adopting one conformation in the 
uncleaved, monomeric form and cleaved active dimeric state while adopting another in 
the cleaved monomeric state (Fig. 5.11).Therefore, it appears that the most unique 
regions within the caspase class of enzymes, the pro domain and intersubunit linker may 
combine efforts to regulate the activity of caspase-9, providing evidence for the active 
site stabilizing model of apoptosome activation. 
 
Figure 5.11 Model of caspase-9 activation states in the presence of CARD. 
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 Further studies on the interconversion properties of the caspase-9 catalytic core 
and CARD domains, utilizing a preformed caspase-9 dimer
21
, could provide insight into 
the dependence of the oligomeric state on the cooperative unfolding property of the full-
length enzyme. Single charge swap mutations on the surface of the protein distal from the 
active site were not strong enough or properly positioned to disrupt the activating affect 
of CARD. A more extensive alanine scanning mutagenesis study or charge repulsion 
analysis around the substrate-binding groove could further define the region of 
interaction between the CARD and core domains mediated by the active-site region of 
the enzyme. 
5.4. Materials and Methods 
5.4.1. Caspase-9 Expression and Purification 
The caspase-9 full-length gene (human sequence) construct, encoding amino acids 
1-416, in pET23b (Addgene plasmid 11829
4
) was transformed into the BL21 (DE3) T7 
Express strain of E. coli (NEB). The cultures were grown in 2xYT media supplemented 
with ampicillin (100 mg/L, Sigma-Aldrich) at 37°C until they reached an optical density 
at 600 nm of 1.2. The temperature was reduced to 15°C and cells were induced with 1 
mM IPTG (Anatrace) to express soluble 6xHis-tagged full-length protein.  Cells were 
harvested after 3 hrs to obtain single-site processing at Asp315. Cell pellets stored at -
20°C were freeze-thawed and lysed in a microfluidizer (Microfluidics, Inc.) in 50 mM 
sodium phosphate pH 8.0, 300 mM NaCl, and 2 mM imidazole. Lysed cells were 
centrifuged at 17,000 rpm to remove cellular debris. The filtered supernatant was loaded 
onto a 5-ml HiTrap Ni-affinity column (GE Healthcare). The column was washed with a 
buffer containing 50 mM sodium phosphate pH 8.0, 300 mM NaCl, and 2 mM imidazole 
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until 280 nm absorbance returned to base line. The protein was eluted using a linear 
imidazole gradient of 2 to100 mM over the course of 270 mL. The eluted fractions 
containing protein of the expected molecular weight and composition were diluted by 10-
fold into a buffer composed of 20 mM Tris pH 8.5, 10 mM DTT to reduce the salt 
concentration. This protein sample was loaded onto a 5-ml Macro-Prep High Q column 
(Bio-Rad Laboratories, Inc.). The column was developed with a linear NaCl gradient and 
eluted in 20 mM Tris pH 8.5, 100 mM NaCl, and 10 mM DTT buffer. The eluted protein 
was stored in -80°C in the above buffer conditions. Purified caspase-9 was analyzed by 
SDS-PAGE and ESI-MS to confirm mass and purity. Caspase-9 variants, C287A, R7E, 
R11E, D23E, R51E E365R, R7E/R11E and the Ser-Gly linker extension, were  produced 
by the Quikchange mutagenesis method (Stratagene), in the full-length expression 
construct, and were purified by the same method as described here for the wild-type 
protein. 
Caspase-9ΔCARD was expressed from a two-plasmid expression system. Two 
separate constructs, one encoding the large subunit, residues 140-305, and the other 
encoding the small subunit, residues 331-416, each in the pRSET plasmid, were 
separately transformed into the BL21 (DE3) T7 Express strain of E. coli (NEB). The 
recombinant large and small subunits were individually expressed as inclusion bodies for 
subsequent reconstitution. Cultures were grown in 2xYT media supplemented with 
ampicillin (100 mg/L, Sigma-Aldrich) at 37°C until they reached an optical density at 
600 nm of 0.6. Protein expression was induced with 0.2 mM IPTG. Cells were harvested 
after 3 hrs at 37°C. Cell pellets stored at -20°C were freeze-thawed and lysed in a 
microfluidizer (Microfluidics, Inc.) in 10 mM Tris pH 8.0 and 1 mM EDTA. Inclusion 
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body pellets were washed twice in 100 mM Tris pH 8.0, 1 mM EDTA, 0.5 M NaCl, 2% 
Triton, and 1M urea, twice in 100 mM Tris pH 8.0, 1 mM EDTA and finally resuspended 
in 6 M guanidine hydrochloride. Caspase-9 large and small subunit proteins in guanidine 
hydrochloride were combined in a ratio of 1:2, large:small subunits, and rapidly diluted 
dropwise into refolding buffer composed of 100 mM Tris pH 8.0, 10% sucrose, 0.1% 
CHAPS, 0.15 M NaCl, and 10 mM DTT, allowed to stir for one hour at room 
temperature and then dialyzed four times against 10 mM Tris pH 8.5, 10 mM DTT, and 
0.1mM EDTA buffer at 4°C.  Typically 5 mL of  of mixed caspase large and small 
subunits was diluted into 80 mL in refolding buffer and dialyzed against 5 L of dialysis 
buffer. The first and last dialysis steps were allowed to proceed for 4 hours at 4 °C while 
the second dialysis proceeded overnight at 4 °C. The dialyzed protein was centrifuged for 
15 minutes at 10,000 rpm to remove precipitate and then purified using a HiTrap Q HP 
ion exchange column (GE Healthcare) with a linear gradient from 0 to 250 mM NaCl in 
20 mM Tris buffer pH 8.5, with 10 mM DTT. Protein eluted in 20 mM Tris pH 8.5, 100 
mM NaCl, and 10 mM DTT buffer was stored in -80°C. The identity of the purified 
caspase-9ΔCARD was analyzed by SDS-PAGE and ESI-MS to confirm mass and purity. 
5.4.2. Oligomeric-State Determination 
Caspase-9 wild-type, full-length and ΔCARD variant protein samples in 20 mM 
Tris pH 8.5, 110 mM NaCl, and 5 mM DTT were incubated alone (monomer) or with 
covalent inhibitor z-VAD-FMK (carbobenzoxy-Val-Ala-Asp-fluoromethylketone, Enzo 
Lifesciences) (dimer) for 2 hours at room temperature. The oligomeric state of the 
caspase-9 samples were determined via gel filtration. 100 μL of 0.5 mg/ml protein sample 
was loaded onto a Superdex 200 10/300 GL (GE Healthcare) gel-filtration column. Apo 
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and z-VAD-FMK-incubated protein samples were eluted with 20 mM Tris pH 8.0, 100 
mM NaCl, and 2 mM DTT.  Eluted peaks were analyzed by SDS-PAGE to identify the  
eluted protein. Four different molecular weight standards from the gel-filtration 
calibration kit LMW (GE Healthcare) were run in the same conditions and a standard plot 
was generated to determine whether the peaks were caspase-9 monomer or dimer. 
5.4.3. CARD Expression and Purification 
 The CARD only construct (amino acids 1-138) in pET23b was made by 
QuikChange mutagenesis (Stratagene) using the oligo-nucleotide primer 5`-CCCAGA-
CCAGTGGACATTGGTTCTGGAGGATTCGGTGATCACCACCACCACCACCAC
TAAGTCGGTGCTCTTGAGAGTTTGAGGGGAAATGCAGATTTGG-3`and its 
reverse compliment on the caspase-9 full-length gene (Addgene plasmid 11829). These 
oligo-nucleotide primers insert a 6xHis-tag and a stop codon after the last amino acid of 
the CARD domain (D138), leaving the remaining portion of the caspase-9 gene in the 
plasmid. The construct was transformed into BL21 (DE3) T7 Express strain of E. coli. 
The cultures were grown in 2xYT media supplemented with ampicillin (100 mg/L, 
Sigma-Aldrich) at 37°C until they reached an optical density at 600 nm of 0.6. The 
temperature was reduced to 15°C and cells were induced with 1 mM IPTG (Anatrace) to 
express soluble 6xHis-tagged full-length protein.  Cells were harvested after 18 hrs. Cell 
pellets stored at -20°C were freeze-thawed and lysed in a microfluidizer (Microfluidics, 
Inc.) in 50 mM sodium phosphate pH 8.0, 300 mM NaCl, and 2 mM imidazole. Lysed 
cells were centrifuged at 17,000 rpm to remove cellular debris. The filtered supernatant 
was loaded onto a 5-ml HiTrap Ni-affinity column (GE Healthcare). The column was 
washed with a buffer containing 50 mM sodium phosphate pH 8.0, 300 mM NaCl, 2 mM 
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imidazole until 280 nm absorbance returned to base line. The column was washed with 
50 mM phosphate pH 8.0, 300 mM NaCl, 50 mM imidazole and the protein was eluted 
with 50 mM phosphate pH 8.0, 300 mM NaCl, 250 mM imidazole. The eluted fraction 
was diluted by 10-fold into a buffer containing 20 mM Tris pH 8.0 and 2 mM DTT to 
reduce the salt concentration. This protein sample was loaded onto a 5 ml Macro-Prep 
High Q column (Bio-Rad Laboratories, Inc.). The column was developed with a linear 
NaCl gradient. Protein eluted in 20 mM Tris pH 8.0, 2 mM DTT, and 130 mM NaCl. 
Eluted protein was analyzed by SDS-PAGE to assess purity and stored in -80°C. 
5.4.4. Thermal Stability and Secondary Structure Analysis by Circular Dichroism 
 Caspase-9 variants and CARD proteins were buffer exchanged via dialysis against 
100 mM sodium phosphate pH 7.0, 110 mM NaCl, and 5 mM TCEP and diluted to 7 μM. 
The samples were split in half and incubated in the presence or absence of four molar 
equivalents of active site ligand VAD-FMK for 3 hours at room temperature. To ensure 
complete binding of the active site ligand to the protein, remaining enzymatic activity 
was assayed using 300 μM substrate, LEHD-AFC (N-acetyl-Leu-Glu-His-Asp-7-amino-
4-fluorocoumarin), (Enzo Lifesciences). Once full inhibition was achieved, samples were 
buffer-exchanged six times with 100 mM phosphate buffer pH 7.0, 100 mM NaCl and 5 
mM TCEP using an Amicon Ultracell 3K concentrator (Millipore) to remove unbound 
inhibitor. For cleavage of the unprocessed caspase-9 C287A variant, the 7μM protein 
sample was incubated with 3% active caspase-3 protein for two hours at room 
temperature. Full processing of caspase-9 C287A by caspase-3 was determined by SDS-
PAGE analysis. Thermal denaturation of caspase-9 variants and CARD was monitored by 
loss of CD signal at 222 nm over a range of 20–90 °C. The circular dichroism spectra 
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were monitored from 250-190 nm. Both were performed on a J-720 CD spectrometer 
(Jasco) with a Peltier controller. Data were collected four separate times on different days 
from different batches of purified proteins. Curves were fit with Origin Software 
(OriginLab) using sigmoid fit to determine the melting temperature. 
5.4.5. Caspase-3 Expression and Purification 
 Caspase-3 full-length gene (human sequence) in pET23b (Addgene plasmid 
11821
22
) was transformed into BL21 (DE3) T7 Express strain of E. coli and protein 
expression was induced with 1 mM IPTG at 30°C for 3 
23
. The protein was purified as 
described previously for caspase-3 
24
. The eluted protein was stored in -80°C in the buffer 
in which they eluted. The identity of purified caspase-3 was assessed by SDS-PAGE and 
ESI-MS to confirm mass and purity.  
5.4.6. Native Gel Analysis and Ni-NTA Pull Down Assay to Determine in trans 
Interactions 
 
 For native gel analysis to diagnose an interaction between caspase-9ΔCARD and 
caspase-9 CARD in trans, full-length caspase-9, caspase-9 ΔCARD and the CARD 
domain only were dialyzed twice against 100 mM phosphate pH 7.0 and 2 mM DTT for 
90 minutes to rid of excess salt.  Samples were incubated either alone or combined with 
CARD to achieve a 1:1 ratio of caspase-9ΔCARD plus CARD. Each protein sample was 
diluted to a final concentration 10 μM in the dialysis buffer. To induce dimerization 
samples were incubated with 5-fold excess z-VAD-FMK. All samples were allowed to 
incubate at room temperature for one hour. All samples were mixed with glycerol loading 
dye and fractionated on a 10% Tris/Glycine pH 8.3 polyacrylamide gel. The oligomeric 
state of the mixed caspase-9ΔCARD and CARD samples were identified by comparison 
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to the Apo (monomer) and z-VAD-FMK (dimer) of both the caspase-9 full-length and 
caspase-9ΔCARD protein in addition to the CARD only sample.  
 For Ni-NTA pull-down analysis of caspase-9ΔCARD plus CARD in trans, 
samples were diluted to 10 μM in 100 mM phosphate pH 8.0, 5 mM TCEP and 100 mM 
NaCl, to avoid nonspecific interactions of the caspase-9 enzyme with the Ni-NTA beads. 
Samples were incubated either alone or combined with CARD to achieve a 1:1 ratio of 
caspase-9ΔCARD (no tag) plus CARD (6x His-tag). Each protein sample was diluted to a 
final concentration of 10 μM in the dialysis buffer. To induce dimerization samples were 
incubated with 5-fold excess z-VAD-FMK for 15 minutes. 200 μL of protein sample was 
added to a tube containing 50 μL of Ni-NTA beads (Qiagen) that were washed three 
times in water and twice in buffer. Ni-NTA plus caspase-9ΔCARD and CARD samples 
were incubated for 3 hours at 4°C while rocking. Samples were centrifuged for 5 minutes 
at 13,000 rpm to pellet the Ni-NTA beads. Supernatant was aspirated and the beads were 
washed five times with 100 mM phosphate pH 8.0, 5 mM TCEP and 100 mM NaCl to 
remove any unbound or weakly bound protein. Protein elution was then carried out by 
incubating the Ni-NTA beads with phosphate buffer containing 300 mM imidazole for 10 
minutes at room temperature. Samples were centrifuged for 5 minutes at 13,000 rpm to 
pellet the Ni-NTA beads and the supernatant was used for SDS-PAGE analysis. The Ni-
NTA beads were also tested to ensure there were no remaining proteins bound to the 
resin.  
5.4.7. Activity Assays 
 For kinetic measurements of caspase activity, 700 nM caspase-9 full-length 
protein was diluted in 100 mM MES pH 6.5, 10% PEG 8,000, and 5 mM DTT. Each 
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sample was subjected to a substrate titration, performed in the range of 0-300 μM 
fluorogenic substrate, LEHD-AFC, (Ex365/Em495) which was added to initiate the 
reaction. Assays were performed in duplicates at 37°C in 100 μL volumes in 96-well 
microplate format using a Molecular Devices Spectramax M5 spectrophotometer. Initial 
velocities versus substrate concentration were fit to a rectangular hyperbola using 
GraphPad Prism (Graphpad Software) to determine kinetic parameters Km and kcat. 
Enzyme concentrations were determined by active site titration with quantitative, 
inhibitor z-VAD-FMK. Active site titrations were incubated over a period of 3 h in 100 
mM MES pH 6.5, 10% PEG 8,000, and 5 mM DTT. Optimal labeling was observed 
when protein was added to VAD-FMK solvated in dimethylsulfoxide in 96-well V-
bottom plates, sealed with tape, and incubated at room temperature in a final volume of 
200 μL. 90 μL aliquots were transferred to black-well plates in duplicate and assayed 
with 300 μM substrate. The protein concentration was determined to be the lowest 
concentration at which full inhibition was observed. 
 To test the ability of CARD to activate caspase-9ΔCARD in trans, 700 nM 
freshly purified caspase-9ΔCARD was incubated in the presence and absence of 2-, 10-, 
or 20-fold excess of CARD protein for 15 minutes. Half of each protein sample was 
treated with excess lysozyme as a crowding agent. Samples were assayed for activity 
over the course of 10 minutes in a caspase-9 activity assay buffer containing 100 mM 
MES pH 6.5, 10% PEG 8,000 and 10 mM DTT. 300 μM of the fluorogenic substrate, 
LEHD-AFC (Ex365/Em495), was added to initiate the reaction. Assays were performed 
in duplicate at 37°C in 100 μL volumes in 96-well microplate format using a Molecular 
Devices Spectramax M5 spectrophotometer. 
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CHAPTER VI 
A SURFACE-WIDE VIEW OF THE 
NATIVE REGULATORY MECHANSIMS OF CASPASE-9 
6.1. Regulation of Caspase-9 Occurs at a Variety of Locations on its Surface 
 Control of cellular processes plays an essential role in maintaining the 
homeostasis of a cell. This control is maintained by a complex network composed of 
specific regulatory mechanisms for each individual protein within the cell. These 
checkpoints monitor a variety of different protein characteristics ranging from their initial 
synthesis to their final activation states and even their degradation pathways. In order to 
fully understand how to externally regulate a particular protein, a fundamental 
understanding of the native regulatory pathways and their interactions within those native 
pathways is required. 
 Protein regulatory mechanisms can be categorized into a variety of different 
classes. Regulation can occur by altering the genetic expression levels and timing of 
activation of a particular protein or enzyme. This allows the cell to control not only when 
a protein will be produced but the quantity of protein production, resulting in an 
increased versatility during the lifespan of the cell or organism. Post protein production, 
sequestration or compartmentalization of the protein from its functional partner(s) is 
utilized to control a protein function. In the case of proteases, processing of the zymogen 
form of an enzyme is frequently required to initiate its activation pathway. Alternate 
means of regulation also include post-translational modifications or even allosteric 
regulation. Through the utilization of all or a variety of these regulatory checkpoints, a 
tight control of a protein’s function can be obtained. Ideally, each point within these 
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native regulatory pathways can be targeted to create tools to further study enzymatic 
function or for therapies in cases where there has been disruption of the regulation of a 
particular protein.  
 This dissertation focused on discovering new regulatory pathways for caspase-9 
as well as exploiting a known regulatory pathway of the enzyme due to its pivotal role in 
apoptosis and disease. Our work aimed to mimic the native inhibitory complex of 
caspase-9 with XIAP-BIR3 by stabilized peptides to create a tool to control enzymatic 
activity. Instead, this work underscored the importance of bi-functional binding sites. 
Critical interactions at the protein-protein interface as well as at a distal exosite region 
provide two distinct avenues for protein control. In the case of caspase-9 and XIAP-
BIR3, both sites are necessary for potent inhibition. In other protein:inhibitor complexes 
this bi-functionality determines specificity or can individually be used as independent 
regulatory sites. The viral inhibitor, human adenovirus type 5, of human granzyme B, a 
protein that is essential for targeting cell death of natural killer cells and cytotoxic CD8
+
 
T-cells, utilizes exosite interactions as a specificity factor
1
. Common homologues of 
human granzyme B are capable of recognizing human adenovirus type 5 in the substrate 
binding pocket, however, the exosite was critical for specific inhibition of the human 
enzyme. A similar exosite requirement has also been observed with plasminogen 
activator inhibitor-1 which prevents conversion of plasminogen into plasmin through its 
interactions with both tissue-type plasminogen activator and urokinase-type 
plasminogen
2
. Furthermore, when designing blockades to prevent heparin cofactor II 
binding to α-thrombin, targeting of the exosite position was an essential requirement for 
specificity and affinity
3,4
. These examples not only suggest that the presence of an exosite 
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is a common feature within protein complexes; they also provide an alternate avenue for 
designing regulatory molecules. 
 In addition to underscoring the importance of targeting the multiple regulatory 
regions within a native protein complex, our work has also provided insights towards 
alternate regulatory sites within caspase-9. When determining the regulatory mechanism 
of zinc-mediated inhibition of caspase-9, not only did we discover that one zinc ion binds 
to the catalytic region of the protein, an alternate zinc binding site also exists. The main 
regulatory site, at the active site, sequesters the active site residues which would prevent 
catalysis of the peptide bond of a substrate. Besides controlling function, a possible role 
for active-site zinc binding is to protect the active-site ligands from oxidation via a 
similar mechanism to that observed for protein tyrosine phosphatase
5
.  The other binding 
site identified for zinc is distal from the active site and lies within a conserved Cys-His 
region of the enzyme. Although the functional details of this site remain unidentified, this 
region has been previously shown to be conformationally sensitive in caspase-6
6
. 
Therefore, zinc binding to this site could potentially have a site-specific impact on 
caspase-6 activity via an allosteric mechanism. Furthermore, the distal zinc binding site 
could potentially be utilized as a stabilization factor for a particular conformation in 
caspase-6 or other caspases, similar to that observed in voltage-gated potassium channel
7
.  
The non-native control of protein activity by a metal also occurs in a variety of enzymes 
which natively do not utilize zinc. Glycerol 3-phosphate dehydrogenase
8
, tyrosine 
phosphatase
9
, aldehyde dehydrogenase
10
, and the caspases
11
, are all capable of binding 
zinc which results in a loss of enzymatic function.  This suggests that a wide variety of 
non-metalloproteins have evolved to be influenced by metals as an underlying mode of 
150 
 
regulation and that these sites also exist in locations distal from the active site of these 
enzymes. 
 Furthermore, our work in elucidating the mechanism by which CARD activates 
the enzymatic core of caspase-9 revealed yet another alternate regulatory site on the 
surface of caspase-9. The mechanism reveals that CARD not only mediates interactions 
with Apaf-1 of the apoptosome, it potentially facilitates proper organization of the active-
site loop bundle and strengthens these interactions resulting in a fully active enzyme. An 
alternate role for CARD has also been observed where free caspase-9 CARD has the 
ability to cause activation of NF-κB12. Furthermore, identification of an interaction 
between the CARD domain of a caspase-9 and the substrate-binding groove provides a 
unique regulatory mechanism instilled on this cell-death protease that could be targeted 
for further study. Although this interaction is unique to caspase-9 due to the secondary 
structural elements involved, globally similar observations have been made with the 
prodomains of the executioner caspases -3, -6, and -7 and their individual catalytic cores. 
The prodomain of caspase-3 has been shown to play a role in determining the proper 
active-site conformation
13
, in which the presence of the prodomain enhances the 
efficiency of forming the native active-site conformation as if it was an intermolecular 
chaperone. In caspase-6, a similar structural conformation is observed in the zymogen 
and active states of the enzyme
6
 where an alternate form is adopted for the cleaved 
mature form as seen in caspase-9. Unlike caspase-9, caspase-7 has an observed increase 
in catalytic activity upon removal of the prodomain
14
, suggesting that the prodomain 
inhibits the function of the enzyme and possibly the proper formation of the active site 
loop bundle. Nonetheless, in all cases, the prodomain affects the catalytic function of the 
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caspase class of enzymes. It appears that the prodomains play more active role in 
regulating caspase activity than previously thought and affect function through an 
allosteric binding event. Therefore, investing time into understanding this mode of 
regulation and the location of these particular interactions sites would provide valuable 
information not only to the field of caspase function but also to the field of allosteric 
regulation.  
 By gaining an 
understanding of the additional 
modes of regulation imposed on 
caspase-9 function, it is clear that 
this enzyme uses the majority of 
its surface for regulatory control 
(Fig 6.1). This characteristic can 
also be found for a variety of other 
proteins
15-17
  which exemplifies the 
dynamic nature of the caspase 
class of enzymes and opens up the possibility of the caspases involvement in alternate 
roles within the cell. Furthermore, the discovery of these new regulatory sites native to 
the enzyme and possibly specific to caspase-9, increases the potential for specific drug 
targeting of an individual caspases and even makes the search for additional sites within 
the caspase class of enzymes an alluring concept. 
 Determination of these novel sites would be critical to distinguish one caspase 
from the next in a regulatory or drug targeting standpoint. Although their general 
 
Figure 6.1 Structure of caspase-9 with mapped regulatory 
surfaces. 
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structural properties may be similar, it is suggested by Ranganathan and coworkers, that a 
statistical coupling between amino acids exists within a protein’s architecture and this 
coupling has the potential to impose functional constraints on the enzyme
18-22
. These 
networks provide a means of communication from a surface site on the protein to its 
functional active site and provide the underlying scheme that drives the co-evolution of 
new “hot spots” for protein regulation23,24.  Investigation into these networks allowed for 
design of non-native allosteric control of dihydrofolate reductase
24
 and the PDZ family of 
proteins
23
. Therefore it is plausible to think that all proteins have these sensitive 
regulatory sites over the entire surface and at some point these sites will be exploited by 
nature to increase the ultimate fitness of the cell. 
 A study into the co-evolution of these “hot spot” networks via and computational 
simulations of correlated motions within the family of caspases could help distinguish 
unique patterns within the caspase architecture. An alternate yet parallel investigation 
utilizing NMR dynamics analysis or even thermal fluctuation analysis of crystal 
structures could provide insight into the dynamic properties of these enzymes and provide 
hints into the location of these networks as observed in the case of PDZ domains 
20,25-27
. 
Hints towards these mechanisms within the caspase class of enzymes may already exist 
in the literature. Because  thermodynamic values relating to protein stability under 
various conditions has been linked to functional cooperativity (reviewed in
28
), the 
presence of these networks in caspases seems likely. These studies would provide the 
information necessary for unique regulation of the caspases via a diverse set of novel 
allosteric sites.  
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 A potential venue to observe such networks may already exist by understanding 
the phosphorylation mechanisms of the caspase class of enzymes. Phosphorylation of a 
protein has been shown to increases the possibilities for protein-protein interactions as 
well as conformational regulation in a phosphorylation pathway. Therefore, it is 
intriguing to speculate how the co-evolving networks might change as a result of the 
phosphorylation patterns imposed on the enzyme during cellular signaling.   Within the 
caspase class of enzymes, the function of some phosphorylation sites have been 
characterized to disrupt active site formation such as phosphorylation of S257 in caspase-
6 (unpublished data). However, the molecular details of most phosphorylation sites are 
unknown and determining those mechanisms could potentially link or even expose 
alternate “hot spot” networks to diversify the caspase function at a selected point in 
cellular signaling.  
 In summary, the emergence of allosteric mechanisms that occurs during the 
evolutionary process has the ability to diversify members of a single protein family. 
Therefore, these mechanisms provide a means of specifically controlling a single protein 
from that of an otherwise undistinguishable class of enzymes. For this reason it is 
important to further explore native regulatory mechanisms of not only the caspases but 
other proteins as well to aid in understanding the protein function as well as be a guide 
for future design. 
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APPENDIX A 
SMALL MOLECULE ACTIVATION OF CASPASE-9 
A.1. Introduction 
 A major factor in the activation of caspase-9 is regulation of its oligomeric state 
where the enzyme transitions from an inactive monomer to an active dimer
1
. Disruption 
of this mechanism leads to a down regulation of apoptosis, which is a characteristic of a 
variety of many cancer cells
2-6
. For this reason, molecules to control caspase activation 
are highly desired. To date, the molecule PAC-1 has been developed to activate the 
caspases through relieving their zinc mediated inhibition
7,8
, however, a molecule which 
directly acts on the initiator of the intrinsic pathway of the apoptotic cascade (caspase-9) 
has not been developed. An external trigger of caspase-9 dimerization would be a useful 
tool for understanding the detailed mechanism of caspase-9 activation and provide a 
proof of principal for small molecule development of caspase-9 activators.  
 The small fluorescent molecule, 4`, 5`-bis(1, 3, 2-dithioarsolan-2-yl)fluorescein-
(1, 2-ethanedithiol), otherwise known as Fluorescein Arsenical Hairpin or FlAsH
9
 
recognizes a genetically encoded peptide tag making it 
a useful tool for studying protein localization, folding, 
stability and conformational changes
10-14
 and thus a 
tool for controlling caspase-9 dimerization. This 
fluorescein based molecule contains As(III) 
substituents on the 4`- and 5`- positions (Fig A.1) 
which form a covalent bond with a reduced sulfhydryl 
found on a cysteine residue. The As(III) substituents are protected by 1,2-dithiol such as 
 
Figure A.1 Molecular structure 
of FlAsH-EDT2. 
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ethandithiol (EDT) to prevent non-specific binding to cysteine pairs in the protein, in 
addition to limiting toxicity and background fluorescence.  The FlAsH recognition 
sequence includes two cysteine pairs separated by a two amino acid spacer (C-C-X-X-C-
C) where X could be any amino acid, although tightest binding is observed using Pro-Gly 
in those positions
15
. FlAsH is non-fluorescent in its unbound state. Upon binding to the 
FlAsH recognition motif the small molecule becomes fluorescent with an excitation 
maximum of 508 nm and emission of 528 nm. 
  We aimed to engineer a FlAsH binding caspase-9 variant in which the FlAsH 
specific binding motif was incorporated across the dimer interface, similar to the split 
motif designed as a structural sensor of CRABP I
10
.  FlAsH binding at this engineered 
site would lock the caspase-9 in the dimeric active form of the enzyme. Furthermore, the 
FlAsH fluorescence will be used to confirm binding and the global location of this 
interaction within the enzyme. Ultimately, this study would provide a proof of concept 
that a small molecule can facilitate activation of caspase-9 through inducing dimerization 
of the enzyme and thus activation.  
A.2. Results 
A.2.1. Design of a FlAsH-Activatable Caspase-9 
 Harnessing the natural activation mechanism of caspase-9 will allow development 
of tools to further study this form of caspase regulation and therapeutics for diseases such 
as testicular cancer
3
 and infection of the vaccinia virus 
16
 in which the caspase-9 
activation pathway is targeted. Therefore, our goal is to lock caspase-9 into a dimeric 
state via the small fluorescent molecule FlAsH. This would shift the enzymes equilibrium 
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from inactive monomer to active dimer which would result in an overall increase in 
enzymatic activity. 
 Suitable sites for positioning the FlAsH binding motif across the dimer interface 
were selected based on four criteria; (1) the site would be able to accommodate not only 
the aresnic binding end of the molecule but also the bulky fluorescent portion of the 
probe, (2) the location of binding must be able to facilitate proper FlAsH binding 
geometry, (3) the designs must consider positions that would not disrupt the active site 
loop conformations and (4) if available, place half of the FlAsH motif on a homogeneous 
caspase-9 monomer where upon dimerization, the full binding motif could be formed.  
 Based on these outlined criteria, inspection of the wild-type caspase-9 structure 
(PDB ID: 1JXQ) resulted in two FlAsH-binding models (Fig A.2 A). The first model, 
C9-X, would place FlAsH on the periphery of the protein (Fig A.2 B). This site would 
link the C-terminal end of the α5 helix in caspase-9 to its symmetry partner on the other 
half of the dimer. This model is called C9-helix or C9-X. Amino acid variations at 
 
 
Figure A.2 Models of the caspase-9 FlAsH binding variants. (A) An overall view of the caspase-9 
dimer (blue/cyan) representing FlAsH binding sites for C9-X and C9-β within the dimer interface. 
(B) C9-X model of FlAsH binding to the α5 helix of caspase-9 at positions Q381C and S382C across 
the dimer interface. (C)  C9-β model of FlAsH binding to the β6 strands of caspase-9 at positions 
C403 and N405C across the dimer interface. 
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Gln381 and Ser382 to cysteine would facilitate the formation of the FlAsH binding motif 
upon dimerization of caspase-9 and create a covalent cross-link between the small 
subunit of one monomer to the small-subunit of the opposite monomer. These surface 
exposed residues would allow free movement of the FlAsH molecule while the 
positioning of this site is distant from the active site loop bundle which allows the C9-X 
model of FlAsH binding to fit all the desired criteria.  
 The second designed FlAsH binding motif focuses on the allosteric cavity 
observed within the dimer interface of the caspases
17
 (Fig A.2 C). The base of this site is 
lined with two β6 strands which are critical for the dimerization of caspase-918. This 
strand contains a native cysteine residue, Cys403, which became a focus for the design 
due to its location in the allosteric pocket and its close proximity to its symmetry related 
partner about the two-fold axis.  The nearby residue, Asn405, sits directly across the 
dimer interface from the native cysteine, Cys403, and is in proper positioning for FlAsH 
binding.  A cross-link at this position would link the small subunit from one monomer to 
the small-subunit of the opposite monomer. Therefore, Asn405 would complete the 
FlAsH binding motif with native Cys403 for the C9-β model of FlAsH activation. Further 
inspection also suggests this pocket would be able to accommodate the entire FlAsH 
molecule. However, the C9-β model could potentially disrupt the inactive down 
conformation of the active site loops. Although avoiding disruption of loop conformation 
was a criterion for the design, at this position, binding of FlAsH could potentially shift 
the active site loop equilibrium towards the up or active conformation. Therefore, this 
model would not affect the overall goal of designing an active caspase-9 enzyme. Both 
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the C9-X and C9-β FlAsH binding motifs fit the design criteria for activation of caspase-
9 via FlAsH binding.  
A.2.2. Production of Caspse-9 FlAsH Variants 
 The caspase-9 gene construct encoding amino acids for the small subunit only, 
residues 331-416, in the pRSET was used for converting the wild type gene sequence into 
a version of the caspase-9 ΔCARD FlAsH variants. The oligo-nucleotide pimer 5`-
GCTCACTCTGAAGACCTGTGTTGCCTCCTCTTAGGGTCGC-3`was used to convert 
caspase-9 wild type sequence into the C9small-X variant for FlAsH binding studies via 
converting Gln381 and Ser382 to cysteine.  Due to an error within the original primer 
sequence, a second oligo-nucleotide primer, 5`-CCTGCAGTCCCTCCTGCTTAGGG-
TCGCTAATGC-3`, was designed for correction of a base pair deletion at Leu384 which 
can be found in position 54 of the Hardy Lab DNA Archive Box 1. To make C9small-β, 
the oligo-nucleotide primer 5`-CAGATGCCTGGTTGTTTTTGCTTCCTCCGGAAA-
AAACTTTTC-3` was used for converting N405 to cysteine, found in position 51 of the 
Hardy Lab DNA Archive Box 1.  The previously described primers were also used for 
conversion of the caspase-9 full-length gene (human sequence), encoding amino acids 1-
416, in the pET23b vector (Addgene plasmid 11829) into a full-length version of the 
caspase-9 FlAsH variants, C9F-X and C9F-β, located in position 33 and 35 of the Hardy 
Lab DNA Archive Box 2 Respectively.  Furthermore, a FlAsH binding control variant 
was produced in the caspase-9 full-length construct (C9F-FC). The oligo-nucleotide 
primer, 5`- CCGGAAAAAACTTTTCTTTAAAACATCATGCTGCCCGGGCTGCT-
GCCACCACCACCACCACCACTAATCTAGCG-3`, was designed to incorporate the 
FlAsH binding motif on the C-terminal end of the protein sequence just prior to the 6xHis 
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tag. All caspase-9 FlAsH variants were produced via the Quikchange mutagenesis 
method (Stratagene).  
 The C9small-X and -β FlAsH constructs were separately transformed into the BL21 
(DE3) T7 Express strain of E. coli (NEB). The recombinant large and small subunits 
were individually expressed as inclusion bodies for subsequent reconstitution.  Cultures 
were grown in 2xYT media with ampicillin (100 mg/L, Sigma-Aldrich) at 37°C until 
they reached an optical density at 600 nm of 0.6. Protein expression was induced with 0.2 
mM IPTG. Cells were harvested after 3 hrs at 37°C. Cell pellets stored at -20°C for future 
use. The resultant inclusion bodies were refolded and purified ion exchange column 
purification step only which is outlined in Chapter III. 
 C9F-X and -β FlAsH variants were also transformed into the BL21 (DE3) T7 
Express strain of E. coli (NEB). The cultures were grown in 2xYT media with ampicillin 
(100 mg/L, Sigma-Aldrich) at 37°C until they reached an optical density at 600 nm of 
0.8. The temperature was reduced to 20°C and cells were induced with 1 mM IPTG 
(Anatrace) to express soluble 6xHis-tagged full-length protein.  Cells were harvested 
after 18 hrs and stored at -20°C. The resultant protein was purified using the standard 
caspase-9 imidazole gradient purification followed by an ion-exchange column 
purification step outlined in Chapter IV. The purified C9F-X and -β FlAsH variants 
proteins are estimated to be approximately 95% pure with a two-site cleavage (at residues 
D315 and E306 (Large) or D330 (small)) within its intersubunit linker was used for 
further analysis. 
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A.2.3. Analysis of FlAsH Binding  
 Initial FlAsH binding studies were performed with the ΔCARD version of 
caspase-9. Caspase-9 ΔCARD -X, -β, and wild-type enzymes were concentrated to 10 
μM in Amicon Ultracell 3K concentrator (Millipore). The protein samples were then 
diluted to 4.5 μM in a degassed buffer that contains 0.1 M MES pH 6.5, 10% sucrose, 0.1 
% CHAPS and 10 mM DTT which was then incubated at 4 °C to reduce the cysteine 
thiols. After an incubation time of 15 hours, each caspase-9 variant was incubated with 0, 
0.5 or 2-fold excess FlAsH at room temperature. Samples of caspase-9 proteins with 
FlAsH were anaylzed at 0.5, 3, 7 and 24 hours of incubation time by SDS-PAGE for 
detection of the cross-linked facilitated by FlAsH between two caspase-9 small subunits 
(20 kDa) followed by an in-gel fluorescence for detection of FlAsH binding (Fig A.3).  A 
 
Figure A.3 Analysis of FlasH binding to caspase-9 ΔCARD. Analysis was performed via SDS-
PAGE and in gel fluorescence at 0.5 hr (A) or 24 hr (B). FlAsH proteins assessed for small 
subunit cross-linking and FlAsH binding are the caspase-9 wild type (WT), and the engineered 
caspase-9 variants C9-X (X) and C9-β (β). 
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fluorescent signature was observed just below the 20 kDa molecular weight marker as 
expected of a cross-link between two small subunits within the dimer of caspase-9. Upon 
further inspection of the wild type control, it was discovered that FlAsH was non-
specifically binding to the large subunit of the enzyme (18 kDa). This phenomenon has 
been reported prior for other cysteine rich proteins
19
.  To alleviate fluorescence within the 
expected 20 kDa region, the caspase-9 -X and -β variants were produced in the full length 
version of the enzyme in which the large subunit is connected to the CARD domain 
resulting in a 36.5 kDa fragment while the small subunit still remains at approximate 10 
kDa. By using this form of the enzyme, a clear image of FlAsH fluorescence can be 
observed around the 20 kDa marker. A full-length caspase-9 variant which incorporates 
the FlAsH binding motif -CCPGCC- on the C-terminus was also created for a FlAsH 
binding control, labeled as C9F-FC (position 38 in the Hardy Lab DNA Archive Box 2). 
10 μM of the C9F-WT, C9F-X, C9F-β and C9F-FC FlAsH variants were diluted to 4.5 
μM in a reducing buffer containing 0.1 M MES pH 6.5, 10 % sucrose, 50 mM TCEP, 
which was used as a non-thiol based reductant. This mixture was allowed to incubate for 
one hour at room temperature. Samples were then subjected to FlAsH binding by addition 
of 0.5 mM 1,2-ethandithiol and a 2-fold excess of the FlAsH fluorescent compound. 
Samples were then anayzed by SDS-PAGE (Fig A.4 A) and in-gel fluorescence methods 
(Fig A.4 B). The small subunit of C9F-FC variant appears as a fluorescent band 
indicating these conditions result in a functional assay for detecting FlAsH fluorescence. 
Furthermore, fluorescent bands are also observed for a molecular weight band 
corresponding to large + CARD (36 kDa) and large + small (28 kDa) as expected from 
the non-specific binding of the FlAsH molecule observed in the caspase-9ΔCARD 
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version of the enzyme. Although the non-specific FlAsH binding is observed for the large 
subunit, under these conditions, detectable fluorescence of a molecular weight band is 
visible corresponding to a ~20 kDa fragment.  This particular fragment is identified to 
contain the small subunit as judged by western blot analysis with an anit-caspase-9 small 
subunit antibody (Fig A.5). However, this band is also observed in the SDS-PAGE 
analysis, in the absence of FlAsH, suggesting potential disulfide bond cross-linking at the 
designed sights. Reductant 
concentration, identity as well as 
time of incubation was tested 
however this band still remained 
intact. It is possible that this band 
is a contaminant protein or the 
caspase-9 large subunit only cross 
reacts with the caspase-9 antibody 
and is cysteine rich explaining the 
 
Figure A.5. Western blot analysis of FlasH binding to full-
length caspase-9. Analysis was performed using an 
antibody specific for the small subunit of caspase-9. 
FlAsH. proteins assessed for small subunit cross-linking 
and FlAsH binding are the full-length caspase-9 FlAsH 
binding control (FC), full-length caspase-9 wild type 
(WT), and the engineered caspase-9 variants C9F-X (X) 
and C9F-β (β). 
 
Figure A.4. Analysis of FlasH binding to full-length caspase-9. Analysis was performed via (A) 
SDS-PAGE and (B) in gel fluorescence. FlAsH proteins assessed for small subunit cross-linking 
and FlAsH binding are the full-length caspase-9 FlAsH binding control (FC), full-length caspase-9 
wild type (WT), and the engineered caspase-9 variants C9F-X (X) and C9F-β (β).  
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minimal FlAsH fluorescence detected. Further studies are needed to determine whether 
this 20 kDa band is a pre-formed small-small dimer, caspase-9 large subunit only, or a 
protein contaminate.   
 Considering there was not a robust appearance of FlasH induced caspase-9 
dimerization or fluorescence, efforts turned towards identifying the location of the non-
specific FlAsH binding for further characterization and potential future design. The full-
length caspase-9 contains thirteen cysteines in its amino acid sequence. Therefore, the 
cysteine residues that are solvent exposed were targeted as potential FlAsH binding sites. 
Selected positions, C162, C172, C229, and C239 were interrogated for their role in the 
non-specific FlAsH binding observed due to their proximity to other cysteine residues. 
Each position was converted to either a serine or an alanine by Quikchange mutagenesis 
(Stratagene) and tested for a reduction in FlAsH binding. Single caspase-9 variants, 
C162A, C172A, C229A, C239S, and the double variant C229A/C230A did not show a 
significant decrease in FlAsH fluorescence. This suggests that an alternate positioning of 
the FlAsH binding site exists or there is a need for construction of a caspase-9 variant 
which incorporates multiple cysteine locations other than C229/C230 due to the fact that 
fluorescence by FlAsH has been reported to occur when bound to less than four 
cysteines
19
.  
A.3. Discussion 
 The initiator caspase of the intrinsic pathway of apoptosis, caspase-9, has the 
potential to be a good target for regulation by a small molecule. Caspase-9 plays a pivotal 
role in the activation of the cleavage cascade of apoptosis and its activation mechanism is 
targeted in a variety of diseases anywhere from viral infections to cancer. Taking 
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inspiration from natural activation pathways of caspase-9, such as dimer formation, we 
designed two variants of caspase-9, C9-X and C9-β that could potentially dimerize upon 
binding of a small fluorescent molecule known as FlAsH. This would provide a proof-of-
concept that caspase activation can be controlled by a small molecule regulator. 
  Upon analysis, distinct induction of the caspase-9 dimer was not observed, in 
addition to the lack of a robust fluorescence signal expected from binding of the FlAsH 
molecule, which was observed for the control protein. Although precautions were taken 
when designing FlAsH binding sites across the dimer interface, C9-X and C9-β were 
unsuccessful. Unforeseen pitfalls such as improper geometric binding angles for FlAsH 
binding within the designed cysteine motif or limited access to the designed site could 
have prevented FlAsH from binding the engineered caspases. In addition, it is possible 
that FlAsH could only bind to a pre-formed dimer of caspase-9 which is limited in vitro
1
. 
This hypothesis can be tested by addition of a covalent active site inhibitor which shifts 
the enzyme’s equilibrium from monomer to dimer. Further analysis of the geometric 
restrictions imposed by these sites as well as the discovery of alternative FlAsH binding 
sites or alternative molecules could result in a caspase-9 variant that can be activated 
through a small molecule trigger.  
 Although the desired outcome was not obtained, new information was discovered 
about caspase-9. A natural FlAsH binding site exists within the large subunit of caspase-
9. Once the location of the non-specific FlAsH site is determine, this site can be 
optimized to obtain a more robust FlAsH signal and potentially exploit the site for 
allosteric control as in the case of protein tyrosine phosphate 1B
20
. 
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APPENDIX B 
DESIGN OF AN ACTIVATABLE INITIATOR CASPASE 
B.1. Introduction 
Caspases, proteases that control apoptosis, have been a target in cancer research 
for many years.  In particular, caspase-9, an initiator of the caspase cleavage cascade, has 
been shown to be down regulated in tumor cells
1,2
. Therefore, activating the caspase 
cleavage cascade, via the intrinsic pathway of apoptosis by utilizing caspase-9 within 
these tumors, would be a useful tool to study apoptosis in tumors and to halt tumor 
progression. Critical steps within the caspase-9 activation pathway, such as dimerization 
and active site loop conformation, can be used as inspiration for designing such a tool. 
Caspase-9’s equilibrium in solution lies toward the monomeric state3. Therefore 
designing a way to shift the equilibrium of caspase-9 from monomer to dimer would aid 
in increasing the active population of caspase-9 molecules. Additionally, if creating a 
dimeric variant of caspase-9 could also be facilitated via control of the active site loop 
bundle, further enhancement of caspase-9 activity would be expected.   
 Nature provides naturally occurring amino acids, such as cysteines, that form 
covalent, redox-controllable cross-links, which became a useful protein-engineering tool 
for controlling a proteins conformation. The disulfide cross-link has been used for a 
variety of applications including stabilization of protein conformational states and 
analyzing functional mechanisms
4-10
 on anywhere from viral proteins
11
 to critical cellular 
transcription factors
12
 and even for release from a delivery system
13-17
. Wide applicability 
and controlability of this technique, based upon redox environment
18,19
, makes disulfide 
cross-linking an intriguing tool for activating caspase-9. Therefore we aim to rationally 
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design a caspase-9 variant to become activated by inducing dimerization and formation of 
the active site loop bundle via a disulfide cross-link.  
B.2. Results 
B.2.1. Rational Redox Controllable Caspase-9 
Like other caspases, caspase-9 undergoes distinct structural conformation changes 
based upon the state of the enzyme. Caspase-9 exists as an inactive monomer within the 
cytosol and becomes active upon dimerization
3
. Crystallographic evidence shows an 
active site loop bundle that adopts a disordered conformation in the absence of substrate 
and changes conformation to a more ordered state upon binding substrate
3
. The active 
state of the enzyme is a dimer in which the active site loop, L2, from one half of the 
dimer interacts with the L2` loop from the other half. Our goal is to lock caspase-9 into 
the active state, overcoming the slow step of the caspase-9 activation process and thus 
preparing it to cleave substrate. 
The natural residue, cysteine, was utilized to create a redox controllable link 
between both halves of the dimer. Wild-type caspase-9 protein contains thirteen native 
cysteine residues, where a natural redox regulation event or a native disulfide bond 
linkage has not been observed within the enzyme to date. These thirteen native cysteines 
within the caspase-9 amino acid sequence were initially investigated for potentially 
forming a natural disulfide link. The only native cysteine capable of this would be C403, 
which resides within the dimer interface.  Based on conformation with the β-sheet 
secondary structure and distance from the corresponding C403 across the two fold axis of 
the dimer interface, disulfide cross-linking at this site would not be feasible. Therefore a 
computational tool to predict the availability of residues for disulfide engineering, known 
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as MODIP, was utilized to predict which amino acid positions would facilitate proper 
amino acid pairing for potential disulfide linkage. The best prediction across the dimer 
interface comprised the residues Lys399, found at the top of the L4 loop, and Pro339 of 
the L2` loop from the opposite monomer. However, cross-linking two active site loops 
which have different functions would most likely have a negative effect on activity of the 
enzyme. Therefore, the caspase-9 crystal structure, in the active state, was inspected for 
alternate designs. Inspired by MODIP’s prediction of locking active site loop, interaction 
between L2 and L2`of caspase-9 in the substrate bound state (PDB ID: 1NW9) was 
investigated. The L2 and L2` loops naturally interact upon binding of substrate therefore 
the addition of a cross-link at this position would enhance the probability of the 
conformational state. Upon inspection of the caspase-9 active conformation, Glu297 on 
the L2 loop and Ser334C on L2` appeared to be within optimal distance and 
conformation as they reside just past the intersection point of the L2 and L2` (Fig B.1).  
Optimal distance for disulfides was defined as 4.4-6.8 Å from Cα-Cα20. A disulfide at 
this site would link the large and 
small subunits of the enzyme 
together. Therefore these two 
sites were chosen as the link site 
for the redox controllable 
caspase-9 variant. 
B.2.2 Production of a Redox 
Controllable Caspase-9 
The caspase-9 full-length 
 
Figure B.1 Model of the designed caspase-9 disulfide 
cross linked variant.  
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gene (human sequence) construct, encoding amino acids 1-416, in pET23b (Addgene 
plasmid 11829 ) was used to design a genetic construct for expression and purification 
from Bl21(DE3) E.coli strain of bacteria of the disulfide activatiable caspase-9 variant. 
The oligo-nucleotide pimer 5’ GCAGAAAGACCATGGGTTTTGCGTGGCCTCCA-
CTTCCCC 3’converted position 297 from a Glu to a Cys while and a second primer was 
designed, 5’ GCTGGACGCCATATCTTGTTTGCCC-ACACCC 3’, to convert position 
344 from a Ser to a Cys utilizing the Quikchange mutagenesis method. First, C9F-E297 
was changed to cysteine, found in position 37 of the Hardy Lab DNA Archive Box 2. The 
final construct of C9F-E297C/S334C, alternately named C9F-DS was made by 
performing Quikchange mutagenesis using the Ser334 oligo-primer in the background of 
the C9F-E298 construct stored in the Hardy Lab DNA Archive Box 2 position 38. 
 The C9F-DS construct was transformed into the BL21 (DE3) T7 Express strain of 
E. coli (NEB) for expression. The cultures were grown in 2xYT media with ampicillin 
(100 mg/L, Sigma-Aldrich) at 37°C until they reached an optical density at 600 nm of 
0.8. The temperature was reduced to 20°C and cells were induced with 1 mM IPTG 
(Anatrace) to express soluble 6xHis-tagged full-length protein.  Cells were harvested 
after 18 hrs and stored at -20°C. The resultant protein was purified using the standard 
caspase-9 imidazole gradient purification followed by an ion exchange column 
purification step, in which a detailed protocol can be found in Appendix D: Protocol D1. 
The purified C9F-DS protein, estimated to be approximately 95% pure with a two site 
cleavage within its intersubunit linker was used for further analysis.  
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B.2.3 Analysis of Designed Caspase-9 Disulfide Variant 
 The caspase-9 disulfide variant was tested for its ability to cross-link caspase-9 
into an active state. Activity and cross-linking of the large and small subunits were used 
as readouts for success of the design. Initial titrations with reductant, DTT, did not show 
a change in activity between the engineered mutant, C9F-DS, and wild type protein. 
Therefore, the purified proteins in 20 mM Tris pH 8.5, 100 mM NaCl, and 5 mM DTT 
were subjected to a Nap-5 desalting column (GE Healthcare) for removal of the DTT 
reductant and to buffer exchange the proteins into an activity buffer of 10% sucrose and 
0.1 M MES pH 6.5. Caspase-9 exhibits a high propensity of precipitation in these 
conditions; however, sufficient protein of both C9F-DS and WT was recovered from the 
soluble fraction for experimentation. Proteins were diluted to 5 μM, as judged by 
absorbance at 280 nm,  in assay buffer containing either 10 mM DTT for reduction of any 
pre-formed disulfide cross-links, 500 μM oxidixed glutathione, or slowly bubbled with 
air as an oxidant to facilitate formation of the engineered disulfide bond (Fig B.2). 
 
Figure B.2. Disulfide cross-linking of wild type caspase-9 full-length and disulfide variant. SDS-PAGE 
analysis of caspase-9 wild type and disulfide variant in the presence and absence DTT, oxidized 
glutathione (GSSG), and air. Expected disulfide cross link would be represented as the full length form 
of the enzyme. 
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Samples of the reaction were pulled at time points 0, 0.5, 1, and 2 hours to monitor the 
potential cross-link. A cross-link between the large and small subunits, forming the 
expected intact monomer, was not observed pre or post treatment with oxidized 
glutathione. However, a minimal amount of cross-linked monomer was detected upon 
oxidation with air at the one and two hour time points. Reduction in protein concentration 
was also observed due to precipitation of protein during the experimental timeframe, 
indicating a need for further optimization of experimental conditions. Protein precipitate 
was also observed for the wild type version of the enzyme (data not shown), therefore 
alternate ways to obtain the cross-linked form of C9F-DS need further exploration. 
 The designed redox controllable variant, C9F-DS, was successful to some degree 
under air oxidizing conditions only. Due to protein precipitation issues, studies of 
enzymatic activity posed to be troublesome, therefore  investigating whether this variant 
can induced dimerization of the small and large subunits via a cross-link between the L2 
and L2` loops was perused. This would verify this site alone can enforce the dimer form 
of the enzyme, which is required for activity. Small maleimide-based cross-linkers, 
BMOE (bis-maleimidoethane) and BMDB (1,4 bismaleimidyl-2,3-dihydroxybutane) 
(Pierce), of arm spacer lengths of 8.0 Å and 10.2 Å respectively, were used as cross-
linking agents (Fig B.3 A-B). 300 μM of BOME or BMDB was added to 10 μM C9F-DS 
and WT protein that was reduced for 30 minutes in 5mM TCEP and equilibrated in 0.1 M 
phosphate buffer pH 7.0, 0.15 M NaCl and 5 mM EDTA. Samples were incubated for 
two hours at room temperature and immediately analyzed via SDS-PAGE (Fig B.3 C-D). 
For both BMOE and BMDB cross-linking compounds, the expected large plus small 
molecular weight band is present; however, it is only slightly more concentrated than 
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samples that do not include the maleimide compounds. This result indicates that the 
E297C/S334C site is capable of associating the large and small subunits via sulfhydryl 
cross-linking compounds in addition to formation of this complex under different buffer 
conditions.  
B.3. Discussion 
  The initiator of the caspase cleavage cascade for the intrinsic pathway of 
apoptosis, caspase-9, is a promising target for activating apoptosis in tumor cells. Taking 
inspiration from natural activation pathways of caspase-9, such as dimer formation and 
active site loop orientation, we designed a disulfide cross-linked version of the caspase-9 
enzyme. A cross-link between the large and small subunits of caspase-9, due to the 
altered amino acids E297C and S334C within the intersubunit linker, was observed under 
air oxidation as well as the presence of sulfhydryl cross-linking agents. However, 
precipitation of both the control wild type protein, as well as the disulfide variant posed 
 
Figure B.3. Chemical cross-linking of wild type caspase-9 full-length and disulfide variant. (A-B) 
Small spacer arm maliemide based cross linking compounds. (A) BMOE (B) BMDB. (C-D) SDS-
PAGE analysis of caspase-9 wild type and disulfide variant in the presence and absence of BMOE 
(C) and BMDB (D). Expected disulfide cross link would be represented as the full length form of the 
enzyme. 
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as a large issue within these experiments potentially due to intramolecular disulfides 
being formed between the thirteen native cysteines within the enzyme. The incidence of 
cross-linking between the large and small subunits of caspase-9 was observed to a greater 
degree (Fig B.3.D) than in the control experiments, suggesting induced dimerization of 
the enzyme. However protein precipitation and the intrinsic requirement of reductant 
prevented activation analysis. 
Verification of caspase-9 increased activation is critical for making this disulfide 
mediated caspase-9 variant a useful tool. Therefore, optimization of the assay conditions 
is required to enforce the disulfide cross-link, while still being able to assay for activity 
and avoid precipitation of the enzyme. Identification of the lowest amount of reductant 
necessary for caspase-9 activity and solubility would also be useful for solving these 
issues. Potentially a redox buffer that includes both reduced and oxidized glutathione is 
more closely related to that of the chemical cross-linking studies, would be more 
appropriate. In addition, removal of any surface exposed cysteines would aid in this 
endeavor.  
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APPENDIX C 
EXPRESSION AND PURIFICATION OF A YEAST METACASPASE YCA1 
C.1. Introduction 
Saccharomyces cerevisiea yeast has served as a model organism for a huge 
number of genetic and regulatory pathways due to its ease of genetic manipulation and 
strikingly conserved pathways in comparison to other eukaryotic organisms.  
Furthermore, this model system has demonstrated apoptotic-like cell death with such 
markers as DNA fragmentation and chromatin condensation
1
. Since the discovery of 
apoptosis in yeast, a number of yeast orthologs to key players in the mammalian 
apoptotic cycle have been identified, indicating conserved cell death pathways for 
proteasomal and mitochondrial-type cell death
2
. 
An apoptotic-like phenotype in yeast has even been observed upon a variety of 
triggers including exposure to reactive oxygen species 
3
 and aging
4
.  Characteristic 
homologues for apoptotic regulators such as the Bcl-2 family of proteins have not yet 
been discovered in the yeast model system; however, a caspase-like protein has been 
identified in the S. cerevisiea genome. Yeast caspase-1 (YCA1 also known as 
YOR197W) has been classified as an evolutionary ancestor to human caspases
5
, or a 
metacaspase, due to primary sequence identification of a catalytic cysteine-histidine diad 
as well as a predicted caspase like fold. YCA1 has been highlighted as the protein 
responsible for apoptotic like cell death in yeast
6
. For example, knockout of the YCA1 
gene in S. cervisiea has been shown to abolish an H2O2 induced form of apoptosis
7
. In 
addition to YCA1’s ability to control the apoptotic properties of yeast, this protease 
shows caspase like character in both its cleavage properties and substrate recognition 
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sequences, VEID and IETD. YCA1 studies have mainly been performed in whole yeast 
cells to understand how overexpression of the enzyme affects cell survival rates as well 
as how different apoptosis inducing factors, such as H2O2, affect survival when in the 
presence and absence of the YCA1 gene
4,6,8,9
. Additional studies involved removal of the 
soluble protein fractions from the yeast cells for measurement of YCA1 expression levels 
under normal and stress conditions
7
 and utilizing cellular extracts to test the enzymatic 
activity of YCA1
10
. These caspase-like characteristics therefore make this metacaspase 
an intriguing target for protein engineering and structural studies.  We aimed to express 
and purify YCA1 to perform biochemical characterizations for further elucidation of the 
proteases similarities to its human homologues. This ultimately would allow solution of 
the crystal structure of YCA1 to observe its structural similarities and to design alternate 
ways to regulate the enzyme though protein engineering which can be easily tested in 
yeast as the model system.  
C.2. Results 
C.2.1. Gene Construction 
 The S. cervisiea YCA1 gene was used to design and prepare a genetic construct 
for expression and purification from Bl21(DE3) E.coli strain of bacteria. The gene was 
amplified from a yeast plasmid by PCR for insertion into the pET21(+)b expression 
vector. Oligo-nucleotide pimers, 5`-AGTCGTGCTAGCATGTATCCAGGTAGTGGA-
CGTTACACC-3` and 5`-AGTATACTCGAGCTACATAATAAATTGCAGATTTAC-
GTCAATAGGG-3`, encode the NheI and Xho1 endonuclease restriction sites for the 5` 
and 3` primers, respectively, were utilized for the amplification. The PCR product was 
digested to expose complementary DNA overhangs and gel purified, resulting in a 64 
 182 
 
ng/μl digested YCA1 DNA gene product. Ligation of the YCA1 gene to the digested the 
pET21(+)b expression vector was performed through incubating one molar ratio of vector 
with three molar ratios of YCA1 gene insert with T4 DNA ligase at 16°C overnight. The 
ligation reactions were transformed into the TAM1 cloning strain of E.coli cells and 
plated onto 100 mg/ml ampicillin plates. Transformants were tested for successful 
ligations through enzymatic digest with NheI and XhoI to reveal the insertion of the 
YCA1 gene which was subsequently confirmed through DNA sequencing.  The resulting 
plasmid encodes the YCA1 gene with a C-terminal 6xHis tag driven by the T7 promoter 
with apmicillin resistance (Fig C.1). This plasmid is housed in the Hardy Lab DNA 
archive box 1 position 9. 
C.2.2.  Protein Sequence 
        10         20         30         40         50         60  
MYPGSGRYTY NNAGGNNGYQ RPMAPPPNQQ YGQQYGQQYE QQYGQQYGQQ NDQQFSQQYA  
 
        70         80         90        100        110        120  
PPPGPPPMAY NRPVYPPPQF QQEQAKAQLS NGYNNPNVNA SNMYGPPQNM SLPPPQTQTI  
 
       130        140        150        160        170        180  
QGTDQPYQYS QCTGRRKALI IGINYIGSKN QLRGCINDAH NIFNFLTNGY GYSSDDIVIL  
 
Figure C.1. Schematic representation of expression vector, pYCA1. The T7 promoter, YCA1 gene, 
6xHis tag, and ampicillin resistance are shown. 
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       190        200        210        220        230        240  
TDDQNDLVRV PTRANMIRAM QWLVKDAQPN DSLFLHYSGH GGQTEDLDGD EEDGMDDVIY  
 
       250        260        270        280        290        300  
PVDFETQGPI IDDEMHDIMV KPLQQGVRLT ALFDSCHSGT VLDLPYTYST KGIIKEPNIW  
 
       310        320        330        340        350        360  
KDVGQDGLQA AISYATGNRA ALIGSLGSIF KTVKGGMGNN VDRERVRQIK FSAADVVMLS  
 
       370        380        390        400        410        420  
GSKDNQTSAD AVEDGQNTGA MSHAFIKVMT LQPQQSYLSL LQNMRKELAG KYSQKPQLSS  
 
       430  
SHPIDVNLQF IM  
C.2.3. YCA1 Expression  
The YCA1 gene is expected to produce ~50 kDa 6xHis-tagged protein of 438 
amino acids in length. YCA1 is reported to undergo autoprocessing upon induction of 
apoptosis or overexpression of the enzyme in yeast. Therefore, two cleavage products 
would be observed, a ~12 kDa portion of the enzyme which is noted as the small subunit 
and ~38 kD molecular weight piece of the remaining enzyme that would comprise the 
large and pro-domains.   
In order to obtain a homogenous sample of the active form of the YCA1 protein, 
expression and purification of the YCA1 was performed. Cell growth of the BL21(DE3) 
strain of E.coli transformed with the YCA1-pET21(+)b plasmid in 2xYT media was 
performed. When OD600  reached 0.6, cells were induced for protein expression with 
1mM IPTG at 14, 30, or 37 °C.  A standard 6x-His tag purification protocol was utilized 
in order to obtain the desired protein from cellular lysates as outlined by the Current 
Protocols in Protein Science
11
. Under these standard expression and purification 
conditions, protein induced at OD600= 0.6 with 1 mM IPTG 14°C for 18 hrs produced an 
elution fraction that contained minimal amount of protein of the expected molecular 
weight of full length YCA1 as judged by Western blot analysis with an antibody specific 
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for the 6xHis-purification tag (Fig. C.2) However, in addition to low expression levels, 
the enzymatic autoprocessing was incomplete and breakdown products are observed. 
Activity of protein identified in the elution fraction was assessed though cleavage of 
fluorogenic substrate VEID-AMC (Ex= 380nm; Em= 460), a previously reported 
cleavage sequence for YCA1 in yeast. Unfortunately, no activity was detected. Human 
homologue, caspase-6, was used as a control for activity against the fluorogenic 
substrate. ARR-2NA, a previously reported fluorogenic substrate for YCA1 was also 
tested. Activity was observed within the supernatant of lysed cells, however, no 
detectable activity was observed for the purified protein. The lack of observed YCA1 
activity is thought to be due to the presence of the inactive full length version of the 
protein or the multiple breakdown products of the processed enzyme. 
 In order to optimize expression conditions for overexpression of the YCA1 
protein in E.coli with the proper molecular weight products, theYCA1-pET21(+)b 
 
Figure C.2. Purification of YCA1. (A-B) SDS-PAGE of the loaded supernatant (L), flow through 
(FT), wash (W) and elution (E) fractions from a Ni-affinity purification of YCA1. Molecular weights 
determined from marker (M) and caspase-7 was used as a control (C7). (A) Coomassie stain. (B) 
Anti-his western blot. 
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expression vector was transformed into various forms of the BL21(DE3) E.coli cell line 
including the original BL21(DE3) strain as well as the  PLysS, Codon +, and Rosetta 
strains. Induction of protein expression was performed at an OD600 = 0.4 and 0.6 in a 5 
mL 2xYT media culture format by addition of IPTG in a concentration intervals of 0.05, 
0.2, 0.5, 0.75, and 1 mM of protein growth or through utilizing auto-induction media.  
Protein expression was allowed to be induced for a time course of 3, 6 or 18 hours at 
temperatures of 15, 28 or 37 °C. Cells cultures were stored in a 96-well format at -80°C 
for future analysis. Stored cells were collected by centrifugation and resuspended in 
phosphate buffer pH 8.0 containing lysozyme. The samples were subjected to five freeze- 
thaw cycles to lyse cells, spun at 3700 rpm to remove cellular debris. Supernatants 
diluted in 0.1M HEPES pH 7.5, 0.1% CHAPS, 10% sucrose, and 5mM β-Me. buffer 
were then analyzed for activity using the fluorogenic substrate VEID-AMC. Activity was 
only observed for control protein caspase-6, indicating that changing the bacterial strain 
induction conditions such as cell density, temperature, and [IPTG] did not improve 
YCA1 expression levels or cleavage patterns to result in an active enzyme judged by 
protease activity.  
C.3. Discussion 
Yeast caspase 1, a homologue of human caspases, would be a good surrogate for 
studying regulation of YCA1 in the yeast apoptotic cascade. A genetic construct 
containing the YCA1 gene was created for expression of YCA1 in E.coli. Upon analysis 
of expression, induction, and purification conditions, minimal amounts of the inactive full 
length form of protein was obtained. In addition, a non-homogeneous mixture of cleavage 
products was observed, which did not possess any enzyme activity. Due to this lack of 
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activity, the observed cleaved forms of the enzyme are thought to be breakdown products 
which occurred during expression or purification by an endogenous E.coli protease. This 
would also reflect on the low yield that was obtained. Due to these issues, further 
progression of this project was halted.  
 Future studies could include purifications in which protease inhibitors such as 
PMSF are utilized. These inhibitor cocktails, however, will also target the enzyme of 
interest, limiting analysis to only structural based methods in which a peptide is bound to 
the active site. Additionally, avenues to express YCA1 in its native system, yeast, could 
also be explored. Although over-expression of YCA1 in yeast has been shown to induce 
apoptotic cell death, potential purification from natural abundance or leaky expression 
would most likely lead to the proper cleavage of the enzyme resulting in the active 
enzyme.  
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